aspho
abstract
background
children
undergo
hematopoiet
stem
cell
transplant
hsct
increas
risk
potenti
fatal
viral
infect
includ
adenoviru
major
caus
morbid
mortal
popul
cidofovir
nucleotid
phosphat
analogu
competit
inhibit
incorpor
deoxycytidin
triphosph
dna
viral
dna
polymeras
therebi
disrupt
chain
elong
demonstr
invitro
activ
number
dna
virus
includ
adenoviru
herpesviru
poxviru
papillomaviru
polyomaviru
given
intraven
iv
recent
case
repot
describ
safe
success
administr
inhal
treatment
respiratori
viral
infect
object
report
case
pediatr
hematopoiet
stem
cell
transplant
recipi
treat
inhal
cidofovir
adenoviru
pneumon
designmethod
case
report
literatur
review
result
year
old
hispan
femal
past
medic
histori
fanconi
anemia
develop
multiorgan
failur
requir
dialysi
respiratori
support
adenoviru
pneumon
day
umbil
cord
stem
cell
transplant
tracheal
aspir
time
intub
posit
adenoviru
pcr
despit
maxim
dose
iv
cidofovir
adjust
renal
failur
viral
load
continu
trend
clinic
deterior
obtain
parent
consent
treat
inhal
cidofovir
dilut
normal
salin
administ
daili
via
et
tube
total
dose
base
previous
publish
case
report
progress
improv
clinic
eventu
requir
minim
ventil
support
adenoviru
viral
load
tracheal
aspir
drop
progress
dna
copiesml
immedi
complic
observ
conclus
though
adenoviru
pneumon
major
caus
morbid
mortal
among
pediatr
hsct
recipi
treatment
challeng
inhal
cidofovir
offer
altern
iv
cidofovir
patient
renal
failur
iv
cidofovir
might
contraind
due
nephrotox
well
design
studi
need
assess
safeti
efficaci
inhal
cidofovir
background
invas
fungal
infect
ifi
lifethreaten
complic
neutropen
children
treat
acut
myeloid
leukemia
aml
earli
diagnosi
crucial
nonspecif
clinic
sign
isol
prolong
fever
often
make
correct
identif
ifi
challeng
bdg
major
cell
wall
compon
invas
fungi
detect
serum
facilit
diagnosi
ifi
bdg
posit
valid
diagnosi
ifi
adult
popul
correl
bdg
ifi
remain
unproven
pediatr
cancer
object
assess
correl
detect
serum
bdg
via
fungitel
c
assay
ifi
atrisk
pediatr
popul
aml
designmethod
retrospect
cohort
studi
pediatr
subject
aml
year
diagnosi
treat
miller
children
women
hospit
long
beach
least
one
report
bdg
assay
antifung
prophylaxi
quantiti
detect
bdg
associ
ifi
evalu
cultur
radiograph
imag
aspergillu
galactomannan
antigen
patholog
collect
independ
review
studi
posit
ifi
defin
probableproven
accord
consensu
eortcmsg
guidelin
exclud
bdg
multipl
receiv
oper
characterist
roc
curv
gener
vari
bdg
threshold
rang
pgml
use
best
fit
curv
analyz
specif
sensit
true
posit
likelihood
ratio
lr
across
threshold
determin
optim
boundari
limit
serum
bdg
associ
ifi
pediatr
oncolog
popul
result
total
report
bdg
assay
ifi
evalu
review
chemotherapi
cycl
administ
elig
subject
routin
antifung
prophylaxi
administ
subject
fluconazol
echinocandin
posit
ifi
diagnos
subject
inspect
best
fit
roc
curv
auc
identifi
bdg
threshold
pgml
associ
highest
correct
classif
lr
balanc
specif
sensit
increas
threshold
pgml
decreas
correct
classif
markedli
affect
sensit
minor
improv
specif
conclus
detect
bdg
threshold
pgml
suffici
specif
aid
diagnosi
ifi
pediatr
popul
aml
neonat
abstin
syndrom
leukopenia
background
chronic
administr
opioid
associ
lymphocyt
abnorm
affect
immun
system
function
littl
known
effect
matern
drug
use
neonat
immun
system
lymphocyt
count
hypothes
matern
drug
use
pregnanc
lead
neonat
lymphopenia
recogn
possibl
increas
risk
infect
popul
allow
appropri
counsel
precaut
object
identifi
newborn
expos
intrauterin
drug
experienc
hematolog
abnorm
specif
lymphopenia
designmethod
retrospect
chart
review
neonat
born
document
drug
withdraw
syndrom
conduct
medic
record
obtain
electron
search
infant
follow
code
drug
reaction
intox
specif
newborn
drug
withdraw
syndrom
newborn
nondepend
abus
opioid
gestat
age
infant
birth
birth
weight
type
matern
drug
use
durat
hospit
treatment
neonat
abstin
syndrom
na
infant
absolut
lymphocyt
count
document
comorbid
durat
drug
exposur
record
result
neonat
document
diagnosi
na
time
period
review
complet
blood
count
drawn
mean
time
hour
life
avail
review
manual
differenti
util
avail
use
alc
cutoff
percentil
neonat
diagnosi
drug
withdraw
syndrom
lymphopen
lymphopen
infant
note
longer
na
treatment
durat
day
vs
day
well
longer
length
hospit
day
vs
day
lymphopen
infant
preterm
week
gestat
infant
expos
opioid
exposur
confirm
posit
matern
drug
screen
posit
neonat
meconium
drug
screen
conclus
infant
diagnosi
drug
withdraw
syndrom
lymphopen
infant
requir
longer
durat
treatment
na
investig
possibl
relationship
sever
na
neonat
lymphopenia
analysi
need
determin
correl
note
larger
studi
popul
effect
transient
child
clinic
statu
neonat
period
throughout
childhood
may
affect
background
studi
shown
patient
suffer
itp
polar
respons
cytokin
deregul
balanc
well
known
regul
immun
system
normal
condit
impair
autoimmun
diseas
like
itp
order
studi
mechan
lymphocyt
abnorm
children
itp
ensur
homogen
object
due
children
itp
often
abrupt
sever
onset
thrombocytopenia
prescrib
intraven
immunoglobulin
ivig
first
day
hospit
prevent
hemorrhag
well
methypredisolon
mp
often
use
exclus
malign
reason
lymphocyt
function
evalu
involv
detect
cytokin
secret
etc
might
interrupt
treatment
mention
object
studi
design
explor
influenc
intraven
immunoglobulin
ivig
methylprednisolon
mp
cytokin
secret
lymphocyt
children
itp
designmethod
enrol
patient
first
diagnos
itp
ultim
durat
less
month
without
recurr
boy
girl
age
rang
month
median
month
enrol
children
itp
onset
diseas
depart
decemb
march
follow
whole
durat
choos
patient
whose
ultim
durat
less
month
recurr
cytokin
measur
cytometr
bead
array
includ
tnf
ifn
divid
patient
group
accord
treatment
receiv
test
cytokin
level
compar
cell
cytokin
level
among
group
result
enrol
patient
first
diagnos
itp
ultim
durat
less
month
without
recurr
boy
girl
age
rang
month
median
month
found
level
decreas
group
treat
mp
day
n
p
group
patient
treat
ivig
day
n
p
compar
group
without
treatment
n
cytokin
level
differ
among
group
conclus
children
itp
although
pathway
mp
ivig
treat
thrombocytopenia
differ
could
decreas
children
itp
ultim
repres
cytokin
cell
demonstr
import
lymphocyt
activ
mobil
consid
mp
ivig
reduc
cell
activ
product
autoantibodi
decreas
achiev
continu
steadi
dose
maximum
dose
mcgkg
patient
durat
therapi
week
patient
week
patient
due
religi
object
blood
product
patient
receiv
three
weekli
mcgkg
dose
month
period
maintain
platelet
count
receiv
salvag
therapi
relaps
paramening
rhabdomyosarcoma
patient
maintain
platelet
count
goal
follow
discontinu
romiplostim
advers
effect
romiplostim
inject
observ
conclus
romiplostim
success
treat
trt
without
advers
effect
case
seri
possibl
risk
leukem
clone
prolifer
may
limit
use
romiplostim
trt
children
hematolog
malign
romiplostim
could
benefici
treatment
trt
children
solid
tumor
may
limit
treatment
delay
dose
reduct
ultim
lead
improv
overal
surviv
prospect
studi
use
romiplostim
warrant
progress
clinic
symptom
worsen
qualiti
life
qol
unfortun
treatment
option
limit
often
ineffect
surgeri
gener
reserv
local
diseas
convent
medic
treatment
like
steroid
chemotherapeut
agent
produc
substanti
side
effect
variabl
result
current
evid
demonstr
import
regulatori
function
mtor
pathway
vasculogenesi
support
mtor
inhibit
sirolimu
therapeut
target
object
evalu
safeti
efficaci
sirolimu
treatment
patient
gla
gsd
designmethod
studi
analyz
combin
data
multicent
systemat
retrospect
review
medic
record
patient
treat
sirolimu
januari
june
prospect
phase
clinic
trial
assess
efficaci
safeti
sirolimu
treatment
complic
vascular
anomali
diseas
improv
determin
radiolog
imag
qol
measur
clinic
statu
assess
sirolimu
dose
regimen
toxic
side
effect
causal
evalu
result
evalu
patient
nineteen
gla
gsd
gla
gsd
expect
patient
complet
resolut
clinic
symptom
radiolog
diseas
sirolimu
overal
partial
diseas
respons
gla
gsd
patient
improv
qol
improv
clinic
statu
improv
radiolog
respons
improv
occur
patient
pleural
effus
pericardi
effus
patient
preexist
pleural
pericardi
effus
worsen
therapi
diseas
progress
occur
gsd
patient
due
report
decreas
qol
five
patient
experienc
grade
drug
toxic
without
requir
dose
reduct
common
side
effect
bone
marrow
suppress
mucositisstomat
hypertriglyceridemia
conclus
sirolimu
safe
welltoler
treatment
appear
reduc
symptom
andor
stabil
diseas
patient
gla
gsd
given
signific
morbid
mortal
patient
complic
lymphat
malform
futur
treatment
studi
need
address
specif
phenotyp
background
genet
alter
caus
overexpress
cytokin
receptor
associ
form
highrisk
phlike
acut
lymphoblast
leukemia
ball
activ
receptor
cytokin
tslp
result
activ
jakstat
pathway
associ
chemoresist
upregul
famili
prosurviv
gene
object
determin
effect
mediat
signal
express
famili
protein
efficaci
target
famili
prosurviv
protein
ball
designmethod
flow
cytometri
western
blot
use
evalu
famili
protein
express
crlf
ball
cell
cultur
without
tslp
flow
cytometri
use
annexin
caspas
assay
apoptosi
follow
treatment
ball
cell
presenc
absenc
tslp
result
tslp
increas
express
famili
prosurviv
protein
ball
cell
line
activ
jak
mutat
treatment
inhibitor
reduc
cell
count
reduct
maintain
presenc
tslp
reduct
cell
number
due
dosedepend
increas
caspasemedi
apoptosi
reach
cell
death
day
concentr
um
even
tslp
present
saw
increas
express
bclxl
dose
inhibitor
um
higher
littl
chang
lower
dose
suggest
observ
increas
like
select
surviv
cell
express
high
level
altern
famili
prosurviv
molecul
rather
compensatori
upregul
express
conclus
data
suggest
tslp
contribut
chemoresist
via
upregul
famili
protein
even
case
ball
activ
jak
mutat
result
provid
evid
therapi
target
could
effect
treatment
phlike
overexpress
survey
aspho
sig
va
member
webbas
questionnair
distribut
new
york
citi
columbia
univers
medic
center
unit
state
background
vascular
anomali
va
includ
patient
vascular
malform
vm
emerg
field
pediatr
grow
recognit
coagulationrel
complic
specif
popul
date
specif
guidelin
exist
object
describ
clinic
practic
relat
pediatr
vm
patient
coagul
disturb
north
america
order
facilit
futur
develop
standard
practic
identif
research
gap
designmethod
aspho
sigva
conduct
institut
review
board
approv
onlin
survey
sigva
member
includ
gener
practic
question
clinic
vignett
describ
coagulationrel
issu
item
survey
deriv
expert
experi
literatur
review
suggest
survey
committe
result
date
member
respond
highest
rank
center
us
largest
canada
practic
year
around
respond
work
multidisciplinari
clinic
see
simpl
vmyr
combin
vmyr
use
anticoagul
ie
low
molecular
weight
heparin
lmwh
aspirin
asa
coagulopathi
last
month
pt
pt
none
three
basic
scenario
includ
periprocedur
manag
combin
vm
hypofibrogenemia
ddimer
elev
would
prescrib
anticoagul
vs
indecis
enoxaparin
agent
choic
dose
mgkddose
wk
prepostprocedur
b
simpl
vm
isol
ddimer
elev
symptom
would
prescrib
anticoagul
vs
indecis
enoxaparin
agent
choic
similar
regimen
c
simpl
vm
isol
ddimer
elev
local
pain
would
prescrib
anticoagul
vs
indecis
agent
choic
asansaid
compress
garment
common
reason
avoid
lmwh
pauciti
literatur
perceiv
increas
bleed
risk
needl
phobia
conclus
despit
preval
vm
children
survey
highlight
expect
practic
variabl
manag
coagulopathi
lack
evid
recogn
main
obstacl
use
anticoagul
character
coagul
complic
well
risk
stratif
bleedingthrombosi
pave
way
toward
futur
guidelin
background
ikaro
protein
encod
gene
act
tumor
suppressor
acut
lymphoblast
leukemia
regul
express
target
gene
use
chromatin
immunoprecipit
coupl
nextgener
sequenc
chipseq
show
ikaro
bind
promot
gene
human
gene
encod
small
gtpase
act
oncogen
solid
tumor
associ
leukemia
hypothes
ikaro
regul
express
involv
pathogenesi
object
determin
role
ikaro
regul
express
defin
signific
express
test
therapeut
efficaci
target
inhibit
designmethod
ikaro
overexpress
knockout
transduct
retrovir
vector
contain
ikaro
ikaro
shrna
respect
luciferas
report
assay
use
evalu
ikaro
effect
promot
gene
express
assess
use
quantit
realtim
pcr
qrtpcr
western
blot
dna
bind
measur
quantit
chromatin
immunoprecipit
qchip
cell
prolifer
assay
wst
synergist
cytotox
effect
compound
analyz
use
calcusyn
result
gainoffunct
lossoffunct
experi
show
ikaro
repress
transcript
overexpress
ball
tall
compar
normal
bone
marrow
overexpress
correl
high
white
blood
cell
count
treatment
specif
inhibitor
produc
cytotox
effect
leukemia
ikaro
bind
promot
abil
repress
impair
due
phosphoryl
prooncogen
casein
kinas
ii
inhibit
clinicallytest
inhibitor
restor
ikaro
bind
promot
transcript
repress
use
combin
inhibitor
produc
synergist
cytotox
effect
ball
tall
conclus
result
demonstr
overexpress
potenti
therapeut
target
leukemia
express
regul
ikaro
target
combin
inhibitor
potenti
novel
treatment
aspho
abstract
poster
background
lymphat
malform
lm
challeng
manag
particularli
involv
cervicofaci
region
airway
primari
therapi
sclerotherapi
andor
resect
role
sirolimu
evolv
treatment
cervicofaci
lm
object
review
experi
sirolimu
medic
therapi
cervicofaci
lymphat
malform
efficaci
safetytoler
designmethod
irbapprov
retrospect
review
patient
treat
sirolimu
cervicofaci
lm
novemb
octob
result
five
patient
complet
therapi
durat
month
remain
sirolimu
rang
month
age
initi
rang
month
year
nine
patient
microcyst
lm
ten
mix
macrocysticmicrocyst
lm
patient
serial
photograph
patient
serial
imag
gaug
respons
patient
demonstr
reduct
lm
bulk
rang
dramat
visual
modest
younger
patient
mix
macrocysticmicrocyst
diseas
less
prior
therapi
demonstr
signific
respons
patient
report
subject
improv
sirolimu
includ
decreas
lm
bulk
soften
tissu
decreas
bleedingleak
relat
mucos
vesicl
decreas
rate
cellul
patient
n
mucos
vesicl
present
initi
sirolimu
resolv
improv
median
time
initi
respons
month
rang
day
month
six
patient
tracheostomi
one
decannul
maxillofaci
surgeri
two
toler
cap
sirolimu
six
patient
develop
cellul
within
lm
treatment
none
progress
sepsi
episod
cellul
sirolimu
opportunist
infect
occur
two
patient
undergon
surgic
debulk
follow
sirolimu
treatment
decreas
residu
remain
tissu
wound
heal
issu
use
sirolimu
manag
cervicofaci
lm
appear
efficaci
especi
younger
patient
mucos
diseas
limit
advers
event
longterm
followup
durabl
respons
coordin
sirolimu
around
procedur
therapi
need
evalu
aditya
sharma
sunpreet
tandon
christin
mella
jami
burk
steven
kuerbitz
background
shown
previous
neuronatin
gene
nnat
undergo
aberr
dna
hypermethyl
associ
transcript
silenc
major
childhood
acut
leukemia
case
clinic
signific
loss
nnat
express
childhood
leukemia
howev
unknown
object
goal
studi
correl
clinic
characterist
outcom
nnat
express
precursor
b
acut
lymphoblast
leukemia
designmethod
sixti
seven
consecut
case
noninf
precursor
ball
present
analyz
retrospect
util
bone
marrow
sampl
obtain
diagnosi
data
medic
record
sampl
sitespecif
nnat
methyl
quantit
combin
restrictionbisulfit
analysi
cobra
nnat
mrna
express
qualit
determin
end
point
rtpcr
clinic
characterist
includ
age
present
white
blood
cell
count
wbc
present
immunophenotyp
induct
respons
surviv
compar
nnat
hypermethyl
normal
methyl
group
nnat
expressor
nonexpressor
group
result
nnat
methyl
express
statu
determin
case
hypermethyl
defin
sitespecif
methyl
identifi
sampl
nnat
silenc
loss
express
identifi
sampl
found
case
exhibit
loss
nnat
express
like
expressor
associ
wbc
diagnosi
p
also
ef
highrisk
group
approach
statist
signific
differ
expressor
nonexpressor
group
conclus
loss
nnat
express
associ
elev
wbc
count
present
ef
os
differ
significantli
expressor
nonexpressor
group
overal
analysi
restrict
analysi
patient
exhibit
highrisk
characterist
elev
wbc
age
year
ef
advantag
expressor
nonexpressor
approach
statist
signific
given
rel
stabil
tail
ef
curv
analysi
addit
patient
may
yield
statist
signific
differ
nnat
shown
regul
endoplasm
reticulum
calcium
homeostasi
cell
type
biolog
basi
clinic
featur
associ
loss
nnat
express
childhood
pball
remain
determin
background
hepat
hemangioma
common
benign
liver
tumor
infanc
typic
present
usual
involv
palpabl
abdomin
mass
without
sign
anemia
heart
failur
despit
rel
common
occurr
confus
nomenclatur
still
affect
medic
literatur
classif
schema
base
growth
pattern
immunostain
clinic
behavior
emerg
attempt
better
standard
manag
object
present
case
infant
atyp
clinic
cours
hepat
hemangioma
contrast
patient
present
similar
diagnosi
aim
contribut
grow
data
surround
common
vascular
lesion
hope
standard
diagnost
criteria
outcom
well
better
guid
therapeut
option
designmethod
retrospect
chart
review
perform
monthold
babi
boy
texa
children
hospit
compar
previou
case
publish
report
diagnosi
result
patient
boy
born
gestat
present
respiratori
failur
secondari
acut
abdomin
distens
month
age
ultrasound
prior
deliveri
shown
left
hepat
lobe
mass
mri
confirm
cm
left
hepat
lobe
hemangioma
present
repeat
ultrasound
show
hepat
mass
stabl
size
without
signific
shunt
compress
hepat
vessel
larg
amount
ascit
present
alphafetoprotein
afp
level
within
rang
age
workup
fail
reveal
primari
etiolog
ascit
due
critic
statu
decis
made
excis
mass
patholog
reveal
neg
vascular
lesion
consist
hepat
congenit
hemangioma
postop
babi
recov
well
ascit
reaccumul
conclus
wide
rang
clinic
present
focal
hepat
hemangioma
asymptomat
critic
ill
lesion
requir
close
follow
birth
identifi
develop
complic
initi
prompt
treatment
background
transloc
occur
patient
tall
aml
associ
poor
prognosi
leukemia
character
upregul
hoxa
gene
express
known
driver
leukemogenesi
interact
oncoprotein
nuclear
export
factor
essenti
upregul
hoxa
express
previous
demonstr
interact
directli
hoxa
chromatin
suggest
recruit
target
gene
howev
mediat
may
also
involv
particular
compon
nuclear
pore
complex
interact
nucleocytoplasm
transport
macromolecul
transloc
fuse
multipl
differ
partner
describ
highrisk
leukemia
fusion
oncoprotein
bind
activ
transcript
hoxa
gene
object
determin
whether
cooper
transactiv
hoxa
gene
designmethod
previous
creat
retrovir
calmand
fusion
vector
demonstr
abil
activ
transcript
report
design
induc
shrna
retrovir
vector
target
perform
transient
cotransfect
report
shrna
vector
togeth
empti
vector
cell
also
stabli
express
induc
shrna
vector
cell
result
luciferas
assay
show
knockdown
increas
baselin
level
transcript
limit
effect
transcript
activ
induc
knockdown
also
caus
increas
endogen
hoxa
level
cell
conclus
surprisingli
silenc
increas
transcript
activ
endogen
hoxa
transcript
sinc
import
nuclear
export
imped
function
like
result
nuclear
retent
critic
protein
may
indirectli
deregul
hoxa
transcript
experi
underway
determin
role
hoxa
level
cell
express
note
recent
report
demonstr
direct
bind
hox
gene
oka
et
al
elif
highlight
import
interact
among
hox
loci
molecular
basi
leukemogen
hox
gene
dysregul
poster
children
hospit
michigan
detroit
michigan
unit
state
background
infantil
hemangioma
ih
typic
benign
vascular
neoplasm
spontan
involut
time
commonli
found
head
neck
trunk
also
involv
intern
organ
liver
lung
central
nervou
system
oftentim
lesion
treat
conserv
medic
manag
need
consist
laser
treatment
surgic
excis
medic
includ
propranolol
steroid
object
describ
pediatr
patient
diffus
hepat
cutan
ih
failur
thrive
progress
pulmonari
hypertens
ph
due
pulmonari
hemangioma
treat
sirolimu
designmethod
patient
three
year
old
african
american
femal
present
shortli
birth
diffus
cutan
hemangioma
hepatomegali
splenomegali
anemia
abdomin
mrimra
note
replac
entir
liver
parenchyma
numer
nodular
lesion
consist
ih
well
sign
earli
heart
failur
skin
biopsi
confirm
ih
start
propranolol
prednisolon
hemangioma
well
medic
manag
heart
failur
hepat
cutan
hemangioma
improv
time
month
age
howev
develop
sever
idiopath
ph
diagnos
right
cardiac
catheter
system
pulmonari
arteri
pa
pressur
rest
respons
oxygen
nitric
oxid
comput
tomographi
scan
thorax
note
multipl
enhanc
pulmonari
nodul
scatter
throughout
lung
suspici
pulmonari
arterioven
malform
patient
start
sildenafil
given
sever
ph
like
pulmonari
hemangioma
persist
liver
cutan
hemangioma
despit
previou
therapi
subsequ
start
sirolimu
repeat
cardiac
catheter
two
month
initi
sirolimu
note
improv
ph
well
liver
hemangioma
unfortun
patient
develop
signific
hypoglycemia
result
demis
conclus
pulmonari
hemangioma
rare
pediatr
popul
sirolimu
act
inhibit
mtor
pathway
thu
decreas
vascular
endotheli
prolifer
steroid
propranolol
first
line
medic
manag
ih
howev
sirolimu
may
effect
treatment
option
hemangioma
refractori
convent
therapeut
option
univers
rochest
strong
memori
hospit
rochest
new
york
unit
state
background
cure
rate
acut
lymphoblast
leukemia
relaps
occur
quarter
case
particularli
high
risk
diseas
cell
immunomodul
may
valuabl
adjunct
standard
therapi
howev
studi
date
demonstr
direct
effect
immunomodul
tumor
cell
surviv
work
explor
method
manipul
microenviron
treat
poli
c
dsrna
analog
demonstr
direct
effect
tumor
growth
via
ifn
pathway
give
antileukem
effect
howev
sirna
studi
primari
stroma
popul
thu
complet
understand
genet
microenvironment
effect
offer
object
determin
whether
poli
c
sirna
upregul
gene
express
measur
activ
interferon
pathway
indirectli
induc
acut
lymphoblast
leukemia
cell
tumor
cell
death
way
alter
primari
stromal
gene
express
designmethod
revers
transfect
differ
stromal
cell
line
rna
extract
cdna
synthesi
follow
quantit
pcr
determin
poli
c
sirna
mediat
upregul
gene
express
transfect
three
primari
stromal
cell
line
poli
c
follow
cell
wash
subsequ
cell
plate
cell
surviv
measur
flow
cytometri
result
poli
c
induc
gene
express
stromal
cell
cell
underw
apoptosi
presenc
poli
c
treat
stromal
cell
conclus
poli
c
dramat
reduc
capac
nonmalign
stromal
cell
support
viabil
primari
cell
find
suggest
drug
target
marrow
stromal
cell
may
provid
new
approach
control
current
studi
lab
explor
key
chang
gene
express
pathway
induc
poli
c
nonmalign
stromal
cell
lead
cell
death
background
bone
marrow
bm
nich
cell
specif
leptinreceptorexpress
perivascular
stromal
cell
lepr
reticular
cell
car
endotheli
cell
play
essenti
role
mainten
selfrenew
function
hematopoiet
stem
cell
hsc
number
secretoryrel
molecul
like
stem
cell
factor
scf
angiopoietin
mediat
mainten
function
addit
function
autophagi
within
hsc
known
play
critic
role
maintain
hsc
homeostasi
loss
hsc
lead
loss
normal
hsc
function
sever
myeloprolifer
howev
remain
unclear
hematopoiesi
affect
autophagi
select
block
bone
marrow
nich
cell
object
investig
effect
autophagi
defici
within
bone
marrow
nich
cell
hematopoiesi
designmethod
knockout
mous
model
gener
allow
select
ablat
autophagyessenti
protein
lepr
perivascular
stromal
cell
delet
inde
restrict
lepr
cell
loss
suffici
block
autophag
function
evid
accumul
protein
white
blood
cell
count
wbc
significantli
reduc
old
male
ko
mice
compar
wild
type
wt
control
mice
p
myeloid
popul
bone
marrow
peripher
blood
significantli
decreas
ko
mice
p
valu
atg
ko
vs
wt
control
wbc
count
continu
declin
week
old
ko
male
mice
lsk
long
term
hsc
lthsc
popul
decreas
old
male
mice
howev
trend
reach
statist
signific
although
absolut
cell
count
lymphocyt
includ
b
cell
respect
peripher
blood
significantli
drop
ko
mice
compar
wt
control
signific
chang
matur
b
cell
bone
marrow
conclus
preliminari
result
suggest
delet
key
autophagi
regul
lepr
bone
marrow
nich
cell
caus
leukopenia
underli
mechan
current
investig
help
us
better
understand
role
autophagi
hematopoiesi
within
bm
microenviron
cathi
leemil
lori
gardner
jennif
rabe
susan
zelasko
courtney
jone
christoph
porter
background
immunolog
evas
one
hallmark
cancer
mechan
leukemia
evad
immun
system
incomplet
understood
lab
found
calcineurin
bcrabl
leukemia
cell
act
potent
mediat
immun
evas
leukemogenesi
essenti
subunit
calcineurin
knock
immun
compet
host
abl
suppress
leukemia
outgrowth
immunodefici
host
succumb
diseas
hypothes
bcrabl
activ
calcineurin
nfat
nuclear
factor
activ
cell
object
determin
bcrabl
role
activ
calcineurin
measur
nfat
activ
designmethod
cell
transduc
either
empti
vector
mig
bcrabl
cell
kept
cultur
expos
vari
dose
pma
ionomycin
order
stimul
calcineurin
activ
measur
via
analysi
nfat
known
downstream
effector
calcineurin
experi
measur
nfat
express
includ
western
blot
assess
protein
phosphoryl
real
time
pcr
assess
nfat
depend
transcript
nfat
report
assay
assess
transcript
activ
result
nfat
activ
increas
bcrabl
cell
compar
control
mig
cell
evidenc
increas
total
protein
well
activ
protein
increas
dose
pma
ionomycin
also
lead
higher
level
nfat
mig
bcrabl
cell
pronounc
bcrabl
popul
conclus
total
nfat
activ
nfat
protein
present
bcrabl
leukemia
cell
vs
control
suggest
bcrabl
activ
calcineurin
studi
ongo
determin
higher
level
protein
lead
increas
nfat
transcript
activ
mrna
bcrabl
leukemia
cell
compar
mig
increas
activ
may
play
role
abil
bcrabl
leukemia
cell
evad
immun
system
aspho
abstract
poster
background
von
willebrand
diseas
vwd
common
inherit
bleed
disord
character
incomplet
penetr
variabl
express
phenotyp
genet
character
amish
pedigre
autosom
domin
vwd
type
sequenc
analysi
vwf
reveal
heterozygos
missens
mutat
posit
c
individu
even
ident
genet
mutat
vwf
individu
show
great
variabl
bleed
tendenc
measur
quantifi
score
provid
bleed
assess
tool
bat
object
identifi
biolog
genet
variant
outsid
vwf
influenc
bleed
vwd
designmethod
whole
exom
sequenc
perform
member
famili
age
sex
match
carri
mutat
least
sever
bleed
sever
bleed
annovar
softwar
tool
use
function
annot
genet
variant
util
analyz
variant
predict
effect
protein
express
concurr
analyz
plasma
individu
use
somalog
proteom
technolog
quantifi
protein
potenti
associ
process
involv
bleed
ingenu
pathway
analysi
ipa
use
interpret
result
result
ipa
analysi
reveal
differenti
protein
express
within
sever
pathway
signific
includ
cellular
movement
pvalu
immun
cell
traffick
pvalu
hematolog
system
develop
function
pvalu
within
pathway
protein
involv
cell
adhes
ie
coagul
ie
plg
inflamm
ie
differenti
express
high
low
bleeder
analysi
whole
exom
sequenc
reveal
genet
variant
enrich
one
group
compar
interestingli
sever
variant
correl
pathway
identifi
proteom
data
includ
selplg
fgb
conclus
preliminari
analys
show
high
preval
gene
involv
inflamm
cell
adhes
hematolog
system
may
associ
bleed
variabl
within
amish
famili
work
focu
replic
variant
rest
member
famili
affect
unaffect
well
hundr
avail
unrel
case
vwd
background
inhibit
mertk
small
molecul
inhibitor
decreas
tumor
burden
prolong
surviv
acut
leukemia
cell
line
patientderiv
xenograft
model
howev
treatment
reduc
leukemia
peripher
blood
spleen
less
effect
clear
bone
marrow
leukem
blast
mertk
axl
ligand
poor
prognost
factor
aml
mediat
increas
resist
cytotox
chemotherapi
leukemia
cell
present
bone
marrow
stroma
object
determin
bone
marrow
stromal
cell
induc
resist
designmethod
acut
leukemia
cell
line
cultur
presenc
fibroblastlik
cell
line
bone
marrow
deriv
stromal
cell
bmdsc
wild
type
knockout
mice
axlfc
ad
cocultur
bind
deplet
induct
apoptosi
cell
death
determin
flow
cytometri
treatment
vehicl
express
mertk
relat
kinas
axl
determin
immunoblot
result
cocultur
cell
line
significantli
reduc
leukemia
cell
death
respons
treatment
nm
compar
leukemia
cell
alon
versu
p
protect
effect
dosedepend
reduc
titrat
axlfc
versu
p
similarli
bmdsc
wildtyp
mice
protect
leukemia
cell
induc
cell
death
effect
bmdsc
knockout
mice
versu
immunoblot
analysi
demonstr
increas
express
leukemia
cell
respons
cocultur
mertk
ligand
produc
fibroblastlik
cell
line
bmdsc
mediat
protect
leukemia
cell
cell
death
induc
mertk
inhibit
deplet
use
genet
knockout
mice
biolog
axlfc
strategi
decreas
resist
leukemia
cell
presenc
stroma
data
consist
mechan
increas
express
activ
andor
axl
promot
cell
surviv
resist
select
mertk
inhibit
combin
treatment
bone
marrow
mobil
agent
may
effect
therapeut
strategi
novo
nordisk
inc
plainsboro
new
jersey
unit
state
background
noonan
syndrom
ns
genet
condit
individu
involv
characterist
facial
featur
short
statur
congenit
heart
defect
skelet
anomali
development
delay
bleed
problem
hematologist
may
call
upon
evalu
children
ns
bleed
abnorm
particularli
sinc
mani
patient
may
undergo
multipl
surgeri
begin
earli
childhood
object
aim
systemat
review
identifi
specif
laboratori
find
bleed
disord
ns
inform
appropri
scope
diagnost
workup
designmethod
public
review
includ
trial
case
reportsseri
review
identifi
via
medlin
embas
scopu
ns
patient
includ
analysi
studi
presum
bleed
disord
bleed
phenotyp
describ
avail
patient
data
abstract
includ
demograph
bleed
symptom
lab
abnorm
bleed
score
specif
disord
report
result
studi
identifi
relev
data
ns
patient
nearli
half
male
report
bleed
report
bleed
data
bleed
report
bleed
laboratori
test
abnorm
specif
diagnosi
report
abnorm
laboratori
includ
prolong
pt
aptt
ptaptt
plateletrel
singl
factor
defici
vwd
platelet
disord
multipl
defici
overal
factor
xi
defici
common
follow
platelet
abnorm
factor
xii
factor
viii
factor
xixii
xiviii
common
combin
disord
conclus
result
support
import
identifi
bleed
disord
patient
ns
earli
childhood
particularli
preoper
wide
span
disord
frequent
presenc
multipl
disord
factor
defici
platelet
function
disord
vwd
suggest
screen
need
go
beyond
ptaptt
platelet
count
includ
assess
platelet
function
result
highlight
import
earli
consult
pediatr
hematologist
special
coagul
disord
need
rigor
document
extent
workup
accur
describ
type
disord
ruledout
background
receptor
hyaluron
acid
mediat
motil
rhamm
identifi
one
leukemia
associ
antigen
studi
rhamm
alon
associ
protein
promot
invas
inhibit
apoptosi
paediatr
acut
lymphoblast
leukemia
good
prognosi
wherea
acut
myeloid
leukemia
aml
lacuna
studi
rhamm
express
prognost
signific
pediatr
acut
leukemia
object
studi
express
rhamm
paediatr
acut
leukemia
prognost
signific
designmethod
paraffin
block
bone
marrow
trephin
biopsi
paediatr
acut
leukemia
process
immunohistochemistri
standard
autom
techniqu
primari
antibodi
use
abcam
usa
rel
proport
percentag
posit
stain
tumor
cell
quantifi
three
observ
blast
percentag
done
bone
marrow
aspir
taken
day
induct
assess
immedi
respons
percentag
rhamm
posit
cell
respons
induct
therapi
correl
clinic
follow
case
kaplanmei
plot
initi
rhamm
express
also
correl
result
aml
ratio
male
femal
ratio
mean
age
year
year
aml
express
rhamm
aml
express
blast
percentag
induct
therapi
relaps
prognosi
correl
show
statist
signific
neg
correl
type
leukemia
presenc
rhamm
posit
cell
initi
biopsi
correl
residu
diseas
relaps
bad
outcom
conclus
signific
neg
prognost
effect
rhamm
express
evid
acut
pediatr
leukemia
express
aml
henc
marker
mayb
includ
diagnost
panel
parent
patient
counsel
treatment
intensifi
better
prognosi
evolut
inhibitor
marker
promis
target
therapi
patient
warrant
research
kai
jacobson
clifford
takemoto
brandyn
lau
ruchika
goel
ricardo
velazquez
ramind
chadha
background
hospitalassoci
vte
havt
associ
increas
morbid
pauciti
prospect
valid
risk
stratif
tool
venou
thromboembol
vte
hospit
children
object
evalu
perform
electron
vte
risk
assess
pediatr
patient
designmethod
august
vte
screen
tool
incorpor
computer
admiss
order
set
patient
year
hospit
john
hopkin
children
center
nicu
patient
exclud
assess
mobil
vte
risk
factor
bleed
risk
requir
patient
year
age
prior
vte
histori
provid
concern
vte
patient
stratifi
risk
group
base
score
incorpor
age
immobl
risk
factor
pharmacolog
prophylaxi
recommend
patient
high
vte
risk
mechan
prophylaxi
moder
vte
risk
high
vte
risk
bleed
risk
prophylaxi
low
vte
risk
havt
defin
vte
diagnos
hour
hospit
admiss
vte
diagnos
within
day
hospit
discharg
patient
havt
identifi
code
chart
review
result
month
august
januari
total
patient
underw
electron
vte
risk
assess
provid
complianc
complet
screen
within
hour
admiss
identifi
havt
case
rate
per
admiss
ci
similar
rate
ci
observ
prior
implement
screen
tool
rate
havt
per
admiss
increas
vte
risk
low
risk
rate
ci
moder
risk
high
risk
ci
bleed
assess
month
period
rel
risk
patient
receiv
pharmacolog
prophylaxi
ci
bleed
ci
major
bleed
conclus
electron
vte
risk
assess
tool
identifi
patient
increas
risk
havt
howev
vte
rate
significantli
decreas
implement
screen
increas
bleed
associ
pharmacolog
prophylaxi
addit
studi
need
improv
risk
assess
prevent
strategi
trial
includ
younger
patient
older
patient
statist
signific
p
differ
rate
prior
year
age
group
respect
statist
signific
p
current
data
common
reason
low
enrol
rate
lack
open
therapeut
trial
statist
differ
group
factor
analyz
conclus
despit
initi
chp
nation
level
enrol
aya
patient
clinic
trial
recent
data
show
improv
caus
multifactori
primari
reason
found
institut
lack
open
clinic
trial
potenti
remedi
factor
need
priorit
nation
pediatr
medic
oncolog
commun
object
understand
role
cellular
phosphoryl
statu
influenc
mutat
splice
factor
splice
specif
relat
class
vs
class
iv
designmethod
studi
effect
splice
factor
mutat
splice
construct
minigen
consist
exon
cat
gene
atg
site
partial
intron
fuse
intron
region
upstream
exon
retain
intron
present
exon
transduc
cell
minigen
wildtyp
mutant
cell
treat
sodium
orthovanad
phorbol
myrist
acet
pma
inhibit
tyrosin
phosphatas
wherea
pma
promot
activ
protein
kinas
c
pathway
qpcr
use
determin
express
class
class
iv
express
result
site
identifi
nucleotid
sequenc
splice
intron
found
inhibit
tyrosin
phosphatas
activ
result
increas
intron
excis
pma
data
suggest
tyrosin
phosphoryl
import
intron
excis
exogen
express
show
decreas
intron
excis
suggest
mutat
inhibit
class
iv
transcript
format
background
prophylact
factor
replac
therapi
increasingli
util
prevent
bleed
complic
sever
hemophilia
increas
prophylaxi
util
may
lead
decreas
admiss
bleed
complic
may
alter
inhibitor
epidemiolog
public
joint
outcom
studi
jo
phase
random
control
trial
primari
prophylaxi
demonstr
prophylaxi
significantli
improv
joint
outcom
children
moder
sever
hemophilia
highimpact
natur
jo
offer
opportun
studi
epidemiolog
consequ
increas
prophylaxi
use
object
determin
differ
admiss
bleed
episod
inhibitor
bypass
therapi
surrog
marker
inhibitor
well
length
stay
lo
intens
care
icu
util
timefram
public
jo
includ
avoid
bia
relat
random
prophylaxi
activ
studi
period
data
remain
hospit
evalu
discharg
diagnos
defin
intern
classif
diseas
revis
clinic
modif
along
medic
charg
util
defin
bleed
episod
bypass
therapi
result
signific
trend
bleed
episod
bleed
diagnosi
use
factor
replac
bypass
therapi
overal
lo
shorten
day
day
p
icu
stay
decreas
admiss
p
postjo
era
conclus
studi
demonstr
decreas
overal
hospit
lo
icu
util
postjo
era
increas
bypass
therapi
util
suggest
incid
inhibitor
format
remain
stabl
find
directli
attribut
chang
practic
result
public
jo
sinc
hemophilia
sever
util
prophylaxi
directli
determin
phi
howev
suggest
increas
util
primari
prophylaxi
may
decreas
inpati
util
without
alter
inhibitor
epidemiolog
object
describ
use
cripsr
cluster
regularli
interspac
short
palindrom
repeat
technolog
creat
mutant
epigenet
regul
chromodomain
helicas
dnabind
protein
zebrafish
known
interact
spliceosom
studi
determin
vivo
import
interplay
hematopoiesi
designmethod
creat
doublestrand
break
gene
zebrafish
vitro
transcrib
guid
rna
specif
protein
microinject
fertil
zebrafish
embryo
inject
founder
fish
mate
gener
carrier
progeni
screen
presenc
mutat
perform
polymeras
chain
reaction
pcr
amplifi
target
region
follow
endonucleas
assay
detect
indel
exact
mutat
identifi
clone
sanger
sequenc
follow
bioinformat
analysi
result
screen
fish
found
carri
mutat
mutat
mutat
predict
disrupt
protein
function
introduct
prematur
stop
codon
transheterozyg
mutant
fish
incross
defect
overal
morpholog
surviv
note
line
previou
observ
use
morpholinoantisens
oligonucleotid
knockdown
homozyg
mutant
grow
character
hematopoiet
defect
interact
spliceosom
factor
conclus
use
technolog
zebrafish
effect
way
creat
genespecif
mutat
mdsaml
factor
determin
vivo
contribut
diseas
understand
pathophysiolog
interact
spliceosom
mutat
epigenet
factor
help
identifi
prognost
factor
potenti
guid
treatment
md
aml
mild
rest
sever
diseas
famili
histori
posit
patient
present
month
age
sever
hemophilia
aptt
prolong
patient
mean
valu
minut
sever
diseas
famili
histori
signific
relat
p
relat
sever
diseas
age
diagnosi
signific
compromis
p
ie
critic
line
post
circumcis
bleed
observ
promin
primari
symptom
follow
bruis
epistaxi
respect
life
threaten
bleed
report
develop
hemarthrosi
patient
aptt
done
circumcis
patient
demand
factor
replac
therapi
primari
prophylaxi
conclus
basi
earli
present
famili
histori
predict
sever
diseas
perform
ptaptt
circumcis
children
cost
effect
screen
investig
earli
diagnosi
adequ
time
prophylaxi
prevent
earli
late
complic
background
continu
emerg
cellular
therapi
treat
precursorb
cell
evolv
includ
patientderiv
cell
genet
modifi
express
chimer
antigen
receptor
car
bind
lymphoid
leukem
blast
report
use
express
cell
line
chromium
releas
fac
assay
howev
use
patient
deriv
blast
experi
elus
object
identifi
rapid
assay
assess
cytotox
develop
futur
cart
cell
designmethod
cytotox
assay
set
popul
effector
target
cell
effector
cell
popul
cell
collect
pediatr
preb
patient
healthi
donor
cart
cell
manufactur
use
cell
healthi
donor
transduc
retrovir
vector
contain
target
cell
popul
cell
line
bone
marrow
patient
preb
cell
healthi
donor
effector
target
cell
cocultur
hour
increas
effector
target
e
ratio
cocultur
stain
identifi
dead
cell
analyz
fac
percentag
live
target
cell
lc
assay
averag
percent
differ
kill
calcul
use
averag
result
cell
cocultur
untransduc
effector
popul
percent
differ
kill
popul
cart
cell
percent
differ
kill
cell
target
cell
healthi
donor
show
differ
percent
kill
cultur
untransduc
effector
cell
popul
cart
cell
leukem
blast
bone
marrow
percent
differ
kill
cultur
untransduc
effector
cell
e
compar
percent
differ
kill
cart
cell
conclus
amplifi
kill
patient
leukem
blast
cart
cell
compar
untransduc
cell
plan
continu
use
novel
assay
specif
measur
cytotox
ip
deriv
cart
cell
blast
collect
pediatr
patient
complet
decis
regret
scale
tool
score
least
regret
regret
complet
decis
make
compon
pediatr
famili
satisfact
intens
care
unit
pfsicu
scale
tool
score
scale
least
satisfi
satisfi
result
receiv
admiss
discharg
questionnair
parent
patient
patient
rang
age
mean
year
patient
enrol
patient
n
hematolog
cancer
n
solid
tumor
parent
identifi
import
decis
made
child
involv
medic
use
radiat
use
medic
devic
surgic
procedur
gener
care
plan
n
parent
report
receiv
help
commun
doctor
decis
parent
identifi
bedsid
nurs
n
resid
n
fellow
n
social
worker
n
chaplain
n
doctor
subspecialti
n
help
decis
make
process
averag
decis
regret
score
rang
averag
pfsicu
dm
score
rang
live
ill
experi
first
month
accept
engag
novel
indepth
convers
primari
pediatr
oncologist
day
talk
period
prefer
topic
goal
designmethod
conduct
semistructur
interview
children
age
year
parent
allag
children
nonrelaps
cancer
undergo
treatment
week
month
sampl
interview
constant
compar
qualit
analysi
inform
ground
theori
result
five
adolesc
parent
particip
interview
five
particip
children
particip
solid
tumor
brain
tumor
hematolog
malign
mean
treatment
durat
week
emerg
theme
reflect
combin
rel
normalci
earli
treatment
week
still
fight
new
normal
compos
cancer
care
new
relationship
alter
daili
live
particip
speak
emerg
wood
get
sea
leg
earli
treatment
period
abl
engag
care
differ
diagnosi
frequent
one
parent
take
charg
ill
child
care
maintain
work
home
life
role
divis
lead
differ
inform
need
member
famili
overal
parent
endors
adolesc
though
adolesc
endors
desir
discuss
futur
particip
suggest
could
serv
reflect
progress
consolid
ill
understand
creat
share
understand
famili
member
differ
role
ensur
current
treatment
path
still
right
manag
transit
hospitalbas
homebas
care
result
defici
fibrinogen
fv
fvii
fx
fxiii
diagnos
pediatr
patient
male
femal
account
children
inherit
coagul
factor
defici
hypofibrinogenemia
fv
defici
commonest
disord
diagnos
patient
respect
age
rang
day
year
consanguin
marriag
found
case
clinic
spectrum
vari
mild
mucocutan
bleed
seriou
sightthreaten
intraocular
hemorrhag
neonat
afibrinogenemia
initi
present
intracrani
hemorrhag
occur
case
two
patient
one
fv
defici
anoth
fxiii
defici
suffer
global
development
delay
due
sever
intracrani
hemorrhag
earli
infanc
regard
manag
patient
sever
fv
defici
one
sever
fxiii
fresh
frozen
plasma
ffp
prophylaxi
patient
receiv
ondemand
therapi
conclus
children
rbd
constitut
almost
one
tenth
case
hereditari
coagul
factor
defici
centr
uniqu
featur
term
sever
clinic
profil
need
prophylaxi
earli
life
recommend
establish
nationalregion
registri
rbd
collabor
centr
serv
identifi
epidemiolog
clinic
present
genotypephenotyp
correl
therapeut
option
rare
yet
signific
disord
part
world
also
retrospect
review
data
pediatr
oncolog
patient
undergon
pet
scan
institut
identifi
featur
like
associ
bat
uptak
designmethod
propranolol
mg
mgkg
given
one
hour
prior
fdg
inject
vital
sign
blood
glucos
measur
symptom
assess
perform
scan
imag
review
blind
radiologist
chart
retrospect
review
addit
patient
assess
whether
gender
age
bodi
mass
index
bmi
season
year
predict
fdg
uptak
bat
result
nine
patient
receiv
propranolol
median
age
year
rang
clinic
signific
chang
observ
blood
pressur
heart
rate
serum
glucos
follow
propranolol
administr
patient
observ
subject
report
advers
event
four
patient
previou
uptak
bat
none
follow
propranolol
retrospect
review
total
patient
median
age
year
rang
bat
uptak
identifi
patient
multivari
analysi
lower
bmi
factor
associ
bat
uptak
p
conclus
propranolol
conveni
safe
fast
pediatr
oncolog
patient
undergo
pet
scan
effect
elimin
bat
uptak
patient
find
previou
scan
lower
bmi
import
factor
predict
bat
uptak
futur
studi
could
target
patient
low
bmi
compar
efficaci
propranolol
drug
like
fentanyl
use
reduc
bat
uptak
correct
multipl
test
darc
snp
associ
low
absolut
phagocyt
count
apc
p
p
respect
hospit
due
neutropenia
p
also
observ
associ
among
upstream
darc
variant
chemotherapi
cessat
due
neutropenia
p
apc
p
snp
locu
associ
hospit
due
infect
p
hospit
due
infect
neutropenia
p
p
p
studi
identifi
first
time
loci
modul
wbc
neutrophil
count
may
play
role
onset
chemotherapi
complic
may
thu
serv
marker
adjust
followup
treatment
childhood
biomark
lab
valu
analyz
unpair
ttest
compar
pre
post
treatment
determin
differ
biomark
concentr
treatment
result
trefoil
factor
express
higher
concentr
post
cisplatin
treatment
compar
pretreat
p
signific
found
biomark
addit
serum
phosphoru
level
decreas
post
cisplatin
treatment
p
conclus
member
trefoil
factor
peptid
famili
secret
epitheliod
cell
urinari
tract
proxim
distal
collect
duct
studi
children
receiv
cisplatin
signific
chang
concentr
post
cisplatin
treatment
serum
creatinin
chang
post
cisplatin
treatment
suggest
may
sensit
biomark
acut
kidney
injuri
secondari
cisplatin
background
tobacco
use
increas
risk
lung
mani
tobacco
relat
cancer
higher
risk
confer
longer
durat
intens
tobacco
use
tobacco
use
associ
advers
health
outcom
cardiovascular
diseas
stroke
chronic
obstruct
pulmonari
diseas
decreas
physic
fit
may
result
shorten
life
span
smoker
initi
tobacco
use
prior
age
year
million
adult
current
smoke
us
rate
cigarett
smoke
remain
higher
nation
averag
tennesse
start
use
tobacco
master
settlement
fund
tennesse
depart
health
initi
goal
integr
tobacco
cessat
intervent
commun
primari
care
clinic
howev
sever
barrier
aros
success
promot
integr
commun
tobacco
cessat
object
object
studi
identifi
common
barrier
integr
success
commun
practicebas
tobacco
prevent
cessat
intervent
develop
action
plan
facilit
success
program
establish
designmethod
semistructur
key
inform
interview
conduct
seven
tennesse
counti
depart
health
director
assess
facilit
barrier
implement
evidencebas
tobacco
cessat
intervent
within
commun
primari
care
practic
facilit
barrier
organ
theme
includ
intraperson
factor
institut
factor
commun
factor
defin
socioecolog
model
barrier
elucid
includ
time
constraint
document
challeng
organiz
cultur
resourc
avail
alloc
leadership
approv
lack
partnership
barrier
identifi
studi
highlight
need
organ
action
plan
facilit
integr
tobacco
cessat
intervent
action
plan
develop
includ
effect
program
champion
util
local
data
adequ
staff
resourc
commun
educ
strateg
plan
key
stakehold
conclus
leverag
strategi
offset
common
barrier
integr
tobacco
cessat
intervent
essenti
establish
practic
evidencebas
tobacco
cessat
prevent
program
clinic
practic
background
despit
major
advanc
pediatr
leukemia
therapi
toxic
still
concern
morbid
chemotherapi
regimen
detriment
advanc
genom
research
well
precis
medicin
help
identifi
specif
mutat
may
suscept
target
therapi
patient
leukemia
overal
use
target
drug
therapi
rise
pediatr
oncolog
field
object
complement
genom
analysi
leukemia
patient
laboratori
develop
drug
sensit
resist
screen
assay
would
provid
clinic
relev
drug
respons
data
patient
leukemia
cell
designmethod
part
lab
develop
assay
first
prepar
predos
librari
plate
clinic
activ
drug
cell
ad
plate
treat
hour
time
cell
viabil
determin
preliminari
work
laboratori
use
librari
anticanc
target
agent
test
aml
cell
line
cell
line
biolog
replic
perform
cell
line
drug
respons
data
form
area
curv
auc
calcul
hierarch
cluster
perform
determin
similar
respons
cell
line
drug
result
identifi
sever
cell
line
show
hypersensit
specif
drug
among
aml
cell
line
show
sensit
three
fgfr
inhibitor
includ
ponatinib
previous
report
valid
screen
result
done
use
drug
dose
respons
assay
conclus
test
includ
expans
drug
librari
applic
ex
vivo
patient
sampl
result
studi
lead
establish
drug
sensit
resist
assay
could
provid
specif
engin
therapi
patient
form
precis
therapi
would
lead
diminish
toxic
system
therapi
well
allow
increas
cure
rate
background
acut
myeloid
leukemia
aml
compris
pediatr
cancer
report
event
free
surviv
ef
approxim
overal
surviv
os
follow
intens
multiag
chemotherapi
anthracyclin
cornerston
treatment
aml
howev
associ
acut
late
cardiac
toxic
nearli
pediatr
patient
receiv
anthracyclin
may
develop
congest
heart
failur
chf
higher
incid
cumul
dose
exceed
importantli
current
aml
treatment
children
commonli
includ
anthracyclin
dose
excess
known
caus
chf
object
children
hospit
wisconsin
chw
previous
adopt
standard
clinic
practic
administ
dexrazoxan
prior
nonliposom
anthracyclin
begin
report
differ
cardiac
treatment
outcom
children
young
adult
aml
treat
without
dexrazoxan
chw
designmethod
retrospect
chart
review
children
age
year
receiv
chemotherapi
aml
chw
januari
decemb
perform
data
collect
electron
medic
record
includ
variabl
anthracyclin
administr
echocardiogram
measur
relaps
statu
statist
analys
conduct
use
sa
statist
softwar
version
two
side
p
valu
consid
statist
signific
data
express
frequenc
count
percentag
categor
variabl
result
total
patient
median
age
includ
receiv
dexrazoxan
statist
differ
ef
os
significantli
higher
eject
fraction
lower
shorten
fraction
higher
left
ventricular
systol
volum
patient
receiv
dexrazoxan
summari
util
dexrazoxan
prior
anthracyclin
chemotherapi
pediatr
patient
aml
demonstr
signific
differ
either
ef
os
rel
institut
histor
control
appear
improv
cardiac
function
promis
studi
patient
popul
need
confirm
find
success
identif
one
medic
error
reach
patient
prescript
verifi
sinc
prescript
bottl
usual
obtain
visit
verif
actual
bottl
requir
new
workflow
addit
clinic
visit
upload
pictur
via
patient
portal
involv
nurs
review
oral
chemotherapi
identifi
prescript
error
also
highlight
issu
within
aspect
patient
care
includ
need
patientfamili
educ
inconsist
document
treatment
plan
inclus
nurs
review
manag
oral
chemotherapi
potenti
improv
safeti
outcom
patient
background
evidencebas
guidelin
exist
revaccin
childhood
cancer
survivor
follow
chemotherapi
object
prospect
determin
respons
rate
follow
revaccin
ageappropri
immun
cohort
patient
designmethod
conduct
phase
ii
singl
center
studi
patient
remiss
follow
chemotherapi
exclud
receiv
autolog
allogen
hsct
immun
recoveri
defin
absolut
cell
prolif
respons
pha
lower
limit
normal
igg
without
supplement
ivig
respons
vaccin
defin
seroconvers
posit
titer
result
seventyf
patient
year
median
year
male
enrol
median
month
rang
month
postchemotherapi
patient
sr
hr
aml
n
hodgkin
lymphoma
n
nonhodgkin
lymphoma
n
cn
tumor
n
retinoblastoma
n
germ
cell
tumor
n
embryon
rhabdomyosarcoma
n
wilm
tumor
n
thirtysix
patient
complet
plan
vaccin
followup
serolog
test
complet
least
complet
less
reason
incomplet
particip
includ
relaps
poor
complianc
death
time
start
vaccin
rang
month
median
month
baselin
protect
titer
absent
patient
polio
tetanu
diphtheria
mmr
varicella
hepat
b
haemophilu
influenza
b
meningococc
c
w
pneumococc
pertussi
seroposit
tetanu
diphtheria
polio
haemophilu
influenza
b
hepat
b
pneumococc
complet
trial
rate
seroposit
remain
pathogen
pertussi
meningococc
c
w
measl
mump
rubella
varicella
primari
diseas
type
predict
respons
conclus
studi
confirm
poor
residu
immun
mani
vaccin
prevent
diseas
childhood
survivor
cancer
revaccin
ageappropri
vaccin
schedul
may
provid
protect
level
mani
pathogen
howev
patient
continu
risk
pertussi
meningococc
c
w
mmr
varicella
stephen
nelson
jennif
lee
michel
allard
bruce
bostrom
background
children
oncolog
group
cog
play
major
role
improv
surviv
children
cancer
diagnos
patient
treat
pediatr
oncolog
center
much
better
outcom
children
treat
standard
protocol
better
project
everi
child
protocol
recent
launch
cog
registri
elig
screen
biolog
outcom
studi
requir
enrol
order
particip
cog
treatment
studi
requir
may
lead
even
fewer
children
color
abl
benefit
cog
treatment
protocol
object
goal
studi
quantifi
number
refus
enrol
cog
registri
race
ethnic
designmethod
review
databas
oncolog
patient
children
hospit
clinic
minnesota
find
patient
offer
particip
cog
studi
april
decemb
data
collect
race
ethnic
well
refus
enrol
racial
differ
evalu
use
fisher
exact
probabl
test
result
total
patient
offer
enrol
inform
raceethn
avail
children
famili
refus
enrol
white
patient
refus
enrol
refus
rate
much
higher
patient
color
p
asian
patient
highest
refus
rate
p
follow
black
patient
p
biraci
nativ
american
hispan
refus
rate
also
higher
refus
rate
biraci
patient
reach
statist
signific
p
conclus
refus
rate
enrol
significantli
higher
patient
color
fact
alon
would
great
concern
immedi
impact
access
care
outcom
requir
enrol
like
lead
even
fewer
children
color
benefit
cog
treatment
protocol
would
encourag
cog
revisit
requir
enrol
project
everi
child
protocol
like
exacerb
alreadi
inferior
outcom
patient
color
randomli
assign
receiv
first
hdmtx
infus
outpati
inpati
second
infus
altern
set
pediatr
home
health
compani
provid
hdmtx
infus
oversight
support
need
skill
nurs
care
data
includ
bill
charg
pocket
expens
mtx
level
time
clearanc
chang
creatinin
antiemet
usag
emet
episod
patient
serv
control
matchedpair
analysi
comparison
outpati
subject
track
emesi
urin
ph
antiemet
usag
standard
form
result
six
outpati
inpati
infus
success
complet
compar
outpati
inpati
hdmtx
infus
patient
signific
reduct
pocket
patient
expens
median
rang
singl
infus
vs
p
billabl
care
charg
vs
p
safeti
measur
similar
outpati
inpati
infus
includ
time
mtx
clearanc
vs
p
chang
serum
creatinin
start
hdmtx
infus
clearanc
vs
p
number
emet
episod
vs
p
wherea
number
emet
episod
similar
signific
decreas
number
dose
antiemet
outpati
set
vs
p
feasibl
studi
outpati
hdmtx
administr
safe
cost
effect
pediatr
patient
blineag
toler
evidenc
signific
decreas
antiemet
use
object
describ
cipn
balanc
deficit
longitudin
children
follow
treatment
noncn
cancer
impact
diagnosi
chemotherapi
type
cipn
also
investig
designmethod
children
n
mean
age
year
male
treat
noncn
cancer
assess
pediatr
modifi
total
neuropathi
score
pedmtn
balanc
bruininksoseretski
test
month
treatment
base
diagnosi
month
complet
chemotherapi
treatment
categor
neurotox
drug
use
vincristin
v
v
intrathec
methotrex
vm
v
etoposid
result
pedmtn
score
decreas
time
entir
group
initi
mo
mo
f
p
effect
size
adjust
age
sex
compar
n
children
solid
tumor
ost
n
lymphoma
n
higher
pedmtn
score
treatment
lymphoma
ost
f
p
posttreat
lymphoma
ost
higher
pedsmtn
score
lymphoma
ost
f
p
children
treat
n
compar
v
n
vm
n
highest
pedmtn
score
treatment
v
vm
month
followup
time
period
balanc
score
improv
initi
month
month
f
p
effect
size
never
popul
norm
neither
diagnosi
treatment
associ
balanc
recoveri
month
conclus
mani
children
experi
cipn
cancer
treatment
recov
month
posttreat
treat
vincristin
etoposid
may
longerterm
nerv
dysfunct
group
improv
balanc
time
yet
none
achiev
balanc
control
compar
popul
norm
nathan
hall
terri
flatt
alan
gami
gerald
wood
shannon
carpent
gari
doolittl
background
use
telemedicin
pediatr
hematolog
oncolog
popul
greatli
underutil
despit
technolog
advanc
made
telemedicin
visit
effect
inperson
visit
telemedicin
resourc
abil
lower
health
care
cost
bridg
geograph
dispar
mani
patient
famili
face
child
requir
subspecialti
care
howev
willing
util
telemedicin
come
physician
famili
object
evalu
cost
satisfact
patient
famili
could
use
telemedicin
deliv
qualiti
care
patient
hematolog
oncolog
diagnos
live
underserv
area
designmethod
crosssect
studi
two
subject
group
age
year
old
hematolog
oncolog
diagnosi
live
mile
children
merci
hospit
kansa
citi
missouri
evalu
studi
experiment
group
consist
subject
follow
outreach
clinic
telemedicin
capabl
control
group
subject
outreach
clinic
option
must
travel
kansa
citi
total
patient
per
group
evalu
experiment
group
answer
cost
analysi
telemedicin
satisfact
questionnair
follow
telemedicin
visit
wherea
control
group
answer
cost
analysi
util
telemedicin
survey
result
studi
result
preliminari
anticip
closur
februari
point
studi
experiment
group
note
save
hundr
dollar
outofpocket
expens
famili
abl
miss
less
school
work
major
thought
telemedicin
visit
good
inperson
visit
major
would
will
util
telemedicin
subsequ
visit
comparison
control
group
addit
major
control
group
would
will
util
telemedicin
believ
would
allow
famili
save
money
miss
less
school
work
conclus
knowledg
first
costanalysi
satisfact
survey
evalu
use
telemedicin
pediatr
hematolog
oncolog
popul
preliminari
result
favor
futur
research
invest
telemedicin
care
subspeci
patient
popul
underserv
commun
ammonia
expect
product
erwinia
metabol
symptomat
hyperammonemia
previous
report
rare
occurr
yet
find
indic
increas
incid
addit
data
demonstr
correl
ammonia
asparaginas
activ
level
follow
erwinia
dose
furthermor
nearli
asparaginas
activ
level
therapeut
despit
dose
reduct
case
thu
seri
provid
suffici
evid
investig
determin
patient
requir
intervent
prevent
symptomat
hyperammonemia
patient
may
ammonia
level
use
asparaginas
activ
surrog
patient
may
achiev
equival
efficaci
abridg
dose
background
expand
access
also
known
compassion
use
program
provid
opportun
select
patient
access
investig
drug
biolog
medic
devic
outsid
clinic
trial
success
expand
access
applic
requir
treat
physician
obtain
agreement
pharmaceut
compani
develop
investig
agent
author
food
drug
administr
fda
author
hospit
institut
review
board
poorli
understood
difficult
execut
step
especi
pediatr
cancer
case
present
barrier
obtain
access
investig
drug
via
expand
access
program
object
creat
intervent
help
pediatr
provid
make
inform
decis
regard
expand
access
base
analysi
avail
resourc
assess
pediatr
oncologist
experi
challeng
expand
access
applic
designmethod
analysi
current
regulatori
framework
review
literatur
focus
pediatr
oncolog
expand
access
process
physician
experi
survey
develop
assess
pediatr
oncologist
experi
knowledg
expand
access
applic
process
fda
process
simplifi
approv
applic
form
expand
access
current
bill
consider
us
congress
reform
expand
access
program
howev
remain
lack
data
physician
experi
barrier
affect
use
expand
access
program
addit
pauciti
support
physician
guid
process
final
data
number
outcom
expand
access
applic
pediatr
oncolog
patient
distribut
survey
pediatr
oncologist
identifi
experi
challeng
uncov
gap
knowledg
expand
access
approv
data
present
aspho
annual
meet
conclus
limit
resourc
guid
pediatr
oncologist
seek
expand
access
investig
agent
educ
resourc
provid
patient
help
navig
process
need
background
mucos
signific
caus
morbid
treatment
delay
pediatr
patient
receiv
chemotherapi
evid
suggest
role
cryotherapi
adult
patient
mucos
prevent
fulli
studi
prevent
treatment
children
studi
feasibl
cryotherapi
pediatr
cancer
patient
designmethod
particip
patient
activ
chemotherapi
year
old
sampl
ice
chip
ice
water
three
ice
pop
flavor
form
ice
pellet
full
ice
pop
offer
particip
prefer
determin
survey
standard
tast
test
protocol
particip
use
prefer
prepar
sixti
minut
minut
face
scale
use
measur
oral
pain
complet
particip
parent
patient
year
older
complet
survey
regard
challeng
cryotherapi
estim
total
time
cryotherapi
use
result
twentyfour
patient
invit
particip
nine
consent
common
reason
nonparticip
includ
feel
ill
day
invit
reluct
spend
addit
time
clinic
particip
patient
n
male
n
femal
age
rang
year
mean
fiftyf
percent
n
particip
prefer
flavor
ice
prepar
patient
util
cryotherapi
rang
minut
median
time
minut
trend
toward
longer
use
older
patient
mean
pain
score
minut
minut
common
challeng
includ
patient
distract
discomfort
due
temperatur
among
pediatr
cancer
patient
cryotherapi
appear
welltoler
short
period
time
show
greatest
feasibl
older
children
adolesc
like
show
benefit
mitig
mucos
caus
agent
rel
short
halfliv
predict
peak
concentr
addit
children
caregiv
may
amen
cryotherapi
attempt
possibl
therapeut
purpos
rather
feasibl
studi
data
collect
ongo
order
elucid
specif
subgroup
feasibl
chen
journal
oncolog
pharmaci
practic
background
past
sever
decad
signific
advanc
manag
pediatr
malign
result
increas
surviv
rate
averag
life
expect
heighten
awar
previous
underappreci
longterm
treatmentrel
outcom
late
effect
endocrin
system
particularli
growth
hormon
axi
particularli
vulner
deleteri
effect
current
treatment
modal
presenc
absenc
growth
hormon
defici
attain
final
adult
height
becom
princip
measur
interest
current
medic
literatur
focus
heightrel
late
effect
well
document
cranial
craniospin
irradi
neg
impact
height
concurr
chemotherapi
may
intensifi
growth
deter
effect
radiat
howev
effect
chemotherapi
alon
growth
hormon
axi
final
adult
height
absenc
confound
variabl
radiat
exposur
andor
presenc
cn
tumor
less
well
understood
object
investig
effect
chemotherapi
growth
veloc
pediatr
cancer
survivor
variou
stage
therapi
designmethod
studi
retrospect
chart
review
patient
oncolog
longterm
followup
clinic
registri
nationwid
children
hospit
receiv
chemotherapi
without
radiat
primari
brain
tumor
diagnosi
result
first
year
therapi
percentag
patient
growth
veloc
third
percentil
specif
age
gender
respect
associ
specif
cancer
type
chemotherapeut
agent
delay
growth
veloc
discuss
conclus
chemotherapi
alon
lead
delay
growth
veloc
pediatr
cancer
survivor
pediatr
oncologist
gener
practition
low
threshold
workup
includ
bone
age
radiograph
growth
hormon
level
placement
endocrinolog
referr
growth
delay
note
patient
popul
background
phenotyp
associ
pten
hamartoma
syndrom
pht
pediatr
patient
variabl
may
includ
macrocephali
one
featur
pht
mucocutan
find
pathognomon
pht
includ
oral
papillomatosi
gingiva
though
may
appear
adolesc
earli
adulthood
often
dentist
first
refer
patient
evalu
base
oral
papillomatosi
case
report
show
adult
refer
dentist
pten
evalu
individu
pten
gene
mutat
risk
sever
health
problem
includ
vascular
anomali
malign
breast
thyroid
endometrium
follow
appropri
specialist
recommend
surveil
protocol
earli
identif
atrisk
individu
utmost
import
prevent
treat
symptom
object
determin
gingiv
hyperplasia
gingiv
phenotyp
cohort
five
pediatr
patient
pht
follow
vascular
anomali
clinic
texa
children
cancer
center
designmethod
five
pediatr
patient
confirm
pten
molecular
diagnos
follow
vascular
anomali
clinic
texa
children
cancer
center
note
gingiv
hyperplasia
phenotyp
patient
either
refer
dental
divis
texa
children
hospit
evalu
record
primari
dentist
request
review
result
five
five
pediatr
patient
cohort
patient
confirm
pten
molecular
diagnosi
gingiv
hyperplasia
dental
record
confirm
moder
sever
gingiv
three
patient
two
dental
record
review
pend
conclus
gingiv
hyperplasia
gingiv
may
earli
indic
oral
find
associ
pht
pediatr
clinic
provid
includ
dentist
see
patient
macrocephali
gingiv
hyperplasia
gingiv
consid
referr
pht
evalu
may
also
indic
aid
identifi
atrisk
rel
may
young
yet
develop
papillomatosi
pediatr
patient
confirm
pht
refer
follow
dentist
gingiv
hyperplasia
gingiv
surveil
treatment
background
mani
survivor
childhood
acut
lymphoblast
leukemia
exhibit
deficit
neurocognit
function
follow
treatment
despit
gener
uniform
treatment
protocol
individu
neurocognit
outcom
predict
one
potenti
genet
risk
factor
neurocognit
late
effect
apolipoprotein
apo
allel
allel
strongli
associ
increas
risk
dementia
also
implic
risk
factor
cognit
deficit
follow
variou
neurolog
stressor
central
nervou
system
cn
direct
chemotherapi
util
childhood
treatment
may
consid
similar
insult
brain
object
evalu
associ
apo
genotyp
neuropsycholog
function
follow
treatment
childhood
designmethod
particip
survivor
childhood
treat
chemotherapi
current
year
age
routin
clinic
visit
blood
obtain
apo
genotyp
particip
complet
brief
neuropsycholog
assess
batteri
evalu
attent
process
speed
memori
execut
function
analysi
covari
ancova
multipl
analysi
covari
mancova
use
detect
signific
differ
neurocognit
perform
variabl
group
defin
apo
statu
control
age
gender
educ
socioeconom
statu
result
fiftyseven
patient
enrol
male
caucasian
mean
age
year
averag
age
time
diagnosi
year
averag
time
complet
treatment
year
fifteen
particip
found
carri
apo
allel
preliminari
result
indic
pediatr
survivor
carri
apo
allel
signific
differ
attent
process
speed
memori
execut
function
compar
noncarri
allel
p
previou
studi
effect
apo
genotyp
neurocognit
outcom
children
mix
pilot
sampl
found
signific
differ
neurocognit
function
carrier
noncarri
apo
allel
larger
sampl
size
need
evalu
subtl
neurocognit
differ
two
group
thu
enrol
ongo
longitudin
followup
requir
investig
whether
carrier
statu
influenc
neurocognit
outcom
survivor
pediatr
adulthood
blackman
dev
med
child
neurol
background
babi
hug
clinic
trial
hydroxyurea
infant
young
children
sickl
cell
diseas
scd
establish
safeti
clinic
benefit
hydroxyurea
therapi
age
group
studi
establish
howev
escal
maximum
toler
dose
mtd
could
safe
effect
accomplish
age
group
object
sought
determin
safeti
effect
doseescal
hydroxyurea
therapi
children
scd
age
two
year
designmethod
conduct
retrospect
chart
review
children
hbss
hb
thalassemia
age
two
year
start
hydroxyurea
therapi
texa
children
hematolog
center
determin
laboratori
respons
doseescal
therapi
well
clinic
laboratori
advers
event
associ
hydroxyurea
therapi
result
identifi
patient
rang
month
age
mean
median
month
initi
hydroxyurea
therapi
studi
period
mtd
reach
patient
studi
period
remaind
dose
escal
reach
mtd
mean
median
mtd
mgkg
mgkg
respect
mtd
dose
correl
strongli
baselin
absolut
reticulocyt
count
arc
absolut
neutrophil
count
anc
less
baselin
creatinin
bodi
mass
index
patient
signific
increas
hemoglobin
concentr
hbf
declin
arc
anc
magnitud
increas
hb
hbf
greater
seen
babi
hug
cohort
hydroxyurea
clinic
signific
advers
event
attribut
exclus
hydroxyurea
patientmonth
therapi
six
episod
neutropenia
nine
reticulocytopenia
four
thrombocytopenia
associ
intercurr
ill
selflimit
conclus
hydroxyurea
therapi
dose
escal
mtd
appear
safe
infant
young
children
standard
clinic
set
result
signific
increas
hemoglobin
concentr
hbf
seen
fix
dose
babi
hug
studi
background
cardiopulmonari
renal
complic
major
caus
morbid
mortal
sickl
cell
anemia
sca
recent
observ
sca
character
uniqu
cardiomyopathi
featur
restrict
physiolog
diastol
dysfunct
disproportion
left
atrial
la
enlarg
normal
systol
function
anemiarel
hyperdynam
state
ventricular
enlarg
restrict
physiolog
could
lead
secondari
elev
tricuspid
regurgit
jet
veloc
trv
exercis
intoler
independ
pulmonari
arteri
hypertens
albuminuria
earli
manifest
sickl
nephropathi
albuminuria
correl
echocardiographyestim
pulmonari
hypertens
use
trv
surrog
measur
whether
sickl
cardiomyopathi
correl
nephropathi
unknown
object
assess
relationship
sickl
cardiomyopathi
albuminuria
sca
designmethod
echocardiogram
perform
individu
sca
ss
particip
clinic
trial
losartan
sickl
nephropathi
analyz
baselin
prelosartan
result
correl
cardiac
phenotyp
urin
aspho
abstract
albumintocreatinin
ratio
uacr
walk
distanc
hematolog
marker
albuminuria
defin
uacr
mgg
result
thirtysix
sca
patient
includ
mean
age
femal
fifteen
normal
uacr
mgg
patient
albuminuria
uacr
mgg
gdl
p
howev
differ
trv
lv
mass
lv
diamet
reticulocyt
count
group
correl
significantli
diastol
measur
ea
septal
ea
p
p
respect
patient
albuminuria
significantli
shorter
vs
ft
p
restrict
physiolog
sickl
cardiomyopathi
irrespect
elev
trv
associ
albuminuria
marker
sickl
nephropathi
common
mechan
may
underli
complic
albuminuria
studi
predictor
cardiomyopathi
sca
background
vitamin
signific
topic
interest
patient
acut
lymphoblast
leukemia
particularli
longterm
survivor
shown
decreas
bone
densiti
howev
lack
investig
vitamin
level
diagnosi
treatment
leukemia
object
primari
aim
singl
institut
prospect
pilot
studi
evalu
vitamin
level
time
diagnosi
patient
closest
age
sibl
secondari
aim
determin
efficaci
vitamin
supplement
increas
serum
level
vitamin
patient
obtain
patient
match
sibl
control
diagnosi
addit
blood
drawn
patient
month
interv
total
blood
draw
patient
level
less
given
vitamin
supplement
per
institut
medicin
recommend
studi
includ
patient
newli
diagnos
sibl
control
averag
age
respect
signific
differ
vitamin
level
patient
sibl
diagnosi
p
diagnosi
patient
suffici
insuffici
defici
serum
vitamin
level
decreas
vitamin
level
diagnosi
second
blood
draw
p
continu
differ
diagnosi
vitamin
level
p
mainten
latter
higher
patient
get
supplement
second
vitamin
serum
level
lower
patient
compar
patient
without
supplement
conclus
exploratori
pilot
studi
suggest
treatment
associ
signific
decreas
vitamin
level
even
face
supplement
diagnosi
leukemia
appear
effect
vitamin
level
given
find
import
perform
larger
multiinstitut
studi
evalu
level
vitamin
treatment
effect
increas
supplement
serum
level
longterm
bone
health
transfus
acut
chest
ac
vasoocclus
voc
episod
laboratori
data
recent
encount
result
review
patient
chart
contain
inpati
outpati
encount
electrophoresi
data
avail
patient
among
genotyp
distribut
hgb
ss
hgb
sc
median
age
diagnosi
common
present
symptom
fever
anemia
pain
count
total
hospit
admiss
cohort
mean
per
patient
sixtythre
percent
children
requir
least
one
transfus
lifetim
mean
per
patient
mean
number
episod
voc
ac
respect
hepatomegali
splenomegali
document
patient
mean
hemoglobin
concentr
mean
wbc
count
mean
platelet
count
clinic
featur
haitian
children
sickl
cell
diseas
similar
african
countri
patient
present
morbid
encount
studi
provid
valuabl
data
describ
present
clinic
characterist
children
scd
haiti
may
use
consid
initi
newborn
screen
comprehens
care
model
set
background
mani
adult
survivor
pediatr
acut
lymphoblast
leukemia
suffer
unexplain
neurocognit
nc
deficit
magnet
reson
mr
imag
measur
brain
volum
bv
tissu
sodium
concentr
tsc
elev
tsc
reflect
decreas
cell
volum
fraction
cvf
measur
brain
cell
densiti
biolog
mechan
nc
chang
never
studi
object
bv
region
tsc
nc
perform
measur
investig
nc
perform
relat
chang
neuroimag
treatment
intrathec
system
chemotherapi
radiat
hypothes
lower
nc
perform
decreas
bv
possibl
cvf
designmethod
adult
patient
diagnosi
childhood
anticanc
therapi
least
two
year
recruit
sign
inform
consent
imag
nc
test
quantit
mr
imag
provid
tsc
map
region
tsc
bv
valu
measur
mean
bv
valu
linear
correl
region
tsc
valu
bv
valu
perform
group
valid
nc
assess
perform
group
relationship
nc
score
region
tsc
bv
examin
pearson
correl
result
ten
femal
mean
age
year
enrol
bv
decreas
p
agematch
control
signific
invers
linear
correl
exist
bv
region
tsc
frontal
p
pariet
p
lobe
basal
ganglia
p
thalami
p
tempor
p
occipit
p
lobe
ol
nc
perform
relat
bv
suggest
increas
nc
perform
increas
ol
tsc
promin
process
speed
p
conclus
result
exploratori
studi
show
treatment
childhood
result
smaller
cerebr
volum
decreas
correl
region
increas
tsc
reflect
decreas
cvf
frontopariet
deep
gray
matter
region
preliminari
result
also
suggest
possibl
relationship
ol
tsc
process
speed
etiolog
relationship
unclear
small
sampl
size
lack
consist
region
correl
like
reflect
wide
variat
nc
perform
found
futur
larger
studi
warrant
pathophysiolog
mechan
explain
poor
prognosi
propens
sudden
death
elus
object
defin
progress
cardiac
patholog
sca
determin
pathophysiolog
underli
divers
report
cardiopulmonari
phenotyp
includ
sudden
death
designmethod
mous
model
sca
irondefici
anemia
mice
underw
longitudin
comprehens
cardiac
analysi
combin
stateoftheart
cardiac
imag
cardiac
mri
echocardiographi
electrocardiographi
histopatholog
molecular
analysi
determin
basi
cardiac
dysfunct
result
sca
mice
show
anemiainduc
hyperdynam
physiolog
gradual
addit
develop
restrict
physiolog
progress
increas
left
atrial
diamet
diastol
dysfunct
despit
normal
systol
function
restrict
physiolog
notic
absent
chronic
irondefici
anemia
mice
sca
mice
associ
increas
extracellular
volum
cardiacmri
result
microscop
myocardi
fibrosi
mitochondri
ultrastructur
chang
consist
sever
hypoxiaischemiaoxid
stress
significantli
shorten
sarcomer
diastol
length
note
transcript
gene
involv
angiogenesi
extracellularmatrix
circadianrhythm
lipid
metabol
oxid
stresshypoxia
upregul
ionchannel
transport
fattyacid
metabol
gene
downregul
function
interact
network
analysi
suggest
lower
express
gene
essenti
normal
cardiac
conduct
inde
prolong
qtc
remark
increas
prolong
occur
premortem
arrhythmia
ischem
chang
observ
prior
sudden
death
conclus
collect
sca
mice
develop
distinct
sickl
cardiomyopathi
restrict
physiolog
cumul
cardiomyocyt
hypoxiaischemiainduc
fibrosi
result
arrhythmogen
myocardium
sudden
cardiac
death
common
restrict
cardiomyopathi
prolong
qt
syndrom
comprehens
longitudin
analysi
find
cardiomyopathi
preclin
sca
mous
model
may
unifi
cardiac
pathophysiolog
previous
report
divers
cardiac
phenotyp
also
explain
sudden
death
seen
diseas
furthermor
also
open
new
avenu
earli
diagnost
target
therapi
human
scarel
cardiac
diseas
background
neuropath
pain
known
complic
cancer
therapi
worsen
qualiti
life
poor
understand
patient
treatmentrel
risk
factor
neuropath
pain
limit
develop
target
screen
prevent
strategi
decreas
morbid
therapi
object
pediatr
oncolog
patient
determin
preval
neuropath
pain
investig
risk
factor
neuropath
pain
designmethod
conduct
retrospect
cohort
studi
newli
diagnos
relaps
pediatr
oncolog
patient
neuropath
pain
defin
priori
document
one
follow
medic
record
neuropath
pain
pain
nerv
distribut
pain
qualit
neuropath
pain
descriptor
ie
numb
burn
pain
initi
neuropath
pain
medic
demograph
variabl
compar
use
mannwhitney
test
continu
variabl
chisquar
test
categor
variabl
multivari
logist
regress
forward
stepwis
select
method
perform
find
best
set
predict
factor
diagnosi
neuropath
pain
result
chart
review
patient
median
iqr
age
cancer
diagnosi
year
femal
diagnos
includ
leukemialymphoma
solid
tumor
central
nervou
system
tumor
twentyeight
percent
ci
patient
met
definit
neuropath
pain
age
significantli
differ
without
neuropath
pain
p
significantli
lower
treat
vincristin
median
age
vs
year
p
older
age
ci
vincristin
therapi
ci
associ
increas
odd
neuropath
pain
diagnosi
radiat
therapi
ci
associ
decreas
odd
neuropath
pain
diagnosi
gender
ethnic
intrathec
chemotherapi
surgeri
signific
impact
neuropath
pain
diagnosi
conclus
neuropath
pain
diagnos
quarter
children
cancer
older
age
vincristin
therapi
associ
increas
risk
diagnosi
neuropath
pain
improv
prevent
diagnost
treatment
modif
strategi
need
reduc
burden
neuropath
pain
cancer
treatment
background
mortal
children
sickl
cell
diseas
scd
low
middleincom
countri
lmic
high
major
death
like
relat
infecti
complic
unit
state
dramat
decreas
childhood
mortal
scd
past
year
aid
intervent
reduc
mortal
associ
infect
lmic
intervent
ie
penicillin
prophylaxi
rapid
investig
treatment
febril
ill
vaccin
may
consist
avail
object
determin
provid
practic
lmic
regard
prevent
infecti
complic
patient
scd
designmethod
survey
english
frenchspeak
provid
scd
program
lmic
survey
avail
onlin
offlin
distribut
via
email
distribut
list
applic
meet
referr
result
provid
lmic
return
interpret
survey
includ
malariaendem
area
newborn
screen
associ
n
program
pneumococc
conjug
vaccin
avail
n
program
penicillin
prophylaxi
prescrib
patient
n
respond
malaria
prophylaxi
prescrib
n
malarialendem
area
fortyeight
percent
program
n
written
fever
manag
protocol
patient
scd
present
fever
n
respond
alway
give
antibiot
although
n
give
antibiot
almost
alway
first
line
antibiot
given
oral
n
n
would
consid
oral
antibiot
circumst
prefer
first
line
antibiot
ceftriaxon
give
ivim
antibiot
amoxicillinclavulan
give
oral
antibiot
program
malariaendem
area
n
alway
almost
alway
give
antimalari
febril
patient
fortysix
percent
n
respond
report
major
febril
patient
receiv
antibiot
prior
present
malariaendem
area
n
report
major
receiv
antimalari
prior
present
conclus
consider
practic
variat
around
manag
infect
prophylaxi
fever
patient
scd
lmic
major
respond
program
oral
antibiot
accept
use
febril
patient
scd
result
survey
inform
consensusbas
protocol
fever
manag
scd
lmic
background
intracrani
hypertens
ih
character
elev
cerebrospin
fluid
csf
pressur
defin
open
pressur
greater
mmhg
context
normal
csf
composit
normal
neuroimag
studi
ih
uncommon
condit
particularli
childhood
present
per
children
annual
untreat
ih
caus
signific
debilit
particularli
chronic
headach
lead
papilledema
visual
failur
object
aim
studi
determin
incid
ih
pediatr
patient
mainten
therapi
acut
lymphoblast
leukemia
designmethod
studi
conduct
wolfson
children
hospit
jacksonvil
florida
unit
state
open
pressur
measur
routin
schedul
lumbar
punctur
gener
anesthesia
intrathec
chemotherapi
administr
mainten
therapi
ih
defin
open
pressur
greater
mmhg
patient
ih
measur
repeat
addit
time
routin
lumbar
punctur
result
twenti
seven
patient
age
enrol
open
pressur
measur
time
intracrani
hypertens
found
time
patient
overal
incid
ih
particip
except
one
asymptomat
time
diagnosi
ih
patient
symptomat
ih
treat
success
acetazolamid
incid
ih
statist
signific
base
gender
age
group
leukemia
risk
type
addit
number
prior
lumbar
puncturesintrathec
chemotherapi
administr
associ
develop
ih
result
indic
significantli
higher
incid
ih
patient
undergo
mainten
therapi
suggest
treatment
may
associ
develop
ih
given
high
incid
ih
strongli
consid
child
treat
persist
headach
visual
disturb
studi
need
determin
ih
develop
patient
treat
physician
consid
measur
open
pressur
routin
intrathec
chemotherapi
administr
identifi
patient
ih
becom
symptomat
may
prevent
signific
symptom
irrevers
damag
optic
atrophi
lead
blind
background
chemotherapi
induc
acral
erythema
ciae
uncommon
side
effect
highdos
cytotox
chemotherapi
children
prior
case
report
ciae
pediatr
limit
predispos
factor
ciae
remain
unknown
object
identifi
characterist
genet
risk
factor
ciae
children
designmethod
advers
event
databas
frontlin
treatment
protocol
review
identifi
case
ciae
follow
either
highdos
methotrex
cytarabin
confirm
chart
review
control
compris
patient
treat
frontlin
protocol
receiv
either
highdos
methotrex
cytarabin
germlin
dna
genotyp
two
stage
genomewid
associ
studi
gwa
treat
ciae
categor
outcom
measur
perform
stage
perform
gwa
nonacut
lymphoblast
leukemia
case
compar
control
stage
includ
diagnos
adjust
ancestri
chemotherapi
result
patient
experienc
total
episod
ciae
symptom
last
mean
day
hand
feet
involv
initi
episod
ciae
occur
follow
administr
cytarabin
event
patient
matur
bcell
lymphoma
patient
acut
myeloid
leukemia
patient
methotrex
event
patient
patient
osteosarcoma
patient
matur
bcell
lymphoma
patient
also
ciae
follow
cytarabin
administr
agent
togeth
occur
prior
event
patient
matur
bcell
lymphoma
parenter
opioid
requir
symptom
control
patient
genet
variant
reach
genomewid
associ
threshold
p
top
identifi
variant
intron
msra
p
risk
allel
frequenc
case
control
addit
intron
variant
also
associ
increas
risk
ciae
p
patient
develop
ciae
follow
methotrex
carri
risk
allel
conclus
ciae
rare
toxic
children
receiv
highdos
methotrex
cytarabin
genet
variant
folat
metabol
oxid
stress
respons
gene
may
predispos
develop
ciae
rida
abid
bruce
bernstein
jennif
eng
deepti
raybagkar
natali
apollonski
background
patient
sickl
cell
anemia
sca
risk
overt
stroke
risk
silent
infarct
lifetim
routin
screen
transcrani
doppler
ultrasound
tcd
allow
select
patient
highest
risk
provid
chronic
transfus
decreas
risk
stroke
abnorm
veloc
tcd
associ
increas
risk
stroke
also
poor
cognit
perform
irrevers
chang
magnet
reson
imag
mri
subset
patient
even
absenc
mri
abnorm
patient
sca
experi
neurocognit
problem
declin
perform
time
earli
laboratori
predictor
tcd
veloc
would
allow
identif
patient
risk
first
year
life
introduc
appropri
treatment
modal
educ
support
object
studi
linear
correl
earli
biomark
tcd
veloc
differ
age
interv
designmethod
perform
retrospect
chart
review
patient
sca
follow
marian
anderson
center
st
christoph
hospit
children
philadelphia
identifi
consecut
patient
meet
inclus
criteria
pearson
correl
calcul
explor
linear
associ
steadi
state
biomark
anemia
hemolysi
inflamm
patient
maximum
left
middl
cerebr
arteri
mca
veloc
differ
age
interv
year
year
older
year
result
year
age
group
posit
linear
correl
tcd
veloc
left
mca
lactat
dehydrogenas
n
r
p
reticulocyt
count
n
r
p
bilirubin
n
p
p
white
blood
cell
count
n
r
p
neg
linear
correl
hemoglobin
n
r
p
year
age
group
signific
correl
lactat
dehydrogenas
n
r
p
correl
laboratori
biomark
older
age
group
conclus
decreas
hemoglobin
increas
white
blood
cell
count
increas
bilirubin
increas
lactat
dehydrogenas
first
year
life
correl
increas
mca
veloc
year
age
group
may
help
identifi
high
risk
patient
background
antimetabolit
dose
intens
complianc
mainten
therapi
associ
improv
event
free
surviv
focu
racial
dispar
poor
complianc
indic
high
anc
surrog
marker
less
known
influenc
benign
ethnic
neutropenia
ben
prescrib
mtx
dose
object
evalu
whether
prescrib
dose
andor
mtx
vari
patient
race
mainten
therapi
designmethod
singl
institut
retrospect
studi
prescrib
mtx
dose
monthli
visit
first
cycl
mainten
therapi
done
children
treat
children
oncolog
group
studi
band
tall
initi
averag
anc
weight
averag
dose
mtx
prescrib
per
visit
number
visit
prescrib
dose
less
goal
abstract
descript
statist
dichotom
race
univari
analysi
result
among
patient
elig
black
nonblack
differ
key
demograph
risk
characterist
tpmt
statu
race
median
anc
studi
entri
thouul
differ
race
vs
p
averag
anc
cours
therapi
greater
nonblack
vs
p
median
weight
dose
mtx
prescrib
cours
respect
p
p
differ
race
interestingli
number
visit
prescrib
mtx
dose
less
expect
black
nonblack
p
differ
present
respect
conclus
despit
incid
ben
black
children
anc
patient
entri
mainten
differ
race
popul
lack
signific
differ
prescrib
may
reflect
small
number
black
patient
studi
black
children
significantli
visit
less
expect
mtx
prescrib
prompt
need
analysi
factor
influenc
prescrib
antimetabolit
dose
intens
elizabeth
perri
patricia
carter
heather
becker
alexandra
garcia
michael
mackert
karen
johnson
georg
buchanan
background
health
literaci
defin
degre
individu
capac
obtain
process
understand
basic
health
inform
servic
need
make
appropri
health
decis
pauciti
literatur
regard
health
literaci
adolesc
specif
publish
data
describ
state
health
literaci
adolesc
sickl
cell
diseas
scd
object
purpos
studi
evalu
health
literaci
cohort
adolesc
scd
designmethod
crosssect
descript
correl
studi
includ
assess
demograph
measur
evalu
data
result
complet
realmteen
newest
vital
sign
nv
instrument
black
nonhispan
adolesc
scd
follow
children
medic
center
cmc
dalla
texa
conveni
sampl
util
inclus
criteria
diagnosi
one
four
primari
genotyp
scd
age
year
ut
austin
ut
southwestern
institut
review
board
approv
studi
result
thirtyseven
male
femal
recruit
studi
mean
age
year
sd
rang
grade
level
rang
mean
sd
follow
scd
genotyp
repres
ss
sc
score
realmteen
rang
mean
sd
score
nv
rang
mean
sd
health
literaci
score
lower
use
realmteen
nv
instrument
compar
score
healthi
adolesc
adult
control
howev
mean
realmteen
score
sampl
slightli
higher
black
control
valid
studi
current
grade
level
health
literaci
score
show
moder
high
posit
correl
r
p
health
literaci
score
also
significantli
posit
correl
age
r
p
incom
r
p
conclus
health
literaci
adolesc
scd
appear
suboptim
futur
research
includ
identifi
facilit
barrier
health
literaci
level
larger
cohort
adolesc
scd
ratzan
c
parker
r
nation
librari
medicin
current
bibliographi
medicin
health
literaci
background
common
malign
children
treatment
protocol
includ
multipl
bone
marrow
examin
check
treatment
respons
includ
minim
residu
diseas
mrd
countri
follow
protocol
even
absenc
mrd
facil
object
acut
lymphoblast
leukemia
common
hematolog
malign
among
pediatr
popul
differ
protocol
like
ukal
cog
use
manag
protocol
suggest
bone
marrow
biopsi
day
day
induct
phase
vivien
sheehan
anthoni
wood
sachin
allahabadi
sara
curti
allexa
hammond
lingchen
chien
jaden
schupp
matthew
ree
peter
yeh
kate
travi
john
shumway
background
estim
sickl
cell
diseas
scd
patient
reach
adulthood
high
resourc
countri
studi
show
grow
cohort
young
adult
scd
patient
age
year
old
experi
mark
rise
medic
complic
earli
mortal
coincid
decreas
use
lifeprolong
therapi
increas
use
emerg
care
object
survey
scd
patient
previous
transit
adult
care
determin
current
adult
scd
provid
continu
pretransit
therapi
percept
transit
process
designmethod
scd
patient
transit
pediatr
care
texa
children
hematolog
center
tchc
contact
patient
last
known
address
phone
number
request
complet
question
survey
assess
patient
demograph
posttransit
medic
outcom
person
experi
result
survey
complet
patient
lack
provid
top
reason
lack
insurancefund
ca
nt
find
physician
patient
without
adult
physician
within
month
transit
less
like
physician
current
p
patient
hydroxyurea
pediatr
patient
continu
hydroxyurea
therapi
transit
subject
report
difficulti
find
knowledg
adult
provid
medic
insur
inadequ
transit
prepar
exampl
qualit
result
includ
comment
follow
adult
doctor
awar
diseas
call
pediatrician
anoth
said
hard
find
physician
two
year
tchc
insur
loss
health
worsen
nt
get
medic
need
ask
patient
want
dedic
scd
transit
clinic
patient
identifi
deceas
caus
conclus
survey
show
first
month
transit
critic
period
identifi
sickl
cell
healthcar
provid
support
need
dedic
transit
clinic
facilit
transit
scd
patient
also
quantit
qualit
demonstr
lack
sickl
cell
focus
healthcar
provid
adult
barrier
success
transit
background
adolesc
young
adult
ayao
may
experi
greater
toxic
younger
patient
treat
hrall
greater
vulner
steroid
asparaginas
commonli
includ
induct
phase
therapi
rel
role
age
ethnic
bodi
mass
index
bmi
taken
account
address
object
sought
determin
impact
age
number
andor
maximum
grade
chemotherapyrel
toxic
induct
control
bmi
ethnic
gender
designmethod
consecut
nondown
syndrom
patient
hr
age
year
diagnosi
treat
per
children
oncolog
group
protocol
past
year
identifi
pediatr
oncolog
registri
children
health
retrospect
chart
review
conduct
toxic
grade
use
system
patient
characterist
summar
quartil
age
diagnosi
unadjust
trend
toxic
outcom
age
test
use
jonckheereterpstra
nonparametr
method
trend
toxic
outcom
age
adjust
bmi
ethnic
gender
test
use
poisson
regress
model
result
patient
experienc
distinct
toxic
common
toxic
includ
febril
neutropenia
fn
sepsi
hypertens
hyperglycemia
death
induct
age
diagnosi
omit
fn
analys
sinc
patient
infect
unadjust
trend
age
diagnosi
maximum
grade
toxic
number
grade
toxic
signific
p
respect
howev
multipl
regress
analysi
indic
relationship
age
diagnosi
toxic
adjust
bmi
ethnic
gender
relationship
longer
signific
conclus
age
signific
risk
factor
higher
number
greater
sever
chemotherapyrel
toxic
adjust
bmi
ethnic
gender
aspho
abstract
research
allow
better
support
care
measur
counsel
patient
parent
respect
risk
associ
therapi
background
util
electron
medic
record
emr
offer
uniqu
opportun
studi
larg
cohort
patient
time
howev
abil
identifi
follow
cohort
reli
use
valid
comput
phenotyp
consist
defin
set
data
element
form
comput
queri
emr
data
warehous
although
comput
phenotyp
previous
identifi
patient
popul
variou
condit
comput
phenotyp
yet
develop
identifi
patient
sickl
cell
diseas
scd
object
develop
comput
phenotyp
identifi
patient
popul
scd
use
algorithm
approach
valid
refin
comput
phenotyp
mean
improv
accuraci
designmethod
retrospect
studi
util
comput
phenotyp
search
emr
data
warehous
elig
patient
includ
age
year
diagnos
qualifi
scd
code
follow
scd
clinic
children
hospit
wisconsin
comput
phenotyp
develop
seri
queri
data
warehous
aim
identifi
patient
popul
scd
queri
includ
patient
qualifi
diagnosi
scd
also
two
outpati
visit
least
day
apart
one
hospit
emr
valid
studi
use
medic
record
number
clinic
program
databas
run
result
queri
result
comput
phenotyp
identifi
patient
patient
confirm
meet
inclus
criteria
two
patient
identifi
comput
phenotyp
incorrectli
identifi
scd
comput
phenotyp
fail
identifi
patient
meet
inclus
criteria
overal
comput
phenotyp
accur
identifi
patient
known
fit
inclus
criteria
conclus
advent
emr
provid
uniqu
opportun
track
follow
known
cohort
patient
given
diseas
rich
resourc
futur
clinic
trial
comput
phenotyp
develop
studi
allow
rapid
accur
identif
pediatr
patient
scd
provid
distinct
advantag
administr
claim
method
suleimman
alsweedan
rafat
jafri
khawar
siddiqui
ali
alahmari
ibrahim
ghemla
amal
alseraihi
background
hyperleukocytosi
defin
peripher
leukocyt
count
problem
seen
newli
diagnos
case
caus
hyperviscos
culmin
earli
morbid
mortal
patient
result
show
hyperleukocytosi
associ
tcell
less
frequent
favor
cytogenet
slow
earli
respond
poor
outcom
frequent
death
relaps
compar
publish
data
april
naeg
lori
heath
chunmei
zhou
neehar
gupta
carlton
dampier
background
modifi
face
pain
scale
revis
modifi
fpsr
patientreport
outcom
measur
establish
content
valid
use
assess
pain
intens
children
adolesc
year
age
sickl
cell
diseas
scd
daili
evalu
pain
provid
import
insight
clinic
consequ
scd
obtain
occasion
inpati
outpati
healthcar
visit
object
evalu
psychometr
properti
valid
reliabl
respons
modifi
fpsr
pediatr
patient
scd
designmethod
evalu
conduct
context
random
multin
clinic
studi
pediatr
patient
scd
year
age
symptom
intens
report
daili
diari
week
screen
periodprior
random
start
visit
month
modifi
fpsr
ask
patient
consid
pain
relat
scd
report
worst
pain
cours
day
mean
monthli
score
calcul
base
number
chosen
face
select
patient
pain
worst
pain
possibl
intraclass
correl
coeffici
icc
use
testretest
reliabl
month
month
pearson
correl
monthli
mean
intens
sicklecellrel
pain
analges
use
narcot
use
conduct
assess
converg
valid
respons
assess
correl
calcul
chang
baselin
correspond
chang
analges
use
chang
activ
score
month
month
result
icc
n
indic
agreement
among
stabl
patient
moder
associ
shown
modifi
fpsr
analges
use
r
narcot
use
r
moderatetolarg
associ
observ
modifi
fpsr
chang
analges
use
p
activ
score
p
result
quantit
analys
support
use
modifi
fpsr
children
adolesc
age
year
scd
instrument
suffici
reliabl
valid
respons
measur
pain
clinic
studi
provid
valuabl
insight
measur
daili
basi
studi
sponsor
daiichi
sankyo
ltd
eli
lilli
compani
suleimman
alsweedan
khawar
siddiqui
jafri
sy
amal
alseraihi
ibrahim
ghemla
ali
alahmari
background
treatment
often
mar
relaps
patient
main
caus
treatment
failur
case
high
risk
patient
background
perturb
arginin
pathway
hemolysi
associ
nitric
oxid
deplet
play
central
role
pathogenesi
vasoocclus
sickl
cell
diseas
scd
multipl
studi
shown
citrullin
effect
booster
even
condit
inflamm
acut
arginaseinduc
arginin
defici
characterist
scd
object
assess
safeti
pharmacokinet
profil
intraven
iv
lcitrullin
steadyst
scd
clinicaltri
designmethod
cohort
particip
receiv
iv
bolu
lcitrullin
five
minut
dose
increment
mgkg
target
citrullin
level
level
known
elev
base
previou
studi
plasma
sampl
collect
certain
time
point
pharmacokinet
studi
advers
event
follow
accord
nci
common
terminolog
criteria
advers
event
ctcae
first
cohort
four
particip
intraven
bolu
infus
lcitrullin
yield
mean
peak
level
trough
level
rang
hour
infus
averag
rate
citrullin
appear
rapp
sd
averag
constant
citrullin
remov
krem
sd
mean
clearanc
volum
distribut
subject
signific
rise
arginin
level
within
one
hour
receiv
bolu
iv
citrullin
mean
increment
one
subject
transient
drop
diastol
blood
pressur
within
minut
studi
drug
intervent
need
report
side
effect
analysi
use
simul
dose
scheme
show
mgkg
bolu
dose
iv
citrullin
follow
continu
infus
mgkghour
need
maintain
target
citrullin
concentr
conclus
bolu
intraven
lcitrullin
safe
well
toler
patient
scd
rapid
clearanc
studi
need
evalu
pharmacokinet
safeti
profil
continu
dose
iv
citrullin
scd
includ
effect
product
potenti
novel
therapeut
option
sickl
cell
pain
crisi
background
asthma
common
comorbid
condit
patient
sickl
cell
diseas
well
report
patient
sickl
cell
asthma
increas
risk
morbid
mortal
especi
regard
acut
chest
syndrom
limit
research
howev
done
establish
role
asthma
vasoocclus
crisi
studi
design
clinic
assess
hypothesi
patient
sickl
cell
diseas
asthma
increas
sever
frequenc
vasoocclus
crisi
secondari
increas
impair
oxygen
exchang
associ
sickl
designmethod
follow
develop
comprehens
institut
databas
patient
identifi
sickl
cell
diseas
comorbid
asthma
age
year
age
addit
patient
identifi
phenotyp
agematch
control
rate
emerg
depart
visit
hospit
frequenc
vasoocclus
crise
associ
respiratori
symptom
use
asthma
control
medic
retrospect
analyz
year
period
data
collect
interpret
accompani
review
exist
literatur
result
studi
period
patient
sickl
cell
asthma
increas
frequenc
acut
chest
present
respiratori
symptom
previous
establish
note
similar
increas
seen
pain
present
compar
hospit
encount
per
patient
result
definit
show
causat
respiratori
symptom
onset
vasoocclus
crise
data
suggest
direct
correl
addit
statist
signific
associ
use
asthma
control
medic
patient
present
pain
identifi
p
conclus
asthma
manag
may
role
treatment
sickl
cell
vasoocclus
crisi
evidenc
frequent
pain
present
patient
asthma
well
correl
patient
control
therapi
studi
use
asthma
manag
progress
intent
improv
pain
manag
decreas
hospit
encount
hospit
length
stay
initi
less
leukocyt
peripher
blood
commai
cell
common
subtyp
aml
aml
repres
accord
cytogenet
analysi
aml
recurr
abnorm
promyelocyt
aml
background
cerebrovascular
diseas
sever
complic
sickl
cell
diseas
scd
affect
common
cerebrovascular
event
scd
patient
ischem
howev
increas
hemorrhag
decad
life
attribut
moyamoya
ruptur
intracrani
aneurysm
ia
thought
respons
intracrani
hemorrhag
scd
incid
preval
ia
remain
unknown
scd
object
assess
preval
ia
cohort
scd
patient
suffer
stroke
identifi
abnorm
transcrani
doppler
tcd
designmethod
retrospect
review
scd
databas
identifi
patient
meet
object
underw
brain
magnet
reson
imag
mri
angiographi
mra
screen
headach
nonstrok
indic
time
period
includ
patient
scan
demograph
inform
collect
includ
age
scan
gender
genotyp
ia
indic
imag
manag
includ
patient
nt
report
histori
stroke
abnorm
tcd
result
fortythre
patient
averag
age
year
sd
includ
five
fortythre
patient
imag
mrimra
found
incident
unruptur
ia
four
patient
hbss
one
patient
hbsbeta
patient
asymptomat
multipl
aneurysm
seen
patient
ia
locat
anterior
posterior
cerebr
circul
territori
patient
manag
conserv
follow
scan
patient
taken
aneurysm
coil
resect
arterioven
malform
conclus
preval
unruptur
ia
cohort
much
higher
report
preval
ia
gener
scd
patient
ia
like
increas
risk
hemorrhag
stroke
subarachnoid
hemorrhag
age
none
patient
includ
cohort
histori
abnorm
tcd
larger
prospect
studi
need
accur
identifi
preval
outcom
optim
manag
unruptur
ia
scd
addit
maintain
high
index
suspicion
ia
scd
patient
neurolog
symptom
necessari
studi
limit
due
small
sampl
size
select
popul
children
hospit
eastern
ontario
divis
hematolog
oncolog
ottawa
ontario
canada
background
complementari
altern
medicin
cam
includ
therapi
practic
remedi
part
convent
medicin
use
cam
increas
among
canadian
pediatr
popul
incid
within
pediatr
oncolog
known
object
determin
incid
cam
use
within
canadian
pediatr
oncolog
popul
designmethod
questionnair
develop
complet
parentsguardian
pediatr
oncolog
patient
age
year
old
children
hospit
eastern
ontario
januari
juli
questionnair
cam
includ
reason
use
nonus
type
practic
frequenc
use
unwant
side
effect
satisfact
therapi
amount
spent
supervis
demograph
characterist
includ
ethnic
marit
statu
level
educ
profess
also
collect
result
respond
parent
report
use
cam
child
cancer
treatment
use
cam
therapi
common
reason
use
cam
cam
may
interfer
medicin
therapi
child
cam
scientif
base
n
use
cam
therapi
commonli
use
modal
prayersfaith
n
femal
male
equal
like
use
cam
ethnic
play
role
cam
use
identifi
european
aborigin
use
cam
wherea
approxim
half
identifi
canadian
french
asian
african
use
cam
parent
identifi
marri
least
like
use
cam
widow
like
use
cam
parent
complet
univers
degre
least
like
use
cam
attain
colleg
degre
like
use
cam
patient
discuss
cam
use
physician
conclus
signific
variat
hu
prescrib
practic
even
within
region
consortium
protocol
guidelin
studi
pediatr
use
hydroxyurea
need
optim
prescrib
practic
impact
sickl
cell
diseas
background
abnorm
uterin
bleed
aub
frequent
gynecolog
complaint
adolesc
despit
research
manag
strategi
aub
limit
often
variat
acut
care
object
object
improv
pediatr
resid
knowledg
confid
manag
aub
emerg
set
implement
local
consensu
algorithm
electron
health
record
ehr
order
set
concomit
educ
designmethod
use
multidisciplinari
approach
involv
depart
emerg
medicin
adolesc
medicin
hematologyoncolog
creat
implement
algorithm
emerg
manag
aub
along
accompani
ehr
order
set
facilit
test
treatment
educ
aub
manag
algorithm
ehr
order
set
provid
pediatr
resid
via
didact
inperson
electron
mail
resid
knowledg
scenario
question
confid
aub
manag
assess
pre
postintervent
algorithmehr
order
set
implement
didact
electron
survey
statist
use
compar
group
preand
postintervent
survey
complet
resid
respect
knowledg
aub
manag
improv
postintervent
p
resid
report
lack
confid
aub
manag
less
often
postintervent
versu
p
conclus
implement
algorithm
ehr
order
set
may
effect
method
improv
resid
knowledg
manag
aub
emerg
set
futur
hope
assess
associ
implement
clinic
outcom
transfus
rate
p
oxygen
requir
p
readmiss
rate
p
differ
group
conclus
control
bilater
infiltr
studi
suggest
sever
ac
yet
initi
ic
case
significantli
decreas
morbid
despit
less
sever
diseas
case
diagnos
asthma
may
treat
ic
admiss
despit
less
sever
ac
overal
initi
ic
decreas
ac
morbid
measur
need
transfus
oxygen
supplement
picu
intervent
system
steroid
increas
risk
readmiss
voc
case
like
readmit
use
ic
despit
plausibl
pathogen
mechan
reduc
airway
hyperreact
studi
demonstr
signific
benefit
ic
treatment
ac
background
bereav
parent
experi
signific
psychosoci
health
sequela
suggest
popul
may
benefit
ongo
extens
support
resourc
throughout
grief
journey
interact
healthcar
provid
hcp
hospit
staff
patient
famili
end
child
life
death
profoundli
affect
parent
grief
experi
offer
uniqu
opportun
medic
commun
posit
impact
bereav
experi
object
explor
role
health
care
team
institut
grief
journey
parent
lost
child
cancer
designmethod
eleven
bereav
parent
particip
focu
group
respons
main
prompt
code
analyz
independ
use
semant
content
analysi
techniqu
result
four
main
concept
identifi
within
parent
narr
includ
import
strong
ongo
relationship
hcp
bereav
famili
import
high
qualiti
commun
hcp
famili
effect
neg
experi
hcp
famili
parent
grief
import
institut
role
grief
journey
bereav
parent
conclus
bereav
parent
consist
identifi
critic
role
play
hcp
medic
institut
throughout
grief
journey
key
compon
bereav
support
identifi
parent
serv
guid
action
hcp
well
provid
templat
develop
comprehens
bereav
program
within
institut
background
sickl
cell
diseas
scd
associ
airway
hyperreact
ahr
augment
inflamm
leukotrien
product
known
mediat
ahr
zileuton
specif
inhibitor
key
enzym
leukotrien
synthet
pathway
licens
asthma
howev
safetypharmacokinet
investig
patient
scd
liver
renal
function
often
compromis
hypothes
zileuton
safe
patient
scd
pharmacokinet
similar
asthma
object
primari
object
determin
safeti
toler
pharmacokinet
twice
daili
administr
zl
zyflo
cr
patient
scd
designmethod
employ
dose
escalationdeescal
design
twice
daili
zileuton
week
nine
patient
year
age
scd
steadi
state
hydroxyurea
chronic
transfus
enrol
pharmacokinet
perform
first
dose
use
bayesian
model
total
zileuton
exposur
defin
area
concentrationtim
curv
zero
normal
dose
result
zileuton
well
toler
dose
signific
chang
clinic
laboratori
safeti
paramet
occur
advers
event
limit
common
pain
hypertens
pharmacokinet
paramet
zileuton
mean
cv
plasma
clearanc
clf
lhkg
volum
distribut
vf
lkg
absorpt
rate
constant
ka
elimin
phase
halflif
h
per
mg
popul
clf
estim
lhkg
nonmem
analysi
consist
mwpharm
result
lhkg
variabl
smaller
clf
vf
normal
bodi
mass
suggest
differ
bodi
weight
help
explain
variabl
coeffici
determin
bodi
weight
clf
p
bodi
weight
vf
p
conclus
trial
demonstr
zileuton
safe
well
toler
patient
scd
although
signific
interindividu
pharmacokinet
variabl
warrant
futur
phase
trial
studi
efficaci
reduc
ahr
associ
pulmonari
morbid
scd
background
parent
report
end
life
decis
difficult
treatment
relat
decis
face
child
cancer
experi
research
parent
perspect
qualiti
end
life
care
cancer
children
scarc
particularli
develop
countri
like
india
object
studi
aim
identifi
symptom
medicalsocialemot
concern
parent
last
day
child
life
identifi
strategi
parent
found
help
period
designmethod
parent
lost
child
cancer
treat
institut
interview
valid
prepar
questionnair
result
abl
understand
concept
palliat
vs
cur
option
could
understand
abl
come
term
palli
mode
treatment
could
opt
altern
medicin
accept
worsen
symptom
want
child
hospit
period
death
opt
home
place
death
question
made
opt
aggress
therapi
toward
end
life
report
hope
miracl
want
everyth
possibl
reduc
suffer
retrospect
felt
right
want
help
child
possibl
way
toward
death
dull
irrit
withdrawn
surround
common
symptom
encount
children
fear
alon
children
fear
death
pain
fatigu
loss
appetit
main
distress
symptom
child
suffer
parent
perspect
conclus
develop
countri
scarc
financi
resourc
increas
magnitud
compet
problem
littl
resourc
left
hospic
palli
care
servic
howev
human
factor
underestim
end
life
care
far
medic
treatment
pain
killer
greater
attent
paid
symptom
control
overal
wellb
child
end
life
care
background
sickl
cell
diseas
scd
chronic
disord
lifelong
effect
complic
includ
pain
crise
chronic
fatigu
organ
damag
infect
acut
chest
syndrom
stroke
research
show
health
relat
qualiti
life
suffer
along
daili
activ
stem
cell
transplant
option
elig
patient
cure
transplant
markedli
improv
qualiti
life
patient
perceiv
benefit
clear
object
goal
studi
explor
selfreport
effect
scd
work
school
along
common
theme
regard
particip
perspect
life
without
scd
hypothes
patient
perceiv
greater
disabl
scd
age
recogn
transplant
could
reliev
disabl
designmethod
mix
method
survey
administ
person
patient
seen
ui
health
comprehens
sickl
cell
center
hospit
pediatr
clinic
adolesc
transit
clinic
particip
age
rang
exclus
criteria
respiratori
contact
isol
extrem
pain
qualit
respons
examin
use
themat
analysi
result
theme
identifi
age
effect
scd
work
school
includ
disabl
school
absenc
motiv
disprov
odd
themat
analysi
identifi
patient
would
live
live
differ
cure
energi
improv
new
educ
goal
career
aspir
potenti
stem
cell
transplant
would
reliev
disabl
recogn
nearli
subject
older
age
correl
significantli
p
respons
reliev
disabl
almost
univers
patient
would
pursu
career
educ
cure
conclus
advanc
transplant
scd
achiev
cure
adult
often
reduc
disabl
pain
heighten
percept
benefit
adult
support
import
role
adult
scd
transplant
program
survey
first
examin
percept
disabl
among
factor
patient
consid
decis
stem
cell
transplant
sickl
cell
studi
includ
adolesc
adult
sickl
cell
patient
singl
survey
open
door
agerel
differ
percept
stem
cell
transplant
background
famili
caregiv
pediatr
oncolog
patient
get
overwhelm
cope
multitud
task
requir
maintain
health
much
less
improv
health
although
children
hospit
love
care
environ
place
like
home
object
goal
transform
care
deliveri
larg
inpati
focus
solid
tumor
chemotherapi
team
one
could
provid
outpati
forward
observ
involv
facilit
outpati
chemotherapi
b
anticip
prevent
side
effect
c
improv
nutrit
provid
resourc
enabl
famili
caregiv
take
activ
role
encourag
forward
observ
mind
set
designmethod
tool
use
facilit
foster
forward
observ
activ
particip
improv
health
includ
emr
note
use
snip
tool
emb
calendar
imag
photo
emr
note
better
team
commun
resourc
lotsahelpinghandsorg
chemocareorg
aspho
chemo
diseas
orient
group
acor
osteosarcoma
ewe
sarcoma
calendar
famili
pharmaci
infus
nurs
summari
care
includ
contact
inform
previou
treatment
provid
relev
clinic
detail
facilit
meaning
discuss
clinic
visit
improv
anticip
plan
task
drive
contain
articl
nutrit
info
imag
calendar
roadmap
summari
caregiv
direct
inform
thing
look
forward
makeawish
colleg
scholarship
provid
chemotherapi
regimen
safe
outpati
clinic
includ
vac
vdc
ie
hdmtx
fewer
readmiss
forward
observ
mindset
improv
health
patient
metastat
medullari
thyroid
carcinoma
clear
cell
sarcoma
neuroectoderm
tumor
rhabdomyosarcoma
ewe
sarcoma
osteosarcoma
desmoplast
round
cell
tumor
result
provid
success
outpati
care
snip
tool
use
epic
made
note
inform
atagl
mani
children
aya
seem
improv
perform
statu
excel
qol
superl
cope
skill
posit
affect
famili
dynam
outcom
conclus
instead
expect
worst
adopt
forward
observ
mind
set
activ
creat
environ
hope
prepar
best
routin
exceed
expect
clinic
sever
index
correl
soman
percent
carrier
cutoff
valu
decreas
product
due
delet
nondelet
mutat
howev
correl
compound
heterozygot
present
earli
infanc
sever
transfusiondepend
genet
modifi
seem
effect
activ
deoxygenationinduc
clindepend
kflux
ie
psicklelik
permeabl
lack
gardo
channel
activ
minim
activ
potassium
chlorid
cotransport
found
soman
carrier
hbsoman
sever
form
scd
carrier
sever
symptomat
compound
heterozygot
present
thalassemia
major
earli
transfus
depend
alpha
thalassemia
mutat
main
genet
modifi
carrier
soman
cell
increas
sickl
hemolyt
characterist
background
pediatr
symptom
checklist
pscp
well
valid
questionnair
complet
caregiv
minut
screen
children
adolesc
psychosoci
difficulti
pediatr
symptom
checklistyouth
psci
less
extens
studi
parallel
version
psc
design
selfreport
youth
age
year
neither
pscp
psci
studi
adolesc
chronic
hematolog
disord
object
studi
examin
use
pscp
psci
screen
adolesc
sickl
cell
diseas
chronic
idiopath
thrombocytopen
purpura
itp
psychosoci
problem
may
requir
evalu
andor
intervent
designmethod
subject
patient
routin
visit
comprehens
sickl
cell
pediatr
hematolog
clinic
itp
parentcaregiverpati
dyad
age
elig
invit
particip
consent
caregiv
complet
pscp
cbcl
achenbach
child
behavior
checklist
correspond
adolesc
complet
psci
ysr
achenbach
youth
self
report
total
number
evalu
pair
femal
hemoglobin
hb
sc
diseas
hb
ss
diseas
hb
thalassemia
chronic
itp
agreement
parallel
form
analyz
descript
correl
coeffici
calcul
pair
instrument
pscp
cblc
psci
ysr
result
patient
age
rang
year
mean
regard
cbcl
ysr
refer
instrument
four
patient
exceed
cbcl
threshold
score
indic
psychosoci
risk
tscore
also
exceed
pscp
threshold
point
pscp
percent
agreement
cbcl
n
psci
agreement
ysr
n
instrument
detect
risk
detect
parallel
instrument
conclus
result
suggest
psci
may
limit
screen
sickl
cell
diseas
chronic
itp
patient
psychosoci
problem
though
conclus
tent
due
small
sampl
size
contrast
pscp
may
reason
altern
cbcl
explor
report
possibl
chronic
splenic
sequestr
caus
poor
hb
control
patient
scd
ctt
stroke
prevent
suggest
consider
splenectomi
optim
transfus
paramet
select
highrisk
children
designmethod
patient
age
year
hb
ss
diseas
manag
chronic
partialexchang
prbc
transfus
everi
week
follow
standard
institut
protocol
poor
hb
control
indic
ctt
prior
stroke
abnorm
tcd
surveil
magnet
reson
angiographi
show
progress
cn
vasculopathi
spleen
measur
cm
evid
alloimmun
care
consider
patient
underw
laparoscop
splenectomi
mean
hematolog
paramet
compar
pair
ttest
month
pre
post
splenectomi
result
prior
splenectomi
mean
pretransfus
hb
gmdl
reticulocyt
count
hb
post
splenectomi
hb
gmdl
reticulocyt
count
hb
follow
splenectomi
mean
reduct
hb
ci
p
mean
followup
month
periop
infecti
complic
one
patient
appear
reduc
iron
burden
mean
reduct
baselin
serum
ferritin
ngml
perhap
part
transfus
space
due
improv
hb
control
conclus
data
suggest
splenic
sequestr
may
caus
shorten
red
cell
surviv
result
suboptim
hb
control
increas
risk
incid
recurr
stroke
splenectomi
may
reason
therapeut
option
select
highrisk
patient
addit
research
warrant
caus
variabl
hb
control
patient
scd
ctt
therapeut
option
refin
reduc
risk
overt
stroke
background
time
antibiot
administr
febril
neutropen
patient
associ
improv
outcom
analysi
inpati
bmt
unit
reveal
patient
new
onset
fever
receiv
antibiot
within
minut
aim
project
increas
percentag
febril
bmt
inpati
receiv
antibiot
within
minut
octob
use
model
improv
object
recogn
import
time
antibiot
administr
immunocompromis
identifi
potenti
barrier
time
antibiot
demonstr
import
establish
standard
process
provid
notif
antibiot
order
entri
administr
designmethod
pareto
analysi
failur
mode
effect
analysi
fmea
identifi
variabl
underli
caus
associ
delay
pareto
analysi
reveal
order
place
provid
delay
pharmaci
process
delay
order
placement
delay
notif
new
onset
fever
associ
failur
fmea
reveal
insuffici
awar
pharmaci
nurs
provid
new
onset
fever
standard
order
process
lack
provid
nurs
account
like
caus
time
antibiot
deliveri
failur
find
creat
key
driver
small
test
chang
develop
standard
process
consist
bedsid
nurs
notifi
order
provid
charg
nurs
safeti
coach
febril
patient
standard
order
set
specif
use
inpati
first
fever
pharmaci
notif
newli
febril
patient
via
stat
sticker
print
antibiot
enter
via
order
set
monitor
complianc
process
via
softwar
monitor
system
call
vigilanz
result
implement
antibiot
order
set
develop
process
bedsid
nurs
notifi
charg
nurs
safeti
coach
febril
patient
saw
increas
percentag
patient
receiv
antibiot
within
sixti
minut
document
fever
median
median
time
antibiot
administr
decreas
minut
minut
conclus
implement
standard
process
provid
notif
order
entri
result
improv
time
antibiot
administr
patient
month
later
receiv
two
cycl
rituximab
good
respons
januari
platelet
count
went
back
receiv
third
cours
rituximab
sustain
respons
decid
introduc
romiplostin
februari
start
dose
mcgkg
increas
maxim
dose
mcgkg
within
month
normal
platelet
count
romiplostin
titrat
per
standard
recommend
maintain
platelet
count
although
platelet
count
remain
stabl
ofatumumab
given
one
month
later
avoid
relaps
immun
manifest
sle
given
sustain
normal
platelet
count
romiplostin
gradual
wean
ceas
septemb
medic
well
toler
patient
experienc
sideeffect
pain
crisi
conclus
knowledg
first
report
util
romiplostin
patient
scd
medic
efficaci
well
toler
particular
increas
pain
crisi
note
contrast
gcsf
romiplostin
might
safe
use
scd
object
identif
effect
strategi
necessari
optim
uptak
hpv
vaccin
studi
systemat
review
literatur
nation
intern
intervent
success
increas
hpv
vaccin
uptak
designmethod
conduct
search
use
standard
protocol
electron
databas
pubm
scopu
embas
identifi
intervent
design
increas
hpv
vaccin
uptak
among
adolesc
year
old
studi
design
accept
manuscript
includ
post
intervent
vaccin
rate
includ
two
author
independ
review
articl
data
extract
qualiti
assess
three
review
independ
classifi
intervent
accord
predefin
criteria
result
manuscript
classifi
accord
commun
guid
result
report
accord
reaim
framework
manuscript
met
elig
criteria
inform
intervent
behavior
intervent
environment
intervent
factor
associ
hpv
vaccin
uptak
increas
vaccin
avail
decreas
financi
barrier
intervent
target
provid
patient
conclus
popul
base
vaccin
strategi
increas
vaccin
avail
reach
greatest
number
adolesc
success
achiev
high
rate
vaccin
intervent
target
provid
patient
also
success
background
acut
chest
syndrom
ac
common
caus
death
children
sickl
cell
diseas
scd
hematologist
need
awar
assess
ac
sever
guid
therapi
measur
prevent
ac
ac
sever
assess
tool
util
research
valid
realworld
set
exist
guidelin
includ
nhlbi
provid
uniform
grade
ac
sever
contrast
evid
role
incent
spirometri
prevent
decreas
sever
ac
strong
incent
spirometri
recommend
includ
guidelin
object
assess
current
knowledg
resid
physician
nurs
regard
two
aspect
ac
sever
assess
incent
spirometri
designmethod
tertiari
care
hospit
admit
patient
scd
per
month
pediatr
floor
pediatr
resid
nurs
learn
ac
manag
prevent
didact
session
scdyear
bedsid
teach
anonym
survey
administ
pediatr
pediatr
nurs
routin
engag
care
ac
patient
follow
housestaff
educ
session
ac
result
sever
score
nurs
educ
use
ac
sever
assess
past
overwhelm
felt
score
system
would
use
assess
patient
condit
guid
manag
howev
resid
nurs
use
sever
score
ac
past
clinic
vignett
ac
answer
incorrectli
resid
nurs
incent
spirometri
respond
awar
incent
spirometri
decreas
sever
improv
outcom
ac
nurs
thought
patient
compliant
less
time
incent
spirometri
almost
alway
order
knowledg
resid
nurs
regard
sever
assess
ac
limit
greater
effort
need
educ
includ
assess
manag
decis
import
incent
spirometri
recogn
housestaff
howev
patient
complianc
desir
reinforc
need
improv
ac
outcom
pilot
studi
identifi
room
qualiti
improv
sever
step
care
process
scd
data
extract
use
standard
data
collect
form
full
text
refer
identifi
review
base
titleabstract
thirtythre
articl
includ
analysi
articl
exclud
base
predetermin
exclus
criteria
fetal
hemoglobin
hbf
alpha
globin
gene
number
commonli
studi
sever
predictor
studi
hemoglobin
white
blood
cell
count
absolut
reticulocyt
count
round
top
studi
predictor
systemat
review
nearli
three
quarter
hbf
studi
report
benefici
effect
increas
hbf
level
howev
increas
hbf
level
associ
lower
rate
hospit
stroke
risk
two
articl
increas
arc
posit
associ
increas
risk
cerebrovascular
complic
report
studi
alpha
thalassemia
trait
protect
stroke
abnorm
tcd
rate
pain
crisi
abil
predict
sca
complic
mix
studi
variabl
includ
hbf
reliabl
predictor
diseas
complic
urgent
need
guid
therapeut
decis
pediatr
patient
sca
nupur
mittal
paul
kent
background
survivor
pediatr
cancer
risk
longterm
consequ
therapi
one
loss
preexist
protect
antibodi
predispos
ill
measl
measl
recipi
immunosuppress
chemotherapi
mortal
rate
children
year
lose
humor
immun
measl
result
chemotherapi
induc
alter
immun
system
despit
proven
strategi
improv
measl
vaccin
coverag
diseas
still
continu
circul
lead
outbreak
develop
countri
us
experienc
major
measl
outbreak
relat
amus
park
california
case
year
report
across
state
includ
state
measl
highli
contagi
hour
prior
first
symptom
pediatr
oncolog
practic
share
offic
floor
space
pediatr
practic
place
patient
risk
measl
infect
object
measl
protect
humor
immun
statu
check
patient
new
risk
measl
period
outbreak
januaryjun
time
standard
practic
check
measl
titer
prior
initi
chemotherapi
designmethod
patient
year
receiv
chemotherapi
januari
depart
includ
prospect
review
defin
immun
accord
lab
standard
result
total
femal
patient
includ
three
patient
non
protect
measl
antibodi
level
patient
year
diagnosi
leukemia
one
adolesc
sarcoma
three
came
weekli
clinic
admit
floor
chemotherapi
period
thu
share
common
clinic
floor
space
none
patient
develop
measl
remiss
measl
outbreak
us
pose
grave
threat
recipi
chemotherapi
danger
increas
nosocomi
set
share
clinic
space
univers
vaccin
stringent
isol
pediatr
clinic
area
standard
practic
check
measl
immun
patient
prior
chemotherapi
initi
may
prevent
devast
diseas
sensit
popul
result
cohort
includ
patient
scd
male
femal
age
rang
year
accord
transfus
need
prior
surgeri
patient
categor
group
name
transfus
group
simpl
transfus
group
ii
exchang
transfus
group
iii
group
includ
patient
respect
signific
differ
studi
group
regard
main
postop
complic
scd
vasoocclus
crisi
occur
compar
number
case
three
group
respect
acut
chest
syndrom
develop
patient
nontransfus
group
exchang
transfus
group
patient
simpl
transfus
group
pretransfus
averag
hemoglobin
valu
significantli
lower
simpl
transfus
group
comparison
group
note
patient
simpl
transfus
requir
almost
half
blood
volum
compar
exchang
transfus
mlkg
vs
mlkg
statist
highli
signific
differ
group
p
conclud
safe
adenotonsillectomi
without
simpl
exchang
transfus
preoper
patient
scd
maintain
hemoglobin
level
gdl
transfus
improv
surgic
scdrelat
outcom
manag
priapism
controversi
evidencebas
red
cell
exchang
transfus
use
manag
sickl
relat
complic
sever
case
report
describ
acut
neurolog
event
follow
exchang
transfus
priapism
limit
enthusiasm
routin
adopt
therapi
present
littl
data
character
exchang
transfus
util
safeti
treat
priapism
object
determin
compar
incid
advers
event
seen
patient
scd
receiv
red
cell
exchang
transfus
refractori
priapism
secondari
stroke
prophylaxi
designmethod
univers
north
carolina
blood
bank
databas
use
identifi
patient
scd
enrol
chronic
exchang
transfus
program
refractori
priapism
year
agematch
cohort
seven
patient
enrol
exchang
protocol
secondari
stroke
prophylaxi
identifi
first
exchang
procedur
group
use
comparison
advers
event
vital
sign
instabl
acut
neurolog
event
collect
data
collect
analyz
determin
differ
advers
event
priapism
group
compar
receiv
exchang
transfus
secondari
stroke
prophylaxi
identifi
seven
patient
scd
enrol
red
cell
exchang
protocol
refractori
priapism
evalu
episod
exchang
transfus
per
patient
mean
age
six
patient
hbss
one
patient
hbsc
two
episod
hypotens
record
one
patient
two
separ
procedur
resolv
decreas
inlet
pump
flow
rate
patient
advers
neurolog
event
record
one
patient
experienc
lip
tingl
resolv
calcium
carbon
tablet
comparison
data
patient
transfus
secondari
stroke
prevent
collect
conclus
although
exchang
transfus
infrequ
use
treat
refractori
priapism
patient
scd
incid
advers
event
appear
minim
analysi
ongo
compar
safeti
red
cell
exchang
transfus
priapism
stroke
futur
control
trial
use
blood
exchang
transfus
refractori
priapism
need
may
result
preced
restrict
cardiomyopathi
studi
investig
right
left
ventricular
global
longitudin
strain
rvgl
lvgl
among
children
scd
nonsickl
hemolyt
anemia
none
investig
role
diseasemodifi
therapi
hydroxyurea
chronic
transfus
elev
tricuspid
regurgit
veloc
trv
strain
scd
object
compar
rvgl
lvgl
pediatr
scd
pediatr
nonsickl
hemolyt
anemia
investig
associ
age
diseasemodifi
therapi
trv
global
longitudin
strain
scd
designmethod
prospect
measur
rvgl
lvgl
speckletrack
trv
mmode
echocardiographi
children
hbss
n
nonsickl
hemolyt
anemia
hereditari
spherocytosi
hbe
pyruv
kinas
defici
n
age
perform
central
read
one
singl
cardiologist
trv
categor
normal
ms
elev
ms
result
univari
analysi
increas
worsen
rvgl
lvgl
associ
age
diseasemodifi
therapi
children
scd
p
control
age
multivari
model
howev
treatment
longer
associ
strain
year
increas
age
increas
rvgl
p
elev
trv
associ
increas
lvgl
scd
rho
p
nonsickl
hemolyt
anemia
age
associ
increas
lvgl
rho
p
lvgl
rvgl
significantli
decreas
scd
compar
nonsickl
hemolyt
anemia
vs
p
patient
scd
elev
trv
compar
nonsickl
hemolyt
anemia
vs
p
conclus
global
longitudin
cardiac
strain
declin
age
children
hemolyt
anemia
may
repres
earli
marker
patholog
cardiac
chang
elev
trv
common
scd
nonsickl
hemolyt
anemia
may
modul
lvgl
global
longitudin
strain
studi
longitudin
prospect
cohort
patient
hemolyt
anemia
valu
marker
earli
cardiac
damag
background
neuroblastoma
common
extracrani
malign
childhood
myc
famili
protein
regul
cell
growth
prolifer
implic
etiolog
mani
cancer
mycn
amplifi
neuroblastoma
associ
poor
prognosi
investig
specif
tumor
pathway
understand
neuroblastoma
pathogenesi
lead
futur
therapeut
option
member
mad
famili
inhibit
nmyc
activ
altern
splice
variant
differ
first
exon
exon
whose
function
determin
object
test
hypothesi
differenti
impact
nmycdepend
neuroblastoma
cell
prolifer
designmethod
express
shep
neuroblastoma
cell
shep
cell
stabli
transfect
express
high
level
mycn
shepmycn
also
util
nativ
neuroblastoma
cell
line
induc
express
cell
prolifer
surviv
quantifi
use
brdu
mtt
assay
respect
impact
nmyc
express
measur
rtpcr
immunoblot
analysi
result
overexpress
inhibit
neuroblastoma
cell
viabil
convers
overexpress
neuroblastoma
cell
line
lead
increas
viabil
suggest
counterregulatori
role
examin
reveal
chang
viabil
partial
due
chang
cell
prolifer
decreas
prolifer
augment
addit
observ
nmyc
level
decreas
respons
express
increas
express
compar
express
result
enhanc
chemoresist
neuroblastoma
cell
doxorubicin
etoposid
conclus
overexpress
neuroblastoma
cell
line
lead
inhibit
nmycmedi
cell
prolifer
appear
promot
cell
growth
express
enhanc
chemosensit
neuroblastoma
cell
opposit
effect
effect
may
partial
due
alter
nmyc
express
better
understand
interact
among
nmyc
rel
express
level
protein
affect
neuroblastoma
physiolog
may
aid
develop
effect
target
therapi
improv
outcom
pediatr
neuroblastoma
patient
children
hospit
pittsburgh
pittsburgh
pennsylvania
unit
state
background
current
standard
nation
guidelin
regard
optim
time
screen
iron
defici
anemia
ida
infant
children
unit
state
prevent
servic
task
forc
cdc
american
academi
pediatr
recommend
screen
differ
age
group
popul
base
ida
risk
potenti
subsequ
poor
outcom
object
aim
studi
compar
costeffect
screen
ida
vari
age
within
high
risk
group
gener
popul
designmethod
use
markov
decis
analysi
model
estim
costeffect
screen
ida
monthold
within
highrisk
group
entir
popul
ident
hypothet
cohort
evalu
month
track
anemia
sever
time
possibl
neurodevelopment
outcom
undiagnos
sever
anemia
clinic
outcom
util
cost
obtain
via
literatur
review
vari
paramet
estim
oneway
sensit
analys
result
base
case
screen
highrisk
month
old
gain
qualityadjust
life
year
qali
cost
screen
gain
screen
month
old
cost
gain
screen
month
old
cost
gain
strategi
elimin
due
domin
use
accept
standard
dollarsqali
gain
cost
effect
screen
month
old
cost
effect
strategi
vari
uncertain
variabl
model
plausibl
rang
specif
probabl
neurodevelopment
outcom
probabl
anemia
highrisk
popul
probabl
highrisk
prefer
strategi
remain
screen
month
old
probabilist
sensit
analysi
vari
paramet
simultan
plausibl
distribut
result
screen
month
old
favor
threshold
conclus
screen
children
month
age
ida
econom
reason
strategi
light
reexamin
variou
current
suggest
guidelin
may
warrant
background
neuroblastoma
remain
common
solid
extracrani
solid
tumor
children
approxim
new
diagnos
made
year
despit
advanc
therapi
includ
multimod
approach
high
risk
neuroblastoma
remain
difficult
treat
current
long
term
surviv
rate
high
risk
neuroblastoma
approxim
forti
percent
biolog
target
novel
therapeut
potenti
treatment
neuroblastoma
could
improv
cure
rate
aberr
growth
factor
receptor
gfr
express
receptor
kinas
signal
associ
pathogenesi
mani
malign
kinas
therefor
serv
target
number
novel
therapi
fibroblast
growth
factor
fgf
activ
cognat
receptor
stimul
cell
prolifer
migrat
fgfr
inhibit
effect
varieti
preclin
cancer
model
object
test
novel
panfgfr
inhibitor
ponatinib
efficaci
preclin
model
neuroblastoma
designmethod
treat
panel
establish
neuroblastoma
tumor
cell
line
increas
concentr
ponatinib
viabil
determin
use
mtt
assay
addit
neuroblastoma
cell
migrat
wound
treatment
ponatinib
monitor
hour
time
interv
cell
treat
ponatinib
western
blot
use
antibodi
downstream
target
perform
result
neuroblastoma
cell
line
test
sensit
ponatinib
valu
nanomolar
micromolar
rang
migrat
neuroblastoma
cell
inhibit
treatment
ponatinib
phosphomek
phosphoerk
significantli
decreas
treatment
ponatinib
conclus
treatment
neuroblastoma
tumor
cell
ponatinib
caus
cell
death
reduc
cell
migrat
inhibit
fgfr
famili
member
repres
novel
therapeut
strategi
neuroblastoma
preclin
studi
ponatinib
addit
fgfr
inhibitor
warrant
background
inherit
stomatocytos
group
hemolyt
anemia
disord
character
alter
red
blood
cell
rbc
membran
permeabl
monoval
cation
cryohydrocytosi
one
subtyp
cation
leak
mild
significantli
increas
temperatur
approach
singl
amino
acid
substitut
transport
domain
band
caus
mutat
demonstr
caus
phenotyp
object
describ
novel
mutat
associ
monoval
cation
leak
particularli
mark
patient
congenit
hemolyt
anemia
designmethod
nextgener
sequenc
analysi
gene
associ
hemolyt
anemia
perform
old
femal
present
neonat
hemolyt
anemia
jaundic
famili
histori
posit
hemolysi
rbc
phenotyp
analysi
includ
ektacytometri
red
cell
cytogram
measur
intracellular
k
na
content
compar
control
sampl
patient
hemoglobin
normal
gdl
elev
reticulocyt
count
indic
persist
hemolysi
elev
mean
corpuscular
hemoglobin
concentr
gdl
red
cell
cytogram
show
major
cell
hyper
chromic
zone
consist
increas
cell
densiti
ektacytometri
patient
rbc
produc
curv
indic
impress
cellular
dehydr
low
omin
hypoton
osmol
cell
hemolyz
osmot
fragil
assay
mosmkg
normal
low
el
elong
index
max
normal
indic
decreas
deform
low
ohyp
mosmkg
normal
indic
increas
intracellular
viscos
rbc
intracellular
k
cation
content
reduc
mmolkg
hb
control
nextgener
sequenc
analysi
patient
sampl
reveal
novel
heterozyg
variant
gene
g
caus
singl
amino
acid
substitut
transport
domain
band
report
novel
genet
defect
associ
signific
rbc
cation
leak
cold
temperatur
patient
congenit
hemolyt
anemia
substitut
possibl
novel
cryohydrocytosi
mutat
convert
band
anion
exchang
unregul
cation
channel
result
french
canadian
male
incident
found
polycythem
age
yr
old
hb
hct
abnorm
evid
oxygen
desatur
normal
calcul
bone
marrow
reveal
morpholog
cytogenet
abnorm
epo
level
undetect
vitro
test
reveal
increas
erythroid
sensitivi
rare
epoindepend
erythroid
growth
search
exon
somat
mutat
neg
germlin
heterozyg
epor
mutat
detect
although
mutat
previous
report
among
epormut
caus
dominantli
inherit
primari
famili
congenit
polycythemia
pfcp
mutat
found
famili
member
given
develop
moder
sever
headach
phlebotomi
eventu
initi
age
four
maintain
hematocrit
yr
followup
develop
mild
arteri
hypertens
hyperuricemia
never
thrombot
complic
aspirin
prophylaxi
antihypertens
therapi
switch
enalapril
age
yr
old
age
spite
wellcontrol
hematocrit
level
antimigrain
agent
zolimitriptan
serotonin
receptor
agonist
initi
due
worsen
headach
phlebotomi
ceas
week
given
stabl
hematocrit
sinc
introduct
medic
bone
marrow
remain
normal
without
evid
marrow
fibrosi
conclus
although
usual
benign
inherit
epor
mutat
may
caus
vascular
complic
hypertens
given
serotonin
known
role
erythropoiesi
propos
zolmitriptan
alon
combin
angiotensin
antagonist
may
benefici
effect
evalu
studi
background
use
treatment
relapsedrefractori
nb
past
respons
rate
around
use
regimen
often
conjunct
chemotherapi
myeloabl
therapydata
lmic
lackingw
describ
experi
therapi
treatment
nb
result
data
receiv
total
mibg
therapi
median
median
age
male
femal
ratio
intent
palli
total
high
risk
nb
receiv
multipl
cours
treatment
includ
autolog
stem
cell
transplant
respons
rate
patient
aliv
last
follow
median
time
progress
ten
patient
receiv
total
mibg
therapi
part
frontlin
therapi
inoper
refractori
residu
postop
respons
rate
aliv
last
followup
common
toxic
document
patient
often
delay
cours
conclus
limit
retrospect
studi
feasibl
relapsedrefractorya
well
frontlin
nb
lmic
accept
toxic
mibg
therapi
offer
reason
salvag
strategi
lmic
set
aggress
salvag
therapi
often
possibl
hope
incorpor
mibg
therapi
frontlin
treatment
regimen
centr
near
futur
help
improv
outcom
high
risk
nb
compar
gener
popul
competingrisk
approach
use
estim
causespecif
hazard
function
cumul
incid
curv
dba
done
previous
dbar
report
first
quantit
assess
incid
neoplasia
dba
patient
median
age
year
analysi
august
seventeen
patient
receiv
bmt
cancer
patient
md
significantli
elev
oe
observ
expect
ratio
respect
colon
carcinoma
n
osteosarcoma
n
acut
myeloid
leukemia
aml
n
md
n
decemb
n
median
patient
age
year
addit
patient
receiv
bmt
cancer
addit
patient
develop
md
total
cancer
report
patient
includ
patient
gastrointestin
carcinoma
sarcoma
aml
patient
md
statist
analysi
avail
time
present
includ
analysi
patient
develop
colorect
cancer
two
os
one
respect
follow
hematopoiet
stem
cell
transplant
conclus
extend
analys
includ
addit
followup
patient
inform
assess
cancer
type
risk
uniqu
dba
background
hyponatremia
serum
na
frequent
electrolyt
abnorm
children
previou
research
report
hyponatremia
affect
hospit
pediatr
patient
studi
done
evalu
incid
hyponatremia
pediatr
oncolog
patient
oncolog
etiolog
hyponatremia
depend
mani
factor
ill
type
cancer
type
chemotherapi
type
hydrat
chemotherapi
object
determin
incid
hyponatremia
pediatr
oncolog
patient
compar
admit
chemotherapi
admit
acut
ill
designmethod
retrospect
cohort
studi
involv
chart
review
pediatr
oncolog
admiss
children
hospit
illinoi
month
period
result
studi
period
elig
patient
admit
receiv
chemotherapi
due
acut
ill
signific
differ
two
group
regard
sex
p
age
p
patient
receiv
fluid
normal
salin
serum
na
found
patient
admit
chemotherapi
admit
acut
ill
p
even
account
differ
fluid
type
hyponatremia
time
like
occur
patient
admit
acut
ill
contrast
admit
schedul
chemotherapi
p
patient
hyponatremia
present
time
admiss
first
hour
none
patient
symptomat
hyponatremia
differ
hospit
length
stay
p
two
group
conclus
among
oncolog
patient
present
acut
ill
like
develop
hyponatremia
admiss
hyponatremia
subclin
prolong
length
stay
plan
compar
incid
hyponatremia
patient
receiv
differ
regimen
chemotherapi
patient
leukemia
versu
solid
tumor
designmethod
case
report
gene
sequenc
famili
inform
consent
caucasian
male
refer
clinic
evalu
transfusiondepend
nonimmun
hemolyt
anemia
suboptim
reticulocytosi
skelet
deform
involv
finger
toe
child
present
soon
birth
sever
neonat
jaundic
hepatosplenomegali
blood
smear
red
cell
show
mark
anisopoikilocytosi
dacryocyt
red
cell
fragment
macrocyt
bone
marrow
aspir
erythroid
cell
show
promin
dyserythropoiesi
includ
megaloblastoid
matur
binucl
nuclear
contour
irregular
chromatin
bridg
occasion
multinucl
erythroid
present
nextgener
sequenc
analysi
gene
associ
hemolyt
dyserythropoiet
anemia
perform
dna
isol
peripher
blood
patient
found
compound
heterozyg
two
mutat
confirm
suspect
diagnosi
cda
first
mutat
previous
unreport
delet
result
frameshift
second
mutat
missens
variant
affect
highli
conserv
amino
acid
residu
use
mutat
predict
softwar
amino
acid
substitut
predict
deleteri
probabl
damag
variant
known
found
exac
databas
low
maf
patient
current
manag
regular
blood
transfus
iron
chelat
effect
monitor
mri
liver
iron
famili
consid
option
tri
interferonalpha
therapi
conclus
cda
consid
differenti
diagnosi
nonimmun
hemolyt
anemia
suboptim
reticulocytosi
nextgener
sequenc
provid
definit
diagnosi
may
unveil
new
diseasecaus
mutat
may
allow
consider
therapi
like
interferonalfa
found
increas
hemoglobin
level
decreas
iron
overload
patient
cda
stephen
kirchner
jame
bartram
daniel
wechsler
michael
armstrong
background
myc
famili
regul
cell
growth
implic
etiolog
mani
cancer
includ
neuroblastoma
member
mad
famili
inhibit
nmyc
activ
altern
splice
variant
differ
first
exon
exon
whose
function
determin
protein
appear
differenti
function
neuroblastoma
pathogenesi
inhibit
neuroblastoma
cell
prolifer
promot
mostli
homolog
includ
repress
domain
possess
distinct
ntermin
exon
suggest
critic
role
exon
differenti
function
object
determin
role
subcellular
local
potenti
mechan
differenti
function
designmethod
creat
gfptag
construct
exon
assess
cellular
local
protein
protein
express
cell
subcellular
local
exon
detect
immunofluoresc
assess
whether
protein
undergo
nuclearcytoplasm
transloc
cell
treat
leptomycin
b
lmb
block
nuclear
export
result
examin
subcellular
locat
reveal
resid
nucleu
found
primarili
cytoplasm
exon
also
display
cytoplasm
local
indic
presenc
exon
contribut
differenti
local
treatment
lmb
result
accumul
nucleu
suggest
cycl
nucleu
respons
appropri
signal
effect
appear
mediat
exon
also
accumul
nucleu
nuclear
export
inhibit
conclus
exhibit
distinct
subcellular
local
pattern
resid
nucleu
found
predominantli
cytoplasm
exon
direct
cytoplasm
local
final
nuclear
export
inhibit
lead
nuclear
accumul
suggest
protein
transloc
respons
appropri
signal
better
understand
impact
neuroblastoma
physiolog
exon
impart
differenti
function
may
aid
develop
effect
target
therapi
improv
outcom
children
neuroblastoma
background
swisnf
subunit
mutat
identifi
mani
cancer
type
mutat
lead
specif
vulner
may
target
novel
therapi
recent
phase
clinic
trial
inhibitor
adult
advanc
cancer
tumor
respons
seen
patient
loss
subunit
detect
neg
immunohistochemistri
ihc
patient
neg
ihc
data
suggest
loss
function
also
result
suscept
inhibit
background
clostridium
difficil
infect
gain
relev
last
decad
particularli
among
pediatr
cancer
patient
metronidazol
pattern
primari
choic
treatment
wherea
vancomycin
even
long
cours
elect
line
relaps
infect
case
multipl
recurr
refractori
infect
drug
choic
scars
proven
efficaci
pediatr
patient
fecal
microbiota
transplant
evolv
safe
success
tool
patient
fail
antimicrobi
therapi
minim
pediatr
data
avail
warrant
use
childhood
name
immunosuppress
treatment
object
end
point
errad
recurr
c
difficil
infect
end
point
demonstr
procedur
safeti
designmethod
year
old
boy
high
risk
neuroblastoma
develop
abdomin
pain
diarrhea
caus
c
difficil
chemotherapi
metronidazol
use
first
place
induc
symptom
relief
bout
ocur
featur
despit
administr
oral
vancomycin
vancomycin
taper
fecal
microbiota
transplant
consid
father
select
donnat
health
overview
includ
screen
std
viral
infect
parasit
infest
take
day
vancomycin
qid
boy
admmit
duoden
probe
place
stool
donnor
colect
stuff
homogen
salin
filter
twice
infus
final
solut
flush
salin
probe
remov
day
procedur
stool
test
neg
toxin
dna
agent
side
effect
report
neither
transplant
day
conclus
fecal
microbiota
transplant
expect
overcom
unrespons
c
difficil
infect
fidaxomicin
could
option
aprov
set
although
promis
also
children
fecal
transplant
need
extens
studi
abhishek
object
aim
studi
molecularli
character
megnt
provid
insight
biolog
tumor
identifi
potenti
target
treatment
designmethod
whole
exom
sequenc
we
transcriptom
sequenc
rnaseq
perform
pretreat
tumor
sampl
three
patient
megnt
well
two
addit
postradi
sampl
one
patient
blood
avail
germlin
we
one
case
clinic
inform
obtain
retrospect
chart
review
result
three
patient
underw
subtot
patient
gross
total
patient
resect
follow
involv
field
radiat
therapi
patient
diseas
recurr
less
year
treatment
patient
stabl
diseas
six
month
therapi
target
clinic
test
reveal
patient
fusion
braf
mutat
we
identifi
addit
frameshift
mutat
rnaseq
analysi
patient
reveal
infram
fusion
rare
found
pediatr
high
grade
glioma
patient
found
braf
mutat
we
rnaseq
reveal
infram
fusion
previous
report
case
thyroid
cancer
cn
tumor
postxrt
sampl
patient
reveal
mutat
seen
primari
tumor
conclus
potenti
target
somat
alter
target
mapk
pathway
identifi
three
case
megnt
mutat
indic
activ
mtor
signal
also
found
two
tumor
molecular
studi
larger
seri
megnt
need
confirm
primari
role
pathway
rare
tumor
clinic
trial
evalu
efficaci
agent
braf
mek
ntrk
mtor
inhibitor
target
genet
lesion
identifi
patient
indic
background
vorinostat
histon
deacetylas
hdac
inhibitor
interest
adult
pediatr
cancer
howev
concern
effect
hdac
inhibitor
compens
autophagi
hydroxychloroquin
autophagi
inhibitor
treatment
lead
accumul
autophagosom
acceler
tumor
cell
death
hypothes
combin
hdac
inhibitor
hydroxychloroquin
improv
antitumor
respons
compar
hdac
inhibitor
alon
pediatr
cancer
cell
line
object
determin
improv
efficaci
vorinostat
combin
hydroxychloroquin
pediatr
solid
tumor
cell
line
designmethod
differ
pediatr
cancer
cell
line
treat
vari
concentr
vorinostat
hydroxychloroquin
cell
viabil
measur
doserespons
curv
plot
determin
inhibitori
concentr
western
blot
analysi
perform
measur
express
prolifer
autophagi
marker
result
vorinostat
hydroxychloroquin
rang
respect
combin
treatment
result
dramat
decreas
cell
viabil
two
drug
cooper
dosedepend
manner
hydroxychloroquin
treatment
result
profound
convers
indic
autophagi
blockad
effect
greater
cell
treat
vorniostat
hydroxychloroquin
alon
final
exposur
combin
vorinostat
hydroxycholroquin
result
decreas
level
phosphoerk
compar
singleag
treatment
signifi
reduc
cell
prolifer
taken
togeth
data
demonstr
autophagi
inhibit
hydroxychloroquin
presenc
vorinostat
autophagosom
accumul
cell
viabilityprolifer
reduc
conclus
result
show
clear
improv
respons
vorinostat
combin
hydroxychloroquin
compar
vorinostat
alon
also
observ
increas
autophagi
inhibit
well
decreas
cell
prolifer
combin
studi
furthermor
concentr
vorinostat
necessari
effect
well
within
achiev
clinic
rang
combin
drug
yet
explor
pediatr
potenti
enhanc
effect
establish
chemotherapi
agent
wellknown
easili
access
noncanc
drug
background
drug
radiosensit
tumor
cell
spare
normal
tissu
could
signific
impact
efficaci
cancer
radiotherapi
novel
alkyl
phosphocholin
analog
belong
famili
synthet
antitumor
alkyl
phospholipid
compound
demonstr
radiosensit
capabl
show
tumorselect
uptak
wide
varieti
malign
tissu
therefor
hypothes
could
use
tumortarget
radiosensit
augment
radiat
respons
varieti
solid
tumor
object
examin
capabl
tumortarget
radiosensit
augment
radiat
respons
varieti
solid
tumor
designmethod
examin
radiosensit
effect
sever
pediatr
adult
solid
tumorderiv
human
cell
line
vitro
vivo
select
uptak
cancer
cell
versu
normal
cell
evalu
flow
cytometri
use
fluoresc
deriv
vitro
radiosensit
cancer
cell
evalu
clonogen
surviv
assay
use
differ
concentr
without
extern
beam
radiat
xrt
tumor
growth
rate
radiosensit
follow
xrt
examin
vivo
xenograftbear
athym
nude
mice
result
demonstr
significantli
higher
uptak
retent
cancer
line
test
neuroblastoma
skna
rhabdomyosarcoma
rd
ewe
sarcoma
prostat
carcinoma
compar
uptak
normal
human
fibroblast
p
significantli
reduc
clonogen
surviv
dose
depend
manner
combin
xrt
p
treatment
human
tumor
xenograft
fraction
extern
beam
radiat
combin
reveal
signific
increas
tumor
growth
delay
compar
radiat
treatment
alon
p
observ
toxic
treatment
conclud
tumor
target
capac
augment
therapeut
respons
extern
beam
radiat
varieti
solid
tumor
given
import
radiotherapi
pediatr
cancer
treatment
strategi
data
warrant
preclin
test
goal
translat
find
futur
clinic
trial
background
retinoblastoma
common
ocular
tumor
pediatr
standard
care
current
includ
local
control
laser
therapi
surgic
approach
enucl
radiat
chemotherapi
potenti
treatment
option
despit
advanc
chemotherapi
administr
allow
pediatr
oncologist
use
intraarteri
intravitr
chemotherapi
attempt
avoid
system
chemotherapi
side
effect
recurr
case
continu
challeng
treat
tri
preserv
sight
avoid
enucl
use
plaqu
brachytherapi
yet
wellestablish
option
recurr
retinoblastoma
object
discuss
role
brachytherapi
relaps
retinoblastoma
patient
designmethod
case
report
result
month
old
male
diagnos
bilater
retinoblastoma
group
c
diseas
right
eye
group
left
eye
present
pediatrician
mild
strabismu
extens
treatment
histori
due
continu
diseas
recurr
follow
close
exam
anesthesia
eua
local
control
differ
laser
therapi
receiv
five
cycl
system
chemotherapi
vincristin
carboplatin
etoposid
follow
intraarteri
chemotherapi
includ
melphalan
carboplatin
topotecan
etoposid
combin
intravitr
chemotherapi
melphalan
includ
left
eye
enucl
due
continu
diseas
recurr
despit
measur
central
macular
tumor
remain
measur
x
depth
choroid
invas
without
seed
right
eye
decid
attempt
plaqu
brachytherapi
salvag
treatment
plaqu
use
eye
physic
notch
gold
ophthalm
plaqu
seed
diamet
contain
sourc
vari
activ
millicuri
millicuri
deliv
gy
depth
treatment
time
hour
toler
brachytherapi
well
signific
immedi
side
effect
continu
excel
respons
evid
activ
tumor
week
initi
plaqu
placement
conclus
excel
diseas
respons
seen
plaqu
brachytherapi
seen
case
use
plaqu
brachytherapi
consid
viabl
treatment
option
retinoblastoma
relaps
case
research
need
determin
maxim
incorpor
brachytherapi
within
standard
care
practic
retinoblastoma
background
patient
small
welldifferenti
appendic
carcinoid
tumor
low
risk
recurr
current
nccn
guidelin
recommend
monitor
clinic
indic
practic
variat
provid
institut
regard
extent
durat
followup
object
character
followup
patient
appendic
carcinoid
tumor
designmethod
retrospect
chart
review
perform
institut
patient
patholog
diagnosi
appendic
carcinoid
variabl
analyz
includ
demograph
tumor
locat
size
extent
invas
surgic
intervent
postop
stage
surveil
tumor
recurr
cost
followup
includ
financi
time
famili
anxieti
note
result
thirti
patient
incident
diagnos
carcinoid
tumor
appendix
undergo
appendectomi
clinic
indic
averag
age
year
rang
mean
tumor
size
rang
microscop
occur
appendic
tip
n
node
infiltr
found
though
three
patient
perineur
one
patient
lymphovascular
invas
six
tumor
appendic
perfor
five
tumor
transmur
invas
mesoappendix
nineteen
patient
refer
oncolog
postop
stage
surveil
examin
includ
ultrasonographi
n
mri
n
ct
n
scan
major
n
underw
serial
test
mean
oncolog
followup
month
n
continu
surveil
two
patient
ongo
followup
year
diagnosi
includ
referr
cancer
survivor
clinic
surveil
test
normal
patient
requir
intervent
least
two
patient
travel
hour
clinic
visit
one
patient
comment
stressor
relat
cancer
diagnosi
medic
cost
followup
includ
clinic
visit
laboratori
monitor
imag
rang
per
patient
patient
without
oncolog
followup
repres
surgeri
oncolog
clinic
conclus
appendectomi
adequ
treatment
pediatr
appendic
carcinoid
despit
presenc
histolog
risk
factor
length
intens
postop
followup
vari
within
institut
followup
prolong
surveil
base
find
recommend
minim
oncolog
followup
prolong
surveil
lead
identif
recurr
rather
heighten
famili
inconveni
anxieti
cost
medic
care
background
alveolar
rhabdomyosarcoma
armss
aggress
pediatr
malign
origin
primit
mesenchym
tissu
associ
skelet
muscl
lineag
sarcomagenesi
driven
signatur
fusion
gene
use
genet
defin
model
arm
base
earli
express
human
skelet
muscl
precursor
laboratori
identifi
transcript
chang
silenc
hippo
pathway
recent
describ
tumor
suppressor
network
wide
dysregul
human
cancer
taz
transcript
coactiv
pdzbind
motif
transcript
coactiv
ordinarili
kept
check
upstream
hippo
kinas
implic
adult
epitheli
cancer
taz
known
regul
wildtyp
although
convey
mesenchym
phenotyp
role
sarcoma
report
object
investig
oncogen
role
taz
arm
tumorigenesi
designmethod
confirm
taz
upregul
arm
model
determin
use
nih
oncogenom
databas
taz
upregul
human
rm
tissu
sampl
examin
basal
taz
express
human
arm
cell
line
cultur
monolay
sphere
use
lossoffunct
two
independ
lentivirallydeliv
taz
shrna
interrog
role
taz
support
transform
vitro
last
use
doxinduc
taz
shrna
system
murin
xenograft
interrog
role
taz
support
tumorigenesi
vivo
result
taz
express
human
arm
cell
line
enrich
arm
rhabdospher
suggest
increas
stem
tazdirect
shrna
suppress
taz
mrna
protein
level
caus
profound
growth
arrest
vivo
mous
xenograft
studi
render
strong
phenotyp
tumor
mice
treat
doxycyclin
exhibit
decreas
tumor
growth
prolong
surviv
median
surviv
day
sucros
group
vs
day
dox
group
p
transcript
coactiv
taz
support
arm
cell
growth
vitro
vivo
suggest
silenc
hippo
tumor
suppressor
pathway
futur
studi
investig
mechan
occur
determin
taz
alter
transcript
output
physic
interact
current
therapeut
tractabl
hypothes
target
taz
may
attract
approach
treat
patient
arm
background
lymphat
malform
vascular
anomali
typic
occur
head
neck
less
frequent
mesenteri
object
describ
clinic
characterist
treatment
outcom
children
mesenter
lymphat
malform
singl
institut
designmethod
retrospect
analysi
children
diagnos
mesenter
lymphat
malform
perform
median
age
diagnosi
patient
year
approxim
twothird
patient
male
common
present
symptom
abdomin
pain
less
commonli
patient
present
volvulu
n
small
bowel
obstruct
n
four
patient
febril
present
two
document
bacteri
infect
diagnosi
confirm
histopatholog
assess
immunostain
posit
marker
lymphat
endothelium
patient
underw
gross
total
resect
partial
bowel
resect
two
patient
postop
complic
involv
fever
feed
intoler
andor
perfor
one
patient
underw
biopsi
alon
follow
observ
remain
asymptomat
stabl
growth
malform
proportion
size
imag
year
followup
length
followup
patient
rang
month
record
recurr
conclus
mesenter
lymphat
malform
pediatr
rare
patient
commonli
present
abdomin
pain
differenti
diagnosi
includ
abdomin
solid
tumor
surgic
resect
often
standard
care
institut
howev
altern
manag
strategi
includ
medic
therapi
sclerotherapi
warrant
investig
background
rhabdomyosarcoma
common
pediatr
softtissu
sarcomahedgehog
pathway
effector
andor
overexpress
major
embryon
rm
cell
aberr
hh
pathway
activ
confer
poor
prognosi
rhabdomyosarcoma
sixtythre
percent
slct
gynandroblastoma
n
intermedi
poorli
differenti
twentytwo
percent
n
slct
heterolog
element
includ
sarcomat
n
n
retiform
pattern
nineteen
percent
n
patient
thyroid
nodul
n
thyroid
cancer
four
percent
n
patient
develop
metachron
ovarian
stromal
tumor
n
patient
pleuropulmonari
blastoma
addit
n
report
non
tumor
n
recur
n
die
progress
diseas
forti
percent
n
patient
test
germlin
mutat
patient
slct
test
patient
germlin
mutat
patient
gynandroblastoma
preliminari
analys
show
addit
slct
biallel
somat
mutat
compar
germlin
neg
patient
preval
thyroid
nodul
vs
p
thyroid
cancer
vs
p
significantli
higher
among
germlin
posit
patient
germlin
mutat
appear
impact
outcom
primari
tumor
risk
factor
tumor
impact
biallel
somat
mutat
investig
conclus
enrol
ongo
half
individu
slct
patient
gynandroblastoma
germlin
mutat
biallel
somat
mutat
also
found
slct
find
warrant
investig
germlin
somat
mutat
review
screen
guidelin
doxorubicinbas
chemotherapi
use
upfront
receiv
upfront
chemotherapi
vincristin
actinomycin
cyclophosphamid
median
time
relaps
month
rang
month
vit
use
line
therapi
patient
respect
patient
site
relaps
solitari
distant
relaps
remaind
local
relaps
dose
vincristin
irinotecan
intraven
oral
administ
daili
day
temozolomid
administ
oral
daili
x
day
local
control
includ
radiat
surgeri
patient
best
respons
vit
follow
cr
pr
sd
pd
overal
rr
pf
month
median
follow
month
patient
aliv
without
diseas
aliv
diseas
patient
die
progress
diseas
conclus
retrospect
studi
demonstr
vit
moder
activ
patient
relaps
rhabdomyosarcoma
studi
backbon
combin
newer
agent
warrant
background
impair
memori
attent
execut
function
affect
childhood
leukemia
survivor
associ
methotrex
exposur
system
cisplatin
use
treat
varieti
childhood
adult
cancer
yet
risk
extent
cognit
impair
due
platinumbas
chemotherapi
unknown
system
cisplatin
cn
penetr
cytotox
neuron
neuron
stem
cell
hippocamp
dendrit
survivor
nonleukem
cancer
may
risk
signific
memori
impair
relat
cisplatin
driven
neurotox
object
explor
effect
system
cisplatin
hippocamp
amygdaladepend
memori
function
juvenil
rat
model
designmethod
twentyfour
male
spragu
dawley
rat
obtain
wean
postnat
day
cisplatin
consecut
day
intraperiton
administ
infanc
postnat
day
adolesc
postnat
day
match
control
receiv
normal
salin
intraperiton
valid
hippocampusdepend
memori
test
complet
adulthood
postnat
day
includ
novel
object
explor
contextu
object
discrimin
object
explor
record
second
discrimin
ratio
calcul
divid
differ
exploratori
time
object
total
exploratori
time
context
cu
fear
condit
perform
examin
hippocampu
amygdala
function
respect
percent
time
spent
freez
respons
context
stimulu
cu
stimulu
observ
comparison
made
use
unpair
ttest
result
novel
object
test
cisplatin
treat
adolesc
show
significantli
poor
retriev
familiar
object
compar
control
p
cisplatin
treat
infant
adolesc
howev
show
poor
discrimin
outofcontext
familiar
object
compar
control
infant
p
adolesc
p
final
cisplatin
treat
infant
show
near
signific
diminish
freez
respons
condit
context
stimulu
p
cisplatin
treat
infant
also
show
signific
diminish
respons
condit
cu
stimulu
p
conclus
hippocampaldepend
memori
function
impair
rat
expos
system
cisplatin
infanc
adolesc
type
degre
hippocamp
dysfunct
differ
depend
age
time
cisplatin
exposur
exposur
infanc
affect
hippocampu
amygdala
function
signifi
global
effect
memori
function
age
background
optim
treatment
strategi
patient
refractori
andor
metastat
osteosarcoma
os
yet
defin
continu
persist
challeng
high
degre
genet
aberr
tumor
heterogen
imped
identif
test
effect
therapeut
target
therefor
find
character
cellular
mechan
contribut
os
chemoresist
promis
strategi
design
therapi
chang
outlook
patient
diseas
object
endoplasm
reticulum
er
stress
pathway
known
promot
surviv
progress
cancer
cell
object
current
studi
examin
role
pathway
promot
chemoresist
os
designmethod
util
immunohistochemistri
western
blot
qpcr
immunofluoresc
bioinformat
tool
techniqu
examin
role
activ
transcript
downstream
effector
os
cell
patient
sampl
result
use
pathway
analysi
gene
express
dataset
human
os
primari
tumor
protein
process
er
found
significantli
enrich
os
tumor
compar
normal
tissu
confirm
activ
er
stress
pathway
perk
human
os
cell
line
found
three
pathway
differenti
activ
os
cell
line
activ
significantli
enhanc
chemoresist
cisplatin
irinotecan
combinatori
treatment
cisplatin
mtor
inhibitor
rapamycin
occur
via
inhibit
bax
activ
suppress
rhebmtor
inhibit
notch
signal
find
highlight
novel
mechan
chemoresist
os
retrospect
analysi
primari
tumor
patient
os
show
tumor
express
high
level
er
stress
induc
transcript
factor
downstream
prosurviv
effector
bip
pdi
express
associ
poor
histolog
respons
poor
surviv
patient
conclus
find
emphas
previous
uncharacter
role
nexu
uniqu
versatil
signal
network
regul
pathway
crucial
pathogenesi
therapi
resist
os
henc
therapeut
target
pathway
hold
promis
innov
effect
treatment
strategi
os
background
hepat
infantil
hemangioma
hih
benign
vascular
tumor
natur
cours
prolifer
stabil
involut
angiosarcoma
rare
highli
fatal
soft
tissu
sarcoma
endotheli
cell
origin
review
literatur
case
pediatr
hepat
angiosarcoma
coor
preexist
hepat
hemangioma
accept
guidelin
longterm
monitor
hepat
hemangioma
accept
standard
care
pediatr
treatment
angiosarcoma
object
describ
experi
hepat
hemangioma
associ
hepat
angiosarcoma
integr
result
publish
literatur
designmethod
patient
threeyearsold
unrel
present
abdomin
distens
constip
histori
small
untreat
cutan
infantil
hemangioma
result
case
one
girl
admit
multipl
diffus
hepat
hemangioma
requir
liver
transplant
histolog
analysi
resect
liver
reveal
posit
hih
island
highli
prolif
cellular
atypia
malign
transform
one
year
transplant
surveil
imag
detect
pulmonari
nodul
two
nodul
resect
histolog
reveal
patholog
complet
six
cycl
ifosfamidedoxorubicin
remain
complet
remiss
sixteen
month
diagnosiscas
two
boy
admit
larg
hepat
mass
hypothyroid
multipl
pulmonari
nodul
underw
gross
total
resect
tumor
patholog
show
posit
hih
island
angiosarcoma
diseas
progress
rapidli
sorafenib
therapi
therapi
chang
ifosfamidedoxorubicin
initi
partial
respons
diseas
progress
subsequ
switch
bevacizumabgemcitabinedocetaxel
despit
good
qualiti
life
experienc
progress
diseas
newli
form
metastat
hepat
nodul
prove
posit
infantil
hemangioma
die
fourteen
month
diagnosi
due
massiv
intratumor
hemorrhag
conclus
hih
may
risk
factor
develop
angiosarcoma
young
age
recommend
hepat
posit
hemangioma
ad
potenti
cancer
predisposit
condit
patient
monitor
prospect
vascular
anomali
cancer
predisposit
clinic
incidencetru
risk
develop
angiosarcoma
ascertain
hope
earli
detect
atyp
progress
may
lead
lifesav
medic
intervent
background
despit
advanc
diagnost
therapeut
approach
metastat
ewe
sarcoma
es
continu
extrem
poor
overal
surviv
mechan
drive
metastasi
remain
larg
unknown
necessit
examin
molecular
mechan
pathogenesi
novel
target
investig
therapi
integrin
famili
cellsurfac
protein
particip
import
cellsurfacemedi
intracellular
signal
pathway
involv
regul
critic
tumor
cell
properti
differenti
prolifer
dissemin
apoptosi
hypothesi
upregul
downstream
signal
event
perform
import
role
metastasi
es
may
potenti
therapeut
target
object
investig
role
downstream
signal
pathway
drive
establish
metastasi
es
designmethod
perform
vivo
studi
design
gain
insight
metastat
transcriptom
proteom
signatur
es
establish
human
es
cell
orthotop
transplant
tibia
mice
week
primari
bone
tumor
well
distal
metastat
lesion
isol
process
complet
proteom
studi
use
reversephas
protein
array
compar
protein
express
profil
primari
es
tumor
correspond
metastat
lesion
lung
secondari
bone
site
use
western
blot
analysi
valid
result
array
show
signific
alter
key
signal
molecul
includ
upregul
metastat
lung
secondari
bone
lesion
compar
primari
bone
lesion
fold
chang
p
valid
upregul
perform
protein
isol
previous
resect
primari
metastat
tumor
individu
assess
express
use
western
blot
analysi
confirm
consist
elev
express
metastat
site
compar
primari
tumor
es
cell
line
model
conclus
result
suggest
downstream
signal
event
may
play
key
role
abil
es
establish
metastat
foci
may
serv
potenti
therapeut
target
continu
investig
pathway
vitro
vivo
use
knockdown
overexpress
approach
assess
prolifer
apoptosi
invasionmigr
well
small
molecul
inhibitor
investig
pathway
potenti
therapeut
target
background
anthracyclin
commonli
use
antineoplast
agent
pediatr
oncolog
howev
use
limit
due
potenti
sever
cardiac
toxic
attempt
mitig
cardiotox
includ
dose
limit
use
iron
chelat
dexrazoxan
recent
preclin
data
shown
low
moder
intens
exercis
attenu
longterm
cardiotox
anim
receiv
chronic
doxorubicin
treatment
littl
known
effect
exercis
doxorubicin
diffus
cardiac
tissu
object
determin
whether
exercis
precondit
prior
treatment
reduc
doxorubicin
uptak
heart
tumorbear
mice
designmethod
tc
ewe
sarcoma
cell
inject
subcutan
nude
mice
tumor
allow
grow
day
anim
alloc
exercis
exercis
group
anim
exercis
group
exercis
treadmil
minday
rate
consecut
day
follow
day
rest
period
exercis
repeat
second
week
hour
final
exercis
session
anim
receiv
bolu
dose
doxorubicin
via
tail
vein
inject
remain
anim
serv
tissu
control
organ
excis
minut
post
inject
organ
tissu
weigh
prior
homogen
tissu
sampl
evalu
doxorubicin
uptak
use
acid
isopropanol
extract
spectrophotometri
averag
heart
size
exercis
train
anim
larger
nonexercis
train
anim
adjust
cardiac
tissu
size
exercis
precondit
anim
significantli
less
doxorubicin
present
cardiac
tissu
compar
unexercis
control
vs
fluoresc
unit
p
fig
interestingli
may
cardiac
specif
effect
chang
doxorubicin
level
liver
soleu
muscl
exercis
nonexercis
mice
fig
found
exercis
precondit
decreas
doxorubicin
uptak
cardiac
tissu
current
evalu
cardiac
vasculatur
express
mdr
transport
may
impact
doxorubicin
uptak
identifi
mechan
exercis
precondit
reduc
doxorubicin
cardiac
tissu
background
osteosarcoma
os
ewe
sarcoma
ew
common
pediatr
bone
cancer
patient
os
ew
dismal
five
year
overal
surviv
rate
metastat
diseas
adequ
local
control
imper
patient
surviv
littl
done
elucid
mechan
bone
sarcoma
radioresist
ew
consid
radiosensit
os
rel
radioresist
hypothes
specif
mechan
contribut
form
radiotherapeut
resist
bone
sarcoma
object
elucid
mechan
radiotherapeut
resist
os
ew
designmethod
administ
radiat
vitro
three
os
cell
line
three
ew
cell
line
establish
radiationtr
popul
control
popul
respect
wild
type
cell
receiv
radiat
character
radiationtr
popul
phenotyp
prolifer
invasionmigr
clonogen
assay
well
cell
surviv
repeat
radiat
exposur
also
perform
microarray
gene
express
gex
revers
phase
protein
array
rppa
radiationtr
popul
result
signific
chang
cell
prolifer
clonogen
chang
consist
os
ew
popul
note
differ
cell
surviv
radiationtr
cell
line
reexpos
radiat
howev
see
upward
trend
invas
variou
radiationtr
cell
line
gex
rppa
data
also
reveal
two
pathway
interest
statist
signific
differ
rna
protein
express
pathway
mtor
pathway
derang
link
multipl
cancer
mtor
pathway
implic
pathogenesi
bone
sarcoma
conclus
data
suggest
increas
invas
well
demonstr
statist
signific
differ
rna
protein
express
pathophysiolog
relev
pathway
radiationtr
bone
sarcoma
cell
conclud
find
warrant
investig
vitro
vivo
model
elucid
mechan
radiotherapeut
resist
current
develop
ewe
sarcoma
mous
model
use
radiationtr
cell
popul
also
plan
appli
relev
radiosensit
model
goal
translat
signific
result
improv
outcom
patient
bone
sarcoma
background
immunotherapi
reli
sever
patientspecif
paramet
includ
cell
number
expans
ii
target
immun
cell
tumor
iii
cell
surviv
function
infus
iv
onand
offtarget
advers
event
novel
approach
expans
gamma
delta
cell
oppos
alpha
beta
cell
pursu
gamma
delta
cell
reason
candid
antineoplast
immunotherapi
possess
inher
antitumorigen
ii
requir
prime
iii
direct
tumor
kill
via
recognit
stressrespons
ligand
show
iv
expand
cgmp
serum
free
media
sfm
bioengin
gamma
delta
cell
express
chimer
antigen
receptor
car
augment
anticanc
effect
highrisk
neuroblastoma
appropri
choic
gamma
delta
cellbas
immunotherapi
gamma
delta
cell
cytotox
neuroblastoma
cell
neuroblastoma
cell
express
known
target
antigen
object
optim
expans
transduct
antineuroblastoma
gamma
delta
cell
designmethod
effect
gamma
delta
cell
expans
stimul
bisphosphon
evalu
sever
sfm
expand
gamma
delta
cell
evalu
transduct
effici
use
lentivir
vector
expand
modifi
gamma
delta
cell
assess
cytox
toward
neuroblastoma
cell
result
sfm
cultur
one
show
reliabl
expans
clinic
relev
number
optmiz
media
supplement
highdos
led
robust
expans
well
effici
transduct
across
multipl
donor
compar
observ
alpha
beta
cell
similar
multipl
infect
gamma
delta
cell
cytotox
toward
neuroblastoma
cell
line
enhanc
addit
car
conclus
optim
method
gamma
delta
cell
expans
transduct
develop
test
earli
phase
clinic
trial
absenc
mhcrestrict
afford
opportun
appropri
elimin
alpha
beta
cell
use
allogen
set
limit
risk
graft
versu
host
diseas
use
sfm
provid
clinic
safer
potenti
efficaci
cellular
immunotherapi
gamma
delta
cell
display
cytotox
toward
neuroblastoma
increas
addit
car
background
osteosarcoma
common
primari
bone
cancer
children
adolesc
despit
real
improv
patient
outcom
past
decad
diagnosi
metastat
osteosarcoma
portend
except
poor
prognosi
fiveyear
surviv
rate
patient
metastas
less
even
neoadjuv
chemotherapi
treatment
gprotein
coupl
cell
surfac
receptor
activ
intracellular
signal
cascad
act
upon
thrombin
secret
serin
proteas
import
coagul
cascad
express
associ
increas
osteosarcoma
invas
metastasi
sought
determin
molecular
mechan
increas
occur
endotheli
cell
laboratori
observ
stimul
caus
activ
inflammatori
transcript
factor
famili
activ
close
associ
tissu
invas
extravas
step
metastasi
osteosarcoma
cancer
hypothes
intracellular
signal
complex
signalosom
may
play
role
signal
transduct
object
identifi
mechan
activ
osteosarcoma
determin
whether
pathway
suitabl
pharmacolog
inhibit
designmethod
activ
examin
use
immunoblot
phosphoryl
inhibitor
kappab
use
luciferas
report
assay
gene
transcript
evalu
realtim
pcr
studi
osteosarcoma
invas
vitro
use
transwel
chamber
boyden
chamber
assay
cell
invad
matrigel
layer
result
found
treatment
human
osteosarcoma
cell
either
thrombin
peptid
agonist
induc
robust
activ
canon
signal
pathway
specif
observ
phosphoryl
transcript
activ
luciferas
report
plasmid
nuclear
transloc
rela
subunit
discov
sirnamedi
knockdown
complet
abrog
activ
osteosarcoma
cell
addit
gene
express
profil
array
data
detail
metastat
reprogram
osteosarcoma
cell
present
conclus
stimul
caus
activ
fashion
osteosarcoma
cell
proteolyt
activ
inhibit
may
potenti
therapeut
strategi
combat
osteosarcoma
futur
background
central
giant
cell
granuloma
cgcg
benign
osteolyt
neoplasm
jaw
character
mass
infiltr
osteoclast
like
giant
cell
typic
slow
grow
painless
caus
loosen
displac
teeth
well
anatom
distort
teeth
manag
cgcg
conserv
though
minor
patient
may
requir
aggress
surgic
manag
affect
area
denosumab
rankl
inhibitor
demonstr
induc
regress
giant
cell
tumor
bone
gctb
though
distinct
condit
share
mani
similar
cgcg
object
evalu
label
use
denosumab
manag
cgcg
designmethod
male
present
histori
larg
recurr
progress
nontend
mandibular
biopsi
proven
cgcg
although
initi
treat
numer
attempt
curettag
subsequ
progress
also
receiv
intralesion
steroid
calcitonin
recurr
ongo
progress
consider
definit
surgic
manag
consist
partial
mandibulectomi
reconstruct
avoid
potenti
morbid
procedur
label
use
denosumab
initi
base
current
use
patient
gctb
patient
receiv
denosumab
sc
everi
week
three
week
follow
denosumab
sc
everi
month
respons
therapi
base
panoram
dental
radiograph
well
physic
exam
result
initi
exam
prior
start
denosumab
show
opaqu
greyish
lesion
anterior
mandibl
nontend
nonmobil
adjac
teeth
also
loosen
mobil
radiograph
show
radioluc
multilocul
anterior
mandibular
lesion
four
week
treatment
denosumab
lesion
show
regress
later
medial
aspect
lesion
increas
cortic
stabil
radiograph
show
calcif
lesion
month
denosumab
almost
complet
resolut
lesion
toxic
advers
event
denosumab
treatment
conclus
although
underli
pathogenesi
cgcg
unclear
variou
studi
implic
disregul
odontoclast
osteoclast
associ
resorpt
decidu
teeth
hypothes
inhibit
rankrankl
signal
pathway
diseas
may
effect
therapeut
modal
aspho
abstract
poster
background
pediatr
sarcoma
divers
group
malign
bone
soft
tissu
account
approxim
pediatr
cancer
subset
sarcoma
harbor
known
recurr
genom
alter
oncogen
gene
fusion
pathognomon
tumor
lack
recurr
alter
frequent
repres
diagnost
challeng
epigenet
modif
global
specif
chang
dna
methyl
increasingli
recogn
primari
mechan
oncogenesi
pediatr
cancer
genomewid
methyl
profil
emerg
power
tool
identifi
biolog
clinic
relev
subgroup
date
studi
limit
sampl
size
examin
genomewid
dna
methyl
pediatr
sarcoma
object
use
illumina
infinium
human
beadchip
array
array
platform
perform
genomewid
dna
methyl
analysi
pilotdiscoveri
cohort
pediatr
sarcoma
identifi
associ
gene
promot
cpg
island
methyl
signatur
explor
key
clinic
biolog
associ
designmethod
analyz
dna
pediatr
sarcoma
sampl
includ
osteogen
sarcoma
n
ewe
sarcoma
n
rhabdomyosarcoma
n
synovi
sarcoma
n
unsupervis
hierarch
cluster
analysi
perform
compar
epigenet
signatur
among
diseas
subtyp
result
unsupervis
hierarch
cluster
analysi
reveal
osteogen
sarcoma
ewe
sarcoma
synovi
sarcoma
tumour
distinct
dna
methyl
profil
whose
distribut
associ
known
histolog
subtyp
although
dna
methyl
profil
rhabdomyosarcoma
cluster
distinctli
tend
group
either
osteogen
synovi
sarcoma
conclus
abl
identifi
epigenet
signatur
distinctli
associ
known
histolog
subtyp
pediatr
sarcoma
result
suggest
dna
methyl
profil
diagnost
util
tumour
exploratori
analysi
investig
clinic
prognost
signific
geneticepigenet
chang
current
ongo
background
ependymoma
epn
third
common
malign
pediatr
brain
tumor
current
standard
treatment
maxim
safe
surgic
resect
follow
radiat
therapi
chemotherapi
proven
increas
surviv
outcom
event
free
surviv
prognosi
even
dismal
recurr
epn
occur
nearli
half
patient
known
cur
option
therefor
imper
learn
biolog
recurr
diseas
identifi
cellular
driver
epn
recurr
well
understand
mechan
therapi
resist
hypothes
ependymoma
recurr
driven
subpopul
therapyresist
tumor
cell
enhanc
tumorigen
scid
mice
object
studi
tumorigen
recurr
pediatr
ependymoma
differ
clinic
stage
whether
diagnosi
first
recurr
second
recurr
beyond
designmethod
last
year
collect
total
pediatr
ependymoma
patient
tumor
sampl
across
countri
identifi
patient
recurr
ependymoma
collect
tumor
sampl
recurr
n
set
median
age
patient
year
old
rang
year
median
time
first
recurr
month
rang
month
set
recurr
studi
tumorigen
brain
tumor
differ
clinic
stage
directli
implant
tumor
cell
cellsmous
patient
match
locat
brain
scid
mice
eg
human
cerebr
tumor
mous
cerebrum
human
cerebellar
tumor
mous
cerebellum
monitor
tumor
format
result
set
tumor
format
confirm
mous
brain
latest
recurr
patient
tumor
sampl
patient
earlier
stage
either
form
tumor
mous
brain
current
pend
tumor
format
remain
model
still
pend
conclus
preliminari
find
demonstr
progress
enhanc
tumorigen
ependymoma
recurr
becom
uniqu
extrem
valuabl
platform
studi
brain
tumor
recurr
result
seven
patient
analyz
mean
age
year
rang
year
local
recurr
rate
consolid
time
vari
month
occur
averag
month
surgeri
limb
function
consolid
classifi
good
excel
record
three
death
unrel
appli
techniqu
conclus
techniqu
offer
altern
biolog
reconstruct
ad
benefit
allow
perfect
bone
fit
easi
adjust
ligament
tendon
depend
bone
bank
foreign
materi
provid
rapid
consolid
lower
cost
greater
graft
longev
background
vemurafenib
us
fda
approv
treatment
relaps
refractori
braf
mutat
posit
malign
melanoma
demonstr
activ
multipl
nonmelanoma
braf
mutat
cancer
well
resist
alway
develop
monotherapi
preclin
studi
demonstr
concurr
mtor
inhibit
overcom
innat
acquir
resist
braf
inhibit
object
hypothes
combin
vemurafenib
plu
everolimu
mtor
inhibitor
well
toler
secondari
object
includ
efficaci
combin
therapi
posit
pediatr
aya
brain
tumor
designmethod
conduct
phase
studi
vemurafenib
everolimu
braf
mutat
tumor
includ
pediatr
aya
brain
tumor
appli
standard
design
step
wise
dose
modif
dose
vemurafenib
start
mgday
everolimu
start
mgday
result
five
patient
brain
tumor
age
rang
treat
two
glioblastoma
one
optic
pathway
glioma
one
pleomorph
xanthoastrocytoma
one
anaplast
astrocytoma
patient
previous
treat
includ
braf
inhibitor
monotherapi
three
patient
mgday
vemurafenib
mgday
everolimu
given
month
toxic
includ
grade
rash
two
heavili
pretreat
patient
show
progress
diseas
cycl
treatment
one
discontinu
treatment
due
noncompli
although
radiograph
partial
respons
seen
two
patient
activ
studi
partial
respons
stabl
diseas
month
combin
therapi
well
toler
one
except
grade
rash
patient
abl
continu
treatment
dose
modif
treatment
effect
observ
combin
therapi
even
patient
previous
treat
braf
inhibitor
monotherapi
studi
emphas
import
genom
profil
pediatr
aya
brain
tumor
conclus
populationbas
studi
examin
racialethn
differ
surviv
pediatr
medulloblastoma
highgrad
glioma
adjust
socioeconom
neighborhood
characterist
alarmingli
medulloblastoma
patient
public
health
insur
fare
wors
privat
insur
regardless
statu
comparison
racial
dispar
found
pediatr
highgrad
glioma
even
adjust
se
futur
research
need
uncov
remedi
reason
dispar
background
adolesc
young
adult
aya
patient
highrisk
recurrentmetastat
sarcoma
poor
prognosi
live
year
current
standard
treatment
patient
docetaxol
taxoter
bevacizumab
avastin
gemcitabin
gemzar
g
activ
sarcoma
one
studi
children
use
tag
yield
partial
respons
patient
stabl
diseas
one
jpho
object
report
preliminari
experi
novel
combin
highrisk
sarcoma
aya
patient
background
medulloblastoma
mb
common
malign
pediatr
brain
tumor
molecular
profil
recent
enabl
classif
mb
four
distinct
subgroup
group
patient
worst
prognosi
object
aim
discov
valid
target
lesion
mb
use
highthroughput
function
screen
designmethod
perform
kinas
inhibitor
screen
group
mb
cell
line
compar
sensit
individu
cell
line
primari
leukemia
sampl
establish
human
cancer
cell
line
identifi
recur
hit
within
pathway
specif
particular
line
use
target
western
blot
evalu
biochem
correl
pathway
vivo
efficaci
assess
use
murin
model
clinic
avail
inhibitor
lastli
primari
patient
cell
expand
intracrani
murin
model
plate
function
screen
result
interpret
cell
line
data
result
kinas
screen
reveal
cluster
sensit
mtor
inhibitor
igfr
inhibitor
aurora
kinas
inhibitor
cell
respect
western
blot
corrobor
pathway
hyperactiv
cell
line
interest
uniqu
exom
sequenc
reveal
novel
somat
variant
unknown
function
signific
tumor
suppressor
gene
molecular
analysi
mutat
demonstr
diminish
protein
destabil
heterolog
express
system
vivo
studi
show
target
tumor
suppress
use
fdaapprov
mtor
inhibitor
cell
minim
suppress
cell
confirm
screen
reveal
specif
target
pathway
perhap
importantli
success
obtain
inhibitor
data
primari
patient
tumor
import
proofofconcept
tool
provid
reliabl
inform
primari
sampl
less
hour
conclus
taken
togeth
find
indic
subset
highrisk
mb
patient
may
function
relev
hyperactiv
target
pathway
may
found
tradit
exom
sequenc
function
screen
may
offer
addit
tool
inform
adjunct
treatment
decis
complex
heterogen
diseas
background
osteosarcoma
os
common
primari
malign
bone
tumor
children
adolesc
surviv
remain
stagnant
past
year
new
therapeut
combin
desper
need
previou
studi
use
car
tcell
shown
benefit
treatment
os
howev
car
tcell
therapi
alon
complet
erad
tumor
upregul
immun
checkpoint
pathway
program
ligand
tumor
cell
shown
limit
immunotherapeut
efficaci
blockad
shown
surviv
prognost
benefit
variou
tumor
object
investig
combin
approach
use
car
tcell
antibodi
treat
os
cell
similarli
note
myc
induc
lymphoma
model
shrna
direct
essenti
autophagi
gene
augment
cell
death
follow
activ
amravadi
et
al
base
current
literatur
preliminari
data
hypothes
myc
driven
medulloblastoma
high
autophagi
key
mechan
therapeut
resist
cell
surviv
object
primari
object
establish
increas
myc
express
induc
higher
level
autophagi
medulloblastoma
cell
chemic
inhibitor
autophagi
augment
effect
cytotox
drug
use
treatment
medulloblastoma
designmethod
experiment
model
use
test
hypothesi
daoy
cell
medulloblastoma
cell
deriv
pediatr
patient
tumor
known
myc
amplif
oncogen
myc
introduc
use
lentivir
construct
daoymyc
empti
express
vector
daoyctr
control
order
gener
isogen
cell
line
primari
assay
util
assess
autophagi
autophag
flux
use
detect
protein
level
immunoblot
without
lysomotroph
agent
result
daoymyc
cell
consist
demonstr
higher
basal
autophagi
compar
daoyctr
demonstr
detect
higher
protein
treat
lysomotroph
agent
onehour
treatment
hcq
demonstr
similar
flux
cell
line
indic
presenc
function
autophagi
furthermor
phenotyp
lost
myc
inhibit
use
rnai
daoymyc
cell
moreov
protein
express
diminish
daoymyc
cell
conclus
introduc
myc
medulloblastoma
cell
increas
autophagi
basal
growth
condit
phenotyp
autophagi
increas
note
lab
cell
line
driven
kra
oncogen
highlight
share
resist
mechan
two
distinct
oncogen
patrick
leavey
harish
babu
arunachalam
bogdan
armaselu
ovidiu
daescu
anita
sengupta
dinesh
rakheja
stephen
skapek
johnpaul
bach
samuel
glick
kevin
cederberg
background
tumor
necrosi
tn
remain
signific
predictor
surviv
patient
nonmetastat
osteosarcoma
interpret
tn
provid
data
first
week
chemotherapi
provid
inform
late
make
clinic
meaning
adjust
therapi
propos
modern
technolog
digit
whole
slide
imag
wsi
imag
pattern
recognit
provid
basi
enhanc
interpret
import
biomark
object
accur
identifi
featur
tumor
necrosi
imag
pattern
recognit
ipr
histolog
whole
slide
imag
wsi
resect
osteosarcoma
designmethod
develop
investig
team
clinic
scientist
univers
texa
southwestern
dalla
comput
scientist
univers
texa
dalla
archiv
sampl
patient
treat
children
medic
center
dalla
identifi
case
repres
singl
tumor
slide
time
biopsi
avail
use
imag
segment
slide
case
time
resect
necrosi
determin
slide
scan
use
aperio
scanscop
c
store
portabl
terabyt
harddriv
sv
format
compress
tiff
file
format
use
tumor
map
creat
time
origin
histolog
evalu
slide
digit
knit
singl
whole
slide
imag
imag
segment
requir
featur
identif
base
region
color
cellular
shape
region
cellular
densiti
ongo
retriev
tumor
map
tumor
biopsi
tumor
resect
specimen
archiv
store
case
highgrad
osteosarcoma
respect
complet
digit
case
develop
comput
tool
digit
knit
singl
slide
case
singl
whole
slide
imag
wsi
initi
process
imag
segment
prospect
reevalu
tumor
necrosi
test
case
two
pathologist
blind
interpret
develop
necrosisdigit
analysi
softwar
begun
develop
necessari
technolog
autom
interpret
tn
osteosarcoma
prospect
studi
comparison
routin
evalu
tn
newli
diagnos
patient
background
central
nervou
system
cn
tumor
common
solid
tumor
childhood
adolesc
lead
diseaserel
caus
death
one
nineteen
year
age
unit
state
unit
kingdom
uk
recognit
delay
diagnosi
led
develop
program
call
headsmart
design
enhanc
awar
sign
symptom
brain
cancer
children
among
healthcar
provid
gener
public
goal
reduc
delay
diagnosi
apart
singl
report
diagnost
delay
children
lowgrad
glioma
addit
report
evalu
delay
unit
state
sinc
late
object
establish
accur
ohio
baselin
symptom
onset
definit
diagnosi
children
newlydiagnos
cn
tumor
designmethod
medic
record
retrospect
review
children
newlydiagnos
cn
tumor
januari
august
nationwid
children
hospit
sinc
electron
medic
record
system
began
late
usabl
data
patient
record
review
age
gender
tumor
type
present
symptom
number
healthcar
visit
prior
diagnosi
time
interv
month
onset
symptom
definit
diagnosi
associ
genet
syndrom
result
patient
newlydiagnos
cn
tumor
children
known
predisposit
syndrom
neurofibromatosi
type
tuber
sclerosi
among
remain
children
median
time
interv
symptom
onset
definit
diagnosi
day
mean
symptom
interv
day
rang
day
addit
common
present
symptom
among
institut
cohort
headach
nausea
vomit
unsteadi
gait
visual
disturb
seizur
document
quantifi
contemporari
delay
diagnosi
childhood
brain
tumor
central
ohio
serv
benchmark
futur
background
brain
tumor
second
common
caus
cancer
children
common
solid
tumor
neuron
mix
neuronalgli
tumor
central
nervou
system
cn
rel
rare
world
health
organ
classif
revis
includ
four
addit
tumor
type
total
subtyp
although
two
publish
metaanalys
studi
includ
mix
popul
mani
adult
patient
knowledg
avail
neuronalgli
tumor
case
seri
includ
larg
number
pediatr
patient
one
center
object
describ
demograph
clinic
characterist
treatment
outcom
neurogli
tumor
pediatr
patient
tertiari
care
center
designmethod
studi
retrospect
review
patient
age
less
year
diagnos
surgic
patholog
neuron
mix
neuronalgli
tumor
subtyp
base
classif
tertiari
care
children
hospit
case
met
elig
review
data
includ
demograph
clinic
imag
patholog
treatment
morbid
mortal
extract
hospit
cn
databas
neuropathologist
neuroradiologist
particip
patient
select
adjust
patholog
patient
classif
diagnos
prior
guidelin
result
patient
met
elig
criteria
averag
follow
time
three
year
predomin
tumor
subtyp
ganglioglioma
dysembryoplast
neuroepitheli
tumor
patient
treat
surgeri
alon
three
patient
receiv
chemotherapi
two
patient
receiv
radiat
nine
patient
progress
tumor
first
resect
averag
time
progress
month
patient
progress
like
present
seizur
v
like
undergo
subtot
resect
overal
surviv
conclus
neuron
mix
neuronalgli
tumor
cn
extrem
rare
understand
differ
neurogli
tumor
subtyp
remain
difficult
studi
contribut
pediatr
literatur
describ
first
time
diagnosi
treatment
prognos
rare
tumor
type
children
result
nine
patient
male
femal
median
age
diagnosi
year
rang
year
age
median
followup
month
rang
month
eight
patient
paramening
tumor
primari
site
patient
extraoss
tumor
includ
patient
orbit
tumor
patient
present
metastat
diseas
seven
tumor
transloc
initi
chemotherapi
regimen
includ
vdcie
vai
vac
local
control
consist
surgeri
radiat
therapi
surgeri
radiat
therapi
median
dose
radiat
therapi
receiv
rang
gy
last
followup
patient
aliv
evid
diseas
ned
patient
aliv
diseas
four
patient
die
diseas
includ
patient
initi
present
metastasi
patient
paramening
tumor
aliv
ned
aliv
diseas
patient
orbit
tumor
aliv
ned
month
followup
patient
ewe
sarcoma
head
neck
es
locat
presenc
metastasi
diagnosi
singl
import
factor
overal
surviv
small
cohort
size
prevent
subset
analysi
prognost
factor
treatment
h
n
es
patient
requir
multimod
specialti
care
perform
treatment
center
well
vers
treat
rare
bone
tumor
background
choroid
plexu
carcinoma
aggress
grade
iii
tumor
commonli
found
children
despit
multimod
treatment
overal
surviv
close
object
describ
case
patient
recurr
choroid
plexu
carcinoma
evid
diseas
undergo
treatment
abscess
resect
caviti
designmethod
case
report
result
girl
diagnos
right
pariet
choroid
plexu
carcinoma
present
progress
unsteadi
gait
famili
histori
notabl
breast
cancer
mother
subsequ
genet
workup
posit
mutat
li
fraumeni
syndrom
diagnos
underw
near
total
resect
tumor
follow
cycl
chemotherapi
etoposid
carboplatin
cyclophosphamid
three
month
complet
treatment
note
larg
recurr
surgic
caviti
repeat
resect
underw
radiat
therapi
first
brain
mri
radiat
therapi
show
enhanc
nodul
upon
resect
found
recurrentresidu
tumor
start
chemotherapi
temozolomid
irinotecan
bevacizumab
ten
day
initi
chemotherapi
patient
develop
subgal
epidur
intraparenchym
abscess
along
surgic
tract
oper
wound
cultur
posit
methicillinsensit
staphylococcu
aureu
treatment
antibiot
initi
cours
complic
recurr
wound
dehisc
unsuccess
primari
closur
despit
multipl
attempt
due
deterior
qualiti
life
face
tumor
recurr
parent
chose
pursu
palli
care
continu
oral
antibiot
prophylaxi
month
repeat
mri
brain
show
persist
right
pariet
lobe
abscess
peripher
enhanc
around
surgic
caviti
suggest
inflammatori
reaction
rather
tumor
restart
iv
antibiot
palli
purpos
repeat
mri
brain
month
antibiot
therapi
show
resolut
abscess
evid
tumor
conclus
case
rais
interest
question
regard
role
immunomodul
cancer
therapi
given
follow
develop
inflammatori
respons
bacteri
intracrani
abscess
tumor
previous
resist
numer
resect
chemotherapeut
agent
cranial
irradi
appar
resolv
background
primari
histiocyt
sarcoma
hs
rare
neoplasm
common
adult
children
origin
liver
splenic
gastrointestin
lymphoid
cutan
tissu
central
nervou
system
cn
primari
locat
less
common
usual
aggress
poor
prognosi
case
report
children
medic
literatur
among
case
even
fewer
primari
cn
tumor
current
underli
etiolog
hs
unknown
standard
therapi
object
report
case
primari
cn
histocyt
sarcoma
year
old
male
order
increas
knowledg
avail
medic
literatur
regard
rare
tumor
designmethod
review
perform
patient
medic
record
avail
medic
literatur
pertain
pediatr
hs
focu
cn
tumor
review
english
medic
literatur
sinc
identifi
pediatr
patient
cn
hs
among
patient
age
patient
year
old
male
pmh
autism
speech
delay
perinat
hiv
exposur
asthma
sleep
apnea
present
visual
hallucin
new
onset
seizur
disord
mri
brain
identifi
left
pariet
dural
base
mass
surgic
resect
mass
perform
patholog
show
prolifer
histiocyt
nuclear
atypia
consist
hs
patient
receiv
proton
beam
radiat
therapi
start
ice
ifosfamid
carboplatin
etoposid
base
therapi
ongo
evalu
third
cycl
conclus
current
standard
therapi
hs
treatment
strategi
includ
surgic
resect
chemotherapi
radiat
complet
surgic
resect
feasibl
consid
sinc
may
provid
better
prognosi
sever
chemotherapi
regimen
use
includ
type
therapi
high
dose
cytarabin
chop
ice
report
poor
outcom
report
patient
treatment
regimen
highlight
need
collabor
effort
intern
registri
clinic
trial
develop
novel
therapeut
approach
result
age
diagnosi
rang
month
year
locat
tumor
includ
hypothalam
chiasmat
region
ventricl
cerebellar
hemispher
two
case
achiev
gross
total
resect
present
cerebellar
hemispher
three
case
partial
resect
surgeri
progress
observ
period
patient
gross
total
resect
progress
diseas
progress
eventu
receiv
radiat
therapi
age
year
progress
patient
live
diseas
stabl
imag
find
time
review
endocrinopathi
present
noncerebellar
tumor
neurolog
deficit
rare
typic
involv
visual
defect
conclus
gross
total
resect
cerebellar
pma
prevent
tumor
recurr
cohort
similar
find
pa
hypothalam
chiasmat
lesion
tumor
less
apt
complet
resect
henc
requir
differ
manag
hypothalam
chiasmat
tumor
also
experi
differ
late
effect
base
locat
treatment
patient
aliv
henc
reveal
poorer
prognosi
compar
pa
although
import
observ
patient
longer
period
time
definit
establish
progressionfre
surviv
late
effect
pma
patient
compar
matur
pa
patient
seri
children
hospit
eastern
ontario
ottawa
ontario
canada
background
outcom
children
infant
diagnos
acut
myeloid
leukemia
aml
improv
howev
literatur
treatment
infant
aml
diagnos
utero
object
report
first
case
fetu
diagnos
aml
utero
designmethod
parent
consent
background
clinic
inform
histori
present
ill
result
relev
laboratori
investig
intend
cours
manag
review
result
cordocentesi
done
woman
week
gestat
age
ga
investig
fetal
hepatomegali
show
hemoglobin
gl
leukocytosi
thrombocytopenia
investig
includ
morpholog
examin
flow
cytometri
confirm
diagnosi
aml
monocyt
type
fetu
subsequ
cytogenet
analysi
show
mix
lineag
leukemia
mll
aneuploidi
mll
gene
disrupt
exchang
transfus
via
cordocentesi
plan
extend
gestat
optim
neonat
outcom
mother
develop
mirror
syndrom
week
ga
underw
urgent
caesarean
section
live
femal
infant
born
edema
distend
abdomen
petechia
ecchymos
spontan
respiratori
effort
labwork
show
hemoglobin
gl
white
blood
cell
count
platelet
abnorm
coagul
profil
resuscit
unsuccess
two
hour
life
parent
chose
palliat
child
autopsi
demonstr
dissemin
leukemia
involv
central
nervou
system
liver
bone
marrow
placenta
conclus
possibl
diagnos
hematolog
malign
fetu
even
neonat
littl
inform
direct
manag
intend
begin
exchang
transfus
via
cordocentesi
reduc
leukocytosi
therebi
prolong
gestat
stabl
deliveri
use
low
dose
chemotherapi
infant
term
thought
abl
toler
full
treatment
unfortun
mother
infant
well
enough
pursu
cours
fetal
leukemia
consid
differenti
diagnosi
fetu
present
hepatomegali
similar
case
identifi
clinician
share
experi
provid
futur
guidanc
manag
background
indoleamin
ido
natur
counterregulatori
mechan
suppress
antitumor
immun
although
clinic
trial
current
combin
immunotherapi
drug
standardofcar
chemotherapi
preclin
data
suggest
idoinhibitor
indoximod
synerg
chemotherapi
radiat
therefor
develop
firstinchildren
trial
studi
indoximod
companion
adult
glioblastoma
studi
combin
indoximod
temozolomid
well
toler
doselimit
toxic
sixmonth
progressionfre
surviv
pf
adult
patient
compar
relaps
glioblastoma
histor
two
patient
previous
progress
temozolomid
one
patient
one
patient
demonstr
partial
respons
month
therapi
respect
patient
surviv
month
date
continu
therapi
object
present
interim
result
ongo
pediatr
studi
designmethod
trial
assess
feasibl
safeti
preliminari
evid
efficaci
combin
indoximod
either
temozolomid
radiat
therapi
follow
temozolomid
treat
children
age
progress
malign
brain
tumor
exclud
dipg
indoximod
dose
level
start
adult
recommend
dose
one
year
old
patient
recurr
metastat
ependymoma
treat
indoximod
stereotact
radiosurgeri
toler
without
toxic
went
receiv
indoximod
combin
temozolomid
time
enrol
previous
receiv
separ
surgeri
proton
therapi
posterior
fossa
fraction
craniospin
proton
therapi
fraction
proton
therapi
background
hepatoblastoma
common
type
pediatr
liver
malign
signal
abnorm
betacatenin
pathway
associ
tumor
fact
betacateninyap
yesassoci
protein
coactiv
observ
hepatoblastoma
patient
overexpress
yap
betacatenin
mice
led
hepatoblastoma
develop
gene
array
analysi
mrna
isol
tumor
bear
liver
reveal
gene
show
signific
upregul
tumor
also
bind
site
promot
transcript
factor
bind
betacatenin
tead
bind
yap
one
gene
lipocalin
small
molecul
protein
known
antibacteri
properti
found
express
varieti
adult
cancer
object
determin
lipocalin
express
human
hepatoblastoma
designmethod
use
tissu
microarray
patient
hepatoblastoma
sampl
tertiari
care
pediatr
hospit
evalu
presenc
lipocalin
immunohistochemistri
tumor
classifi
histolog
type
degre
lipocalin
stain
grade
scale
stain
stratifi
either
nuclear
cytoplasm
next
cell
lysat
cell
cultur
human
heptoblastoma
cell
line
test
presenc
lipocalin
use
western
blot
analysi
result
lipocalin
normal
express
hepatocyt
found
present
either
nucleu
cytoplasm
pediatr
hepatoblastoma
sampl
degre
stain
lipocalin
vari
within
sampl
base
tumor
histolog
embryon
compon
strongli
posit
lipocalin
stain
score
ninetysix
percent
crowd
fetal
histolog
compon
posit
lipocalin
stain
although
stain
rang
intens
minim
express
lipocalin
blastema
small
cell
undifferenti
compon
lipocalin
also
confirm
present
hepatoblastoma
cell
cultur
western
blot
analysi
identifi
increas
express
lipocalin
downstream
betacatenin
yap
activ
hepatoblastoma
cell
patient
tissu
lipocalin
may
play
import
role
betacateninyap
driven
hepatoblastoma
develop
primari
children
hospit
univers
utah
salt
lake
citi
utah
unit
state
background
cytomegaloviru
cmv
retin
complic
immunosuppress
host
typic
seen
acquir
immunodefici
syndrom
hematopoiet
stem
cell
transplant
patient
howev
cmv
retin
occur
therapi
acut
lymphoblast
leukemia
without
transplant
rare
describ
object
describ
case
adolesc
tcell
acut
lymphoblast
leukemia
tall
mainten
present
acut
vision
loss
due
cmv
retin
designmethod
case
report
review
literatur
acut
vision
loss
right
eye
ophthalmolog
examin
show
rightsid
affer
pupillari
defect
poor
visual
acuiti
larg
visual
field
deficit
left
eye
vision
unaffect
fundoscop
examin
reveal
bilater
optic
disc
edema
peripapillari
hemorrhag
scatter
retin
hemorrhag
central
larg
area
retin
whiten
cotton
wool
spot
differenti
diagnosi
base
ophthalmolog
examin
includ
leukem
versu
infecti
retinopathi
mri
brainorbit
neg
intracrani
patholog
orbit
mass
optic
nerv
edema
total
white
blood
cell
count
absolut
neutrophil
count
anc
absolut
lymphocyt
count
alc
vitreou
aspir
perform
intravitr
inject
amphotericin
vancomycin
ceftazidim
clindamycin
ganciclovir
vitreou
fluid
posit
cmv
polymeras
chain
reaction
pcr
cmv
dna
also
detect
serum
quantit
pcr
vitreou
cell
neg
malign
flow
cytometri
bone
marrow
cerebrospin
fluid
also
neg
malign
therefor
diagnosi
cmv
retin
made
treat
threeweek
cours
valganciclovir
follow
prophylact
dose
visual
acuiti
stabl
improv
retin
fundoscop
exam
remain
visual
field
deficit
conclus
cmv
retin
rare
report
complic
therapi
without
transplant
occurr
cmvreactiv
recogn
especi
patient
cellmedi
immunodefici
patient
alc
time
present
cmv
retin
ophthalmolog
exam
find
alon
may
differenti
leukem
infiltr
cmv
retin
case
vitreou
aspir
consid
confirm
diagnosi
million
patient
receiv
preoper
chemotherapi
platinum
agent
median
cycl
rang
cycl
extend
right
hepatectomi
perform
patient
patient
two
addit
wedg
resect
segment
left
lobe
extend
left
hepatectomi
patient
margin
posit
patient
patient
margin
neg
closest
margin
rang
mm
two
patient
requir
vascular
reconstruct
ivc
month
median
followup
rang
year
none
patient
local
recurr
patient
recurr
pulmonari
diseas
month
surgeri
case
afp
fall
expect
start
rise
soon
surgeri
conclus
patient
advanc
hb
receiv
complex
surgic
resect
posit
microscop
margin
close
neg
margin
margin
mm
good
outcom
hypothes
plan
posit
microscop
margin
highli
select
hb
patient
may
spare
morbid
olt
background
dramat
increas
obes
rate
among
children
unit
state
us
associ
obes
cancer
wide
studi
show
obes
patient
risk
multipl
side
effect
poor
outcom
nonalcohol
fatti
liver
diseas
nafld
common
caus
chronic
liver
diseas
pediatr
patient
us
known
effect
treatment
nafld
except
diet
exercis
lcarnitin
use
prior
studi
treat
chemotherapyinduc
liver
toxic
use
pediatr
oncolog
patient
fatti
liver
identifi
highrisk
group
pediatr
oncolog
patient
risk
develop
fatti
liver
complic
object
describ
pediatr
patient
relaps
tcell
acut
lymphoblast
leukemia
tall
fatti
liver
diseas
treat
lcarnitin
designmethod
review
medic
record
result
obes
thirteen
yearold
boy
relaps
tall
found
persist
elev
liver
enzym
ast
alt
peak
normal
respect
despit
break
chemotherapeut
regimen
imag
perform
show
chang
consist
fatti
liver
due
risk
sinusoid
obstruct
syndrom
so
bone
marrow
transplant
bmt
held
maintain
remiss
given
chemotherapi
addit
start
lcarnitin
gram
oral
twice
day
attempt
lower
liver
enzym
three
month
treatment
ast
alt
gradual
improv
near
normal
level
bmt
haploident
donor
pursu
transplant
regimen
overal
well
toler
without
evid
so
patient
continu
remiss
continu
lcarnitin
side
effect
lcarnitin
observ
conclus
patient
lcarnitin
thought
improv
transamin
enabl
undergo
bmt
transamin
due
fatti
liver
signific
factor
lead
alter
interrupt
chemotherapi
regimen
increas
transplant
morbid
thu
affect
overal
surviv
increas
risk
relaps
lcarnitin
supplement
along
diet
exercis
regimen
may
abl
improv
transamin
revers
fatti
liver
overal
welltoler
without
signific
toxic
prospect
studi
need
background
hepatocellular
carcinoma
hcc
second
common
pediatr
liver
malign
annual
incid
per
million
children
unit
state
hcc
associ
underli
hepat
cellular
injuri
lead
liver
cell
dysplasia
describ
hemochromatosi
defici
hereditari
tyrosinemia
glycogen
storag
disord
niemannpick
diseas
type
c
npc
autosom
recess
liposom
storag
diseas
character
dysfunct
cholesterol
transport
accumul
sphingomyelin
cholesterol
lysosom
result
hepatosplenomegali
hepat
dysfunct
rare
case
hcc
npc
exist
literatur
clear
link
two
establish
object
present
male
npc
present
acut
abdomin
distens
hemodynam
instabl
mri
reveal
larg
heterogeneouslyenhanc
solid
mass
medial
segment
left
hepat
lobe
smaller
lesion
anterior
right
hepat
lobe
concern
intrahepat
metastasi
head
chest
ct
scan
neg
distant
metastas
biopsi
confirm
hcc
stage
iii
diseas
alpha
fetoprotein
afp
diagnosi
elev
iuml
patient
underw
upfront
resect
left
side
mass
biopsi
right
hepat
lesion
designmethod
upfront
resect
improv
likelihood
success
treatment
due
residu
right
hepat
diseas
patient
receiv
cycl
cisplatin
doxorubicin
administ
everi
week
modifi
plado
regimen
twice
daili
sorafenib
fdaapprov
tyrosin
kinas
inhibitor
due
vomit
diarrhea
complianc
issu
approxim
plan
sorafenib
dose
administ
result
patient
respond
treatment
evid
diseas
mri
imag
afp
normal
iuml
follow
surgic
resect
cycl
chemotherapi
three
month
therapi
evid
diseas
recurr
mri
imag
monthli
afp
remain
normal
rang
iuml
conclus
hcc
rare
challeng
entiti
pediatr
oncolog
classic
associ
npc
patient
suffer
hepat
damag
time
risk
malign
transform
rais
question
regard
routin
screen
either
radiograph
laboratori
test
monitor
afp
level
background
invas
fungal
infect
children
cancer
disproportion
affect
leukemia
patient
conidiobolu
entomopthoromycota
found
tropic
region
associ
rhinofaci
infect
although
rare
pediatr
oncolog
high
mortal
spread
rapidli
report
treatment
adolesc
acut
lymphoblast
leukemia
multidrug
resist
mdr
invas
sinopulmonari
conidiobolu
infect
object
describ
manag
strategi
support
neutrophil
function
treat
invas
conidiobolu
infect
patient
receiv
chemotherapi
designmethod
case
report
yearold
male
present
intermitt
fever
fatigu
cough
petechia
sever
neutropen
circul
blast
diagnos
began
induct
chemotherapi
concomit
antifung
prophylaxi
day
induct
develop
congest
leftsid
facial
pain
nasal
endoscopi
reveal
pale
insens
mucosa
imag
show
diffus
nodular
ground
glass
opac
throughout
lung
nasal
biopsi
reveal
branch
hyph
septat
suggest
aspergillu
voriconazol
micafungin
start
empir
day
cultur
fungu
show
zygospor
promin
beak
sporangiola
characterist
conidiobolu
speci
organ
resist
antifung
agent
except
terbinafin
amphotericin
b
anidulafungin
intermedi
treatment
chang
liposom
amphotericin
b
lamb
anidulafungin
terbinafin
bone
marrow
aspir
neg
leukemia
day
induct
due
progress
pulmonari
sinu
diseas
extend
skull
base
chemotherapi
temporarili
halt
neutrophil
support
augment
daili
gmcsf
granulocyt
infus
hyperbar
oxygen
therapi
hbot
granulocyt
infus
discontinu
follow
endogen
neutrophil
recoveri
day
diagnosi
lamb
gmcsf
hbot
continu
sever
week
imag
dramat
improv
sinu
fungal
cultur
becam
neg
week
without
neutropenia
chemotherapi
resum
continu
aggress
neutrophil
support
sever
neutropen
leukemia
remain
remiss
without
evid
progress
fungal
diseas
conclus
multidisciplinari
care
crucial
simultan
treatment
life
threaten
fungal
infect
use
aggress
support
neutrophil
function
effect
control
dissemin
mdr
conidiobolu
infect
allow
deliveri
myelosuppress
chemotherapi
designmethod
two
young
peopl
lost
live
cancer
year
turn
eighteen
thespian
yearold
yo
theatr
lover
burden
osteosarcoma
bladder
sarcoma
tumor
infiltr
spine
leav
parapleg
complet
depend
famili
time
independ
paramount
lay
hospit
bed
twin
brother
search
colleg
dream
endoflif
mom
fire
palli
care
frank
code
statu
discuss
slap
face
mortal
guardian
yo
metastat
ewe
sarcoma
ringlead
gang
aya
male
carri
diagnosi
prognosi
mother
insist
never
told
bad
delirium
plagu
final
day
despit
desper
attempt
keep
truth
throughout
treatment
cours
parent
devast
could
nt
particip
endoflif
decis
make
due
patient
famili
refus
palli
care
involv
two
week
prior
death
guis
call
support
care
team
result
young
men
die
hospit
minim
palli
care
support
uniqu
development
social
emot
ethic
existenti
struggl
aya
popul
benefit
highli
special
interdisciplinari
approach
howev
case
highlight
conflict
autonomi
parent
protect
possibl
deviat
norm
develop
barrier
effect
endoflif
care
aya
popul
earlier
engag
educ
aya
patient
famili
regard
palli
care
may
facilit
improv
commun
weiner
clin
oncol
adolesc
young
adult
poster
ebvdriven
polyclon
bcell
prolifer
occur
mucocutan
tissu
elderli
patient
immunosenesc
patient
immunosuppress
therapi
limit
tcellrepertoir
true
incid
ebvmcu
unknown
due
selfresolv
natur
limit
awar
amongst
clinician
object
gener
awar
ebvmcu
amongst
clinician
designmethod
case
report
result
year
old
male
intermedi
risk
tcell
mainten
phase
chemotherapi
cog
protocol
present
left
side
throat
pain
exud
left
tonsillar
ulcer
concern
abscess
versu
leukem
infiltr
tonsillar
biopsi
show
dens
polymorph
infiltr
lymphocyt
neutrophil
plasma
cell
histiocyt
small
sheet
larg
atyp
blymphoblast
consist
reedsternberglik
cell
promin
rais
concern
larg
cell
lymphoma
lymphoprolif
disord
cellsdemonstr
follow
immunophenotyp
eber
rna
consist
ebvtransform
immunoblast
tdt
immunostain
neg
ebv
pcr
peripher
blood
iuml
peripher
blood
smear
reveal
blast
peripher
blood
immunophenotyp
show
reduct
absenc
cell
whole
bodi
pet
ct
show
local
hypermetabol
foci
left
tonsil
base
clinicopatholog
find
diagnosi
ebvmcu
made
sinc
ulcer
regress
despit
stop
oral
chemotherapi
week
dose
rituximab
tri
tonsillar
ulcer
complet
resolv
week
rituximab
present
month
follow
dose
rituximab
remain
remiss
conclus
despit
strike
histopatholog
immunophenotyp
resembl
b
cell
lymphoma
ebvlpd
ebvmcu
repres
indol
local
variant
ebvlpd
excel
prognosi
extens
workup
includ
imag
bone
marrow
biopsi
serolog
may
need
rule
system
lpd
mandat
aggress
treatment
appropri
diagnosi
help
clinician
make
critic
decis
like
withhold
immunosuppress
drug
necessari
immun
reconstitut
tcell
repertoir
control
ebv
infect
case
resolv
spontan
stop
immunosuppress
therapi
refractori
relaps
case
may
requir
aggress
approach
like
rituximab
radiotherapi
children
hospit
pittsburgh
upmc
pittsburgh
pennsylvania
unit
state
background
background
william
syndrom
ws
genet
syndrom
associ
characterist
faci
hypercalcemia
cardiovascular
anomali
hematolog
abnorm
rare
describ
object
object
present
infant
ws
bone
marrow
bm
failur
found
autosom
recess
ar
infantil
malign
osteopetrosi
op
designmethod
designmethod
case
reporta
full
term
infant
found
murmur
earli
life
echocardiogram
show
supravalvular
aortic
pulmon
stenosi
rais
concern
ws
genet
test
confirm
month
age
find
characterist
delet
soon
evalu
dehdyr
found
anem
thrombocytopen
bm
biopsi
demonstr
fibrosi
requir
period
transfus
workup
bm
failur
syndrom
includ
fanconi
anemia
dyskeratosi
congenita
neg
imag
show
boni
chang
concern
op
repeat
bm
biopsi
show
increas
osteoclast
genet
test
demonstr
mutat
consist
infantil
malign
op
ar
type
patient
underw
hematopoiet
stem
cell
transplant
hsct
result
result
ws
constel
sign
symptom
caus
delet
chromosom
american
academi
pediatr
establish
clinic
guidelin
care
patient
ws
includ
necessari
surveil
hematolog
issu
rare
associ
syndrom
part
guidelinesop
manifest
variou
age
depend
mode
inherit
ar
form
infantil
malign
op
present
earli
life
caus
mutat
rank
rankl
manifest
hypocalcemia
sclerot
bone
frequent
fractur
sometim
visual
loss
hear
loss
bm
failur
due
expans
bone
hsct
halt
slow
diseas
progress
replac
defect
osteoclast
ws
op
previous
describ
togeth
although
ws
mous
model
shown
osteopetrosislik
featur
without
osteoclast
dysfunct
defici
seen
op
conclus
conclus
ws
op
well
character
first
document
case
diagnos
patient
research
potenti
genet
associ
two
diseas
may
elucid
pathophysiolog
background
primari
pleural
synovi
sarcoma
ppss
extrem
rare
tumor
first
describ
case
seri
patient
children
year
report
first
case
ppss
associ
paraspin
ganglioneuroma
serou
cystadenoma
ovari
mutat
met
oncogen
unknown
signific
occurr
multipl
differ
tumor
young
patient
genet
mutat
suggest
possibl
hitherto
unknown
cancer
predisposit
syndrom
object
report
rare
present
ppss
associ
paraspin
ganglioneuroma
serou
cystadenoma
ovari
designmethod
case
report
result
caucasian
femal
present
week
right
chest
pain
august
famili
histori
signific
multipl
solid
tumor
laryng
thyroid
colon
renal
mri
chest
show
right
pleural
mass
biopsi
resect
mass
suggest
monophas
synovi
sarcoma
posit
margin
immunohistochemistri
posit
vimentin
ema
cytogenet
reveal
x
sytssx
metastat
workup
reveal
left
lumbar
paraspin
lesion
right
adnex
mass
biopsi
left
paraspin
lesion
reveal
matur
ganglioneuroma
biopsi
resect
adnex
mass
consist
diagnosi
serou
cystadenoma
ovari
genet
work
reveal
constitut
heterozyg
mutat
met
g
patient
stage
ir
gradeiii
stageiii
pog
grade
iii
receiv
cycl
ifosfamid
doxorubicin
cog
protocol
gy
radiat
current
patient
remain
remiss
conclus
ppss
never
report
associ
tumor
cell
origin
ppss
still
remain
enigma
base
recent
demonstr
immunophenotyp
overlap
ss
malign
peripher
nerv
sheath
tumor
folp
et
al
besid
constitut
express
ss
associ
fusion
gene
sytssx
neuroepitheli
tissu
brujin
et
al
genet
mutat
unknown
signific
patient
hypothes
constel
tumor
patient
may
mere
coincident
tumor
may
aris
common
pleuripot
mesenchym
stem
cell
verifi
hypothesi
immunophenotyp
cytogenet
analysi
ganglioneuroma
cystadenoma
background
sicklecel
diseas
scd
one
common
sever
genet
disord
worldwid
scd
individu
demonstr
increas
adhes
blood
cell
includ
red
blood
cell
neutrophil
eosinophil
platelet
play
fundament
role
vasoocclus
process
aplast
anemia
aa
character
peripher
blood
pancytopenia
hypocellular
bone
marrow
paroxysm
nocturn
hemoglobinuria
pnh
acquir
hemolyt
diseas
associ
intravascular
hemolysi
thrombosi
object
present
rare
occurr
sever
aplast
anemia
saa
pnh
clone
teenag
scd
clinic
challeng
combin
present
result
old
african
american
femal
scd
follow
comprehens
care
clinic
initi
found
isol
thrombocytopenia
later
progress
pancytopenia
bone
marrow
done
consist
diagnosi
saa
start
cyclosporin
immun
suppress
therapi
ist
respond
transient
eventu
becam
transfus
depend
month
later
pnh
clone
increas
declar
pnh
point
underw
transplant
unrel
donor
molecularli
match
without
complic
current
month
post
transplant
evid
pnh
clone
stabl
count
hemoglobin
electrophoresi
consist
sickl
cell
trait
conclus
aa
rare
lifethreaten
disord
thought
due
immunemedi
destruct
hematopoiet
cell
bone
marrow
ist
bone
marrow
transplant
first
line
treatment
option
aa
children
respond
primari
ist
requir
secondlin
therapi
respond
relaps
clonal
evolut
hematopoiesi
pnh
thought
occur
aa
patient
clonal
abnorm
frequent
detect
diagnosi
clonal
hematopoiesi
pnh
may
also
develop
year
ist
treatment
patient
requir
longterm
follow
special
care
center
knowledg
late
manifest
diseas
year
old
indian
male
present
symptom
obstruct
hydrocephalu
found
larg
posterior
fossa
mass
drop
lesion
thorac
spine
level
near
total
resect
patholog
show
grade
iv
medulloblastoma
receiv
radiat
chemotherapi
lomustin
vincristin
cisplatin
treatment
patient
develop
extern
mass
surgic
scar
associ
posterior
cervic
lymphadenopathi
imag
show
new
lesion
subcutan
plane
infiltr
erector
spina
muscl
locoregion
lymph
node
metastasi
simultan
recurr
primari
tumour
bed
metastasi
biopsi
lesion
confirm
subcutan
recurr
medulloblastoma
aggress
surgic
resect
combin
high
dose
chemotherapi
stem
cell
rescu
suggest
cur
option
treat
team
famili
opt
palli
approach
metronom
chemotherapi
use
cyclophosphamid
etoposid
rapid
diseas
progress
worsen
lymphadenopathi
result
intern
jugular
vein
compress
facial
edema
well
right
facial
nerv
palsi
metronom
chemotherapi
withdrawn
patient
ultim
succumb
diseas
five
month
recurr
note
conclus
report
discuss
unusu
subcutan
metastasi
medulloblastoma
subcutan
metastasi
may
indic
aggress
tumour
poor
prognosi
howev
avail
literatur
subcutan
metastasi
shown
almost
alway
metastasi
vicin
surgic
incis
could
impli
implant
surgic
procedur
background
although
tradit
practic
avoid
concurr
use
allopurinol
administr
mercaptopurin
world
oncolog
recent
literatur
describ
intent
use
allopurinol
optim
metabol
treatment
inflammatori
bowel
diseas
process
even
malign
process
acut
lymphoblast
leukemia
reportedli
shown
safe
shunt
metabol
away
hepatoxicmyelotox
metabolit
toward
favorableefficaci
metabolit
metabolit
synergist
potenti
allopurinol
employ
cancer
center
despit
recent
evid
support
potenti
efficaci
natur
drug
combin
user
must
remain
cautiou
possibl
myelotox
even
lifethreaten
effect
report
case
attempt
optim
metabolit
profil
may
result
aplast
anemia
object
describ
aplast
anemia
complic
concurr
allopurinol
mercaptopurin
therapi
pediatr
patient
designmethod
case
report
result
yo
tpmt
wild
type
male
histori
crohn
diseas
diagnos
present
progress
pancytopenia
receiv
combin
mercaptopurin
daili
allopurinol
therapi
daili
combin
therapi
initi
previous
due
unfavor
metabolit
profil
mercaptopurin
monotherapi
daili
risk
toxic
therapeut
metabolit
profil
associ
mild
pancytopenia
addit
allopurinol
even
concurr
dose
reduct
mercaptopurin
result
signific
elev
metabolit
bone
marrow
evalu
reveal
markedli
hypocellular
marrow
panhypoplasia
consist
druginduc
aplast
anemia
evid
infecti
etiolog
malign
lymphoprolif
disord
one
month
therapi
patient
return
peripher
blood
count
pancytopen
patient
requir
one
prbc
transfus
symptomat
anemia
requir
intervent
cytopenia
optim
mercaptopurin
metabolit
profil
concurr
allopurinol
therapi
difficult
balanc
act
potenti
signific
myelotox
effect
includ
aplast
anemia
patient
remain
drug
month
month
respect
though
second
patient
dose
reduct
due
advers
effect
ae
common
ae
relat
cabozantinib
includ
palmarplantar
erythrodysesthesia
loss
appetit
weight
loss
diarrhea
nausea
adult
patient
popul
often
dose
limit
howev
patient
toler
well
overal
one
mild
nausea
requir
dose
adjust
exhibit
erythrodysesthesia
requir
dose
reduct
resolut
ae
also
manifest
hypothyroid
manag
levothyroxin
conclus
cabozantinib
demonstr
clinic
radiograph
benefit
two
pediatr
patient
metastat
rcc
present
addit
therapeut
option
diseas
studi
examin
use
broadli
rcc
pediatr
cancer
object
address
clinic
laboratori
find
yearold
male
probabl
mutat
whose
initi
present
earli
onset
hemolyt
anemia
associ
acut
febril
ill
designmethod
retrospect
review
clinic
laboratori
find
present
case
whose
clinic
featur
domin
hematolog
abnorm
patient
initi
present
coomb
neg
hemolyt
anemia
age
week
subsequ
develop
pancytopenia
hepatosplenomegali
within
month
frequent
episod
febril
ill
worsen
pancytopenia
respond
oral
steroid
gradual
rise
igm
posit
famili
histori
hyper
igm
syndrom
mother
led
immun
workup
although
maintain
ageappropri
immunoglobulin
level
lack
clinic
evid
deep
seat
sinopulmonari
infect
eventu
mother
diagnos
mutat
lead
us
test
result
pend
although
never
exhibit
low
igg
iga
prior
start
supplement
ivig
enumer
tb
cell
subset
reveal
decreas
number
regulatori
cell
isotyp
switch
memori
b
cell
absent
along
invert
ratio
vs
memori
cell
persist
lymphopenia
compensatori
increas
nk
cell
number
unclear
matern
mutat
affect
clinic
featur
patient
clinic
stabl
sirolimu
supplement
ivig
conclus
mutat
manifest
predomin
hematolog
abnorm
without
hypogammaglobulinemia
enumer
tb
cell
subset
may
inform
proceed
gene
mutat
analysi
high
index
suspicion
requir
given
fact
diseas
specif
treatment
ie
sirolimu
avail
report
old
male
histori
kidney
transplant
secondari
arpkd
known
hepat
fibrosi
found
biopsi
proven
hcc
pulmonari
metastas
current
undergo
neoadjuv
chemotherapi
cisplatin
doxorubicin
partial
respons
therapi
base
respons
evalu
criteria
solid
tumor
recist
criteria
primari
lesion
metastas
decreas
size
alphafetoprotein
afp
decreas
cycl
cisplatindoxorubicin
chemotherapi
germlin
patient
exom
sequenc
result
pend
report
time
public
conclus
first
report
case
hcc
pediatr
patient
arpkd
histori
concurr
hepat
fibrosi
like
contribut
progress
hcc
extrem
young
age
present
uncommon
exom
sequenc
may
help
determin
whether
patient
novel
pathogen
variant
polycyst
kidney
hepat
diseas
arpkd
gene
rare
case
lupu
anticoagul
hypoprothrombinemia
associ
thrombocytopenia
nicol
baca
aime
foord
arash
mahajerin
background
lupu
anticoagulanthypoprothrombinemia
lahp
rare
condit
result
hypercoagul
often
seen
patient
underli
autoimmun
disord
thrombocytopenia
found
patient
lahp
associ
bleed
risk
object
describ
case
patient
lupu
anticoagul
hypoprothrombinemia
associ
thrombocytopenia
present
protract
oral
bleed
follow
dental
extract
designmethod
medic
record
literatur
review
result
previous
healthi
boy
present
ecchymos
petechia
oral
bleed
ten
day
follow
dental
extract
initi
lab
signific
platelet
count
kul
prothrombin
time
pt
second
intern
normal
ratio
activ
partial
thromboplastin
time
aptt
second
aptt
mix
studi
demonstr
inhibitor
pt
mix
studi
reveal
factor
defici
later
found
lupu
anticoagul
low
factor
ii
activ
respect
autoimmun
workup
reveal
tripl
antiphospholipid
antibodi
posit
apa
posit
antinuclear
antibodi
ana
doubl
strand
dna
dsdna
antibodi
well
low
complement
compon
posit
direct
antiglobulin
test
given
presenc
lupu
anticoagul
well
low
factor
ii
activ
diagnos
lahp
initi
therapi
includ
intraven
immunoglobulin
ivig
gmkg
hydroxychloroquin
mg
oral
daili
peak
platelet
respons
ivig
bone
marrow
aspir
biopsi
reveal
trilineag
hematopoiesi
megakaryocyt
hyperplasia
normal
cytogenet
neg
myelodysplast
syndrom
panel
fish
third
dose
ivig
platelet
count
remain
clinic
sign
bleed
resolv
conclus
lahp
rare
phenomenon
children
predomin
hematolog
concern
thrombosi
small
percentag
patient
bleed
complic
typic
due
thrombocytopenia
due
contrast
seriou
risk
patient
need
monitor
close
hematologist
futur
assess
includ
serial
monitor
blood
count
renal
function
apa
ana
dsdna
antibodi
futur
therapi
consid
lahp
typic
chosen
base
clinic
symptom
includ
corticosteroid
monoclon
antibodi
therapi
well
thrombopoietin
mimet
worsen
thrombocytopenia
patient
current
stabl
singl
regimen
hydroxychloroquin
background
undifferenti
embryon
sarcoma
liver
uesl
rare
aggress
pediatr
liver
malign
character
frequent
recurr
standard
cur
therapi
involv
complet
resect
system
chemotherapi
transcathet
arteri
chemoembol
tace
commonli
util
treat
liver
tumor
particularli
hepatocellular
carcinoma
hcc
radioembol
emerg
therapi
liver
tumor
current
report
either
modal
use
local
control
pediatr
uesl
object
report
case
femal
extens
uesl
diaphragmat
invas
poor
respons
two
cycl
neoadjuv
ifosfamid
doxorubicin
two
cycl
gemcitabin
taxoter
administ
tumor
show
moder
volumetr
respons
patient
experienc
gemcitabinerel
neurotox
tumor
remain
unresect
sever
tumorrel
pain
persist
therefor
radioembol
perform
largest
portion
tumor
follow
tace
doxoelut
bead
diaphragmat
portion
tumor
via
phrenic
arteri
designmethod
case
report
due
uniqu
approach
local
control
uesl
bead
chosen
tace
larg
inferior
portion
tumor
studi
hcc
show
equival
outcom
less
pain
radioembol
tace
chosen
smaller
superior
portion
attempt
spare
healthi
liver
tissu
share
blood
suppli
phrenic
arteri
procedur
well
toler
within
three
week
embol
long
act
narcot
discontinu
time
tace
procedur
decreas
tumor
size
measur
avail
tace
also
well
toler
requir
one
overnight
stay
pain
control
tumor
deem
resect
within
week
follow
procedur
conclus
case
highlight
possibl
role
embol
uesl
therapi
case
radioembol
tace
util
part
neoadjuv
regimen
facilit
surgic
resect
modal
consid
viabl
option
unresect
uesl
unrespons
upfront
chemotherapi
background
multicentr
reticulohistiocytosi
mrh
rare
multisystem
nonlangerhan
cell
histiocyt
disord
mrh
rarer
children
onset
diseas
typic
occur
fourth
decad
life
clinic
present
includ
papulonodular
skin
erupt
inflammatori
polyarthr
debilit
etiolog
disord
unknown
associ
solid
tumor
hematolog
malign
present
report
case
treatment
mrh
without
associ
malign
includ
nonsteroid
antiinflammatori
drug
corticosteroid
diseasemodifi
antirheumat
drug
object
report
pediatr
patient
multicentr
reticulohistiocytosi
designmethod
singl
case
report
result
year
old
caucasian
femal
present
year
histori
periung
papul
hand
feet
month
histori
bilater
knee
swell
stiff
multipl
joint
periung
papul
initi
treat
wart
fail
improv
subsequ
refer
dermatolog
shave
biopsi
one
lesion
result
mrh
due
associ
mrh
malign
refer
oncolog
evalu
sign
symptom
malign
screen
lab
normal
ct
neck
chest
abdomen
pelvi
obtain
evalu
malign
normal
rheumatolog
diagnos
arthriti
neck
elbow
knee
receiv
methotrex
naproxen
three
month
therapi
improv
skin
lesion
arthriti
futur
evalu
malign
depend
sign
symptom
clinic
exam
plan
routin
surveil
imag
pediatr
case
mrh
report
literatur
due
rariti
current
standard
approach
surveil
malign
pediatr
oncologist
need
awar
associ
mrh
malign
patient
mrh
need
evalu
malign
prior
treatment
mrh
sinc
involv
drug
antineoplast
activ
background
hepatoblastoma
common
liver
tumor
children
hepatoblastoma
affect
mostli
children
year
age
threeyear
eventfre
surviv
patient
nonmetastat
hepatoblastoma
howev
patient
refractori
metastat
diseas
prognosi
dismalbevacizumab
sorafenib
lowdos
cyclophosphamid
use
report
hepatoblastoma
object
report
patient
recurr
resist
metastat
hepatoblastoma
treat
combin
lead
stabl
diseas
fall
afp
excel
qualiti
life
designmethod
male
rightsid
abdomin
mass
initi
alphafetoprotein
afp
proven
pure
fetal
hepatoblastoma
initi
stage
workup
show
evid
metastat
diseas
howev
surgic
resect
possibl
due
compress
inferiorvenacav
standard
adjuv
chemotherapi
cisplatin
vincristin
given
four
cycl
follow
complet
surgic
resect
neg
margin
surgeri
follow
two
cycl
afp
level
fell
gradual
nadir
end
treatment
month
therapi
rise
afp
comput
tomographi
lung
reveal
two
pulmonari
nodul
proven
hepatoblastoma
biopsi
cours
ensu
month
three
distinct
chemotherapeut
combin
util
regimen
includ
ifosfamidecarboplatinetoposid
ii
doxorubicin
ifosfamid
iii
irinotecantemodar
temsirolimu
addit
resect
pulmonari
metastas
patient
develop
transthorac
mass
invad
rib
caus
patholog
fractur
despit
extens
exposur
multiag
chemotherapi
afp
level
continu
rise
serial
ct
scan
demonstr
progress
diseas
background
hemophagocyt
lymphohistiocytosi
hlh
rare
lifethreaten
hyperinflammatori
syndrom
caus
excess
ineffect
immun
system
activ
pulmonari
alveolar
proteinosi
pap
abnorm
accumul
surfact
lung
alveoli
caus
respiratori
diseas
describ
two
case
critic
ill
toddler
present
sign
immunehyperactiv
along
progress
respiratori
compromis
subsequ
diagnos
acquir
hlh
pap
object
increas
index
suspicion
pap
patient
hlh
support
earli
thorough
evalu
similar
case
describ
avail
treatment
option
designmethod
first
patient
week
year
old
girl
chronic
lung
diseas
second
patient
month
old
boy
histori
failur
thrive
recurr
pneumonia
present
persist
fever
respiratori
failur
alongwith
signific
lymphadenopathi
hepatosplenomegali
workup
hlh
show
elev
ferritin
bicytopenia
hypertriglyceridemia
hypofibrinogenemia
hemophagocytosi
bone
marrow
patient
plu
elev
solubl
receptor
patient
one
nk
function
normal
met
criteria
hlh
respect
result
genet
test
hlh
normal
patient
one
show
compound
heterozyg
mutat
associ
lysinur
protein
intoler
lpi
patient
two
lung
biopsi
evalu
progress
respiratori
diseas
show
pap
case
patient
treat
induct
chemotherapi
per
protocol
pap
treat
whole
lung
lavag
ecmo
resolut
symptom
patient
one
howev
treatment
option
pap
limit
patient
two
due
underli
lpi
hlh
pap
describ
independ
patient
lpi
second
patient
unifi
pictur
inborn
aminoaciduria
lead
macrophag
dysfunct
immun
dysregul
caus
hlh
pap
whole
lung
lavag
limit
util
situat
bone
marrow
transplant
describ
conclus
diagnosi
similar
complex
case
challeng
given
multisystem
progress
natur
diseas
broad
rang
differenti
time
requir
diagnost
evalu
howev
high
index
suspicion
earli
thorough
evalu
benefici
lifesav
sever
case
background
soto
syndrom
ss
rare
genet
condit
character
excess
growth
frontal
boss
downslant
palpebr
fissur
dolichocephal
head
shape
hypertelor
promin
jaw
caus
mutat
gene
increas
risk
pediatr
cancer
associ
ss
especi
hematopoiet
malign
present
case
year
old
boy
ss
diagnos
classic
hodgkin
lymphoma
hl
object
describ
case
adolesc
hl
ss
designmethod
conduct
search
pubm
ovid
googl
scholar
search
use
term
soto
syndrom
hodgkin
lymphoma
previous
report
case
hematolog
malign
associ
soto
syndrom
none
hl
note
studi
indic
male
affect
much
often
femal
case
increas
number
report
year
old
young
man
ss
present
firm
fix
anterior
neck
mass
proven
excision
biopsi
hl
workup
confirm
stage
ia
diseas
search
yield
manuscript
patient
success
treat
cycl
doxorubicin
vincristin
prednison
cyclophosphamid
remain
remiss
month
conclus
soto
syndrom
rare
genet
diseas
appear
increas
risk
leukemia
lymphoma
case
case
first
hl
hope
increas
awar
possibl
associ
ss
hl
background
thymic
carcinoma
tc
rare
adult
less
common
children
account
less
childhood
mediastin
tumor
adult
first
treatment
usual
surgic
resect
approxim
tc
metastat
diagnosi
unresect
medial
surviv
current
platinumbas
chemotherapi
regimen
approxim
year
ongo
studi
tyrosin
kinas
inhibitor
tki
advanc
thymic
tumor
report
use
mainten
therapi
metastat
tc
children
object
report
use
cisplatin
docetaxel
follow
sunitinib
mainten
chemotherapi
pediatr
patient
metastat
tc
designmethod
year
old
male
autism
present
mediastin
mass
diagnos
stage
iv
tc
tumor
unresect
multipl
metastat
lung
lesion
patient
treat
cisplatin
docetaxel
everi
week
prevent
regrowth
initi
mainten
therapi
sunitinib
drug
report
stabil
diseas
adult
advanc
thymic
malign
result
cycl
chemotherapi
imag
reveal
reduct
anterior
mediastin
mass
reduct
decreas
pulmonari
metastas
follow
cycl
chemotherapi
repeat
imag
show
decreas
size
reduct
number
pulmonari
metastas
due
aggress
natur
diseas
start
sunitinib
oral
daili
side
effect
includ
discolor
skin
surround
gtube
use
administr
faint
erythemat
rash
chest
sinc
start
sunitinib
patient
continu
reduct
primari
tumor
size
recent
chest
ct
perform
month
initi
sunitinib
show
reduct
origin
mass
resolut
lung
metastas
conclus
thymic
malign
rare
tumor
aggress
difficult
treat
advanc
stage
demonstr
diseas
respons
use
sunitinib
multitki
mainten
therapi
prevent
regrowth
sunitinib
patient
continu
diseas
reduct
minim
side
effect
given
rariti
tumor
promis
therapeut
approach
advancedstag
tumor
pediatr
patient
background
ataxiatelangiectasia
autosomalrecess
dnamismatch
repair
diseas
caus
predisposit
malign
patient
develop
cancer
mostli
lymphoid
origin
patient
pose
uniqu
challeng
due
sensit
radiat
increas
risk
chemotherapi
complic
hemorrhag
cystiti
sever
infect
object
discuss
femal
present
two
week
neck
swell
excision
biopsi
reveal
matur
bcell
lymphoma
stage
petct
scan
show
local
diseas
designmethod
patient
treatment
base
success
treatment
elderli
patient
highgrad
nonhodgkin
lymphoma
cycl
chop
cyclophosphamid
doxorubicin
vincristin
prednison
combin
rituximab
result
complet
respons
cr
rate
modifi
therapi
limit
toxic
receiv
one
cycl
cop
cyclophosphamid
vincristin
prednison
near
cr
mri
first
cycl
rchop
cyclophosphamid
dose
reduc
remain
hospit
count
nadir
recoveri
due
risk
infect
signific
nadir
cyclophosphamid
escal
full
dose
subsequ
cycl
complic
includ
prolong
cultureneg
febril
neutropenia
c
difficil
coliti
right
intraatri
thrombu
requir
anticoagul
result
follow
four
cycl
rchop
mri
show
cr
follow
fifth
cycl
admit
fever
neutropenia
hypotens
requir
vasopressor
support
echocardiogram
reveal
eject
fraction
follow
cumul
anthracyclin
dose
intub
develop
worsen
hypotens
desatur
progress
cardiac
arrest
despit
cardiopulmonari
resuscit
spontan
cardiac
function
return
patient
die
sign
heart
failur
evid
limit
autopsi
chest
howev
underli
etiolog
remain
unclear
conclus
despit
superior
treatment
mani
nonhodgkin
lymphoma
patient
continu
present
obstacl
due
exquisit
sensit
commonli
employ
anticanc
therapi
rchop
may
accept
regimen
patient
may
still
toxic
increas
risk
cardiac
toxic
report
may
anoth
sensit
patient
addit
studi
warrant
understand
special
patient
popul
lead
adapt
treatment
improv
protect
toxic
background
ulcer
primari
melanoma
associ
poor
prognosi
studi
show
ulcer
melanoma
treat
adjuv
pegyl
interferon
improv
recurrencefre
surviv
adult
cutan
melanoma
object
report
experi
use
pegyl
interferon
pediatr
patient
ulcer
stage
iiib
melanoma
designmethod
case
report
result
girl
present
right
lower
extrem
lesion
patholog
reveal
malign
melanoma
spitzoid
featur
invas
least
clark
level
iv
breslow
depth
least
mm
microscop
focu
ulcer
mitot
rate
pet
scan
show
increas
uptak
right
inguin
lymph
node
distant
metastasi
underw
wide
local
excis
fullthick
skin
graft
sentinel
lymph
node
biopsi
patholog
neg
residu
diseas
cm
margin
one
lymph
node
focal
involv
metastat
melanoma
mm
radic
inguin
lymph
node
dissect
perform
neg
diseasegiven
presenc
highrisk
diseas
ulcer
start
induct
therapi
week
limit
pediatr
data
start
mainten
adult
dose
mcgkgdose
weekli
subcutan
inject
dose
increas
mcgkg
week
full
induct
dose
mcgkg
follow
induct
continu
mainten
therapi
mcgkgweek
week
side
effect
organ
toxic
monitor
monthli
throughout
cours
despit
premed
acetaminophen
patient
experienc
lowgrad
fever
chill
myalgia
follow
first
dose
subsequ
inject
follow
schedul
acetaminophen
hour
prevent
symptom
report
mild
fatigu
one
two
day
follow
inject
deni
symptom
depress
headach
nausea
vomit
monthli
laboratori
monitor
myelosuppress
hepat
renal
dysfunct
perform
along
tsh
triglycerid
level
everi
three
month
persist
abnorm
seen
conclus
patient
toler
pegyl
interferon
signific
advers
side
effect
organ
toxic
first
report
pediatr
patient
melanoma
treat
therapi
background
tumor
fusion
recent
describ
entiti
usual
aris
soft
tissu
two
prior
publish
articl
report
six
case
two
children
aris
tongu
object
report
unusu
gastric
tumor
aris
pylor
wall
stomach
old
child
harbor
except
rare
transloc
result
gene
fusion
designmethod
case
report
result
previous
healthi
femal
present
one
episod
abdomin
pain
vomit
epigastr
mass
palpat
comput
tomographi
scan
abdomen
show
local
x
x
solid
cystic
mass
aris
distal
stomach
preoper
differenti
includ
gastrointestin
stromal
tumor
inflammatori
myofibroblast
tumor
child
underw
exploratori
laparotomi
reveal
mobil
mass
attach
anterior
portion
pyloru
mass
complet
resect
heinekemikulicz
pyloroplasti
perform
microscop
examin
mass
reveal
spindl
cell
prolifer
diffus
posit
vimentin
focal
ema
initi
patholog
report
angiomatoid
fibrou
histiocytoma
cytogenet
studi
show
balanc
transloc
involv
short
arm
chromosom
long
arm
chromosom
xx
diagnosi
chang
pericytoma
presenc
fusion
transcript
confirm
rtpcr
genom
dna
amplif
child
remiss
month
followup
conclus
case
first
report
gastric
tumor
transloc
confirm
actbgli
fusion
gene
pediatr
patient
unusu
locat
morpholog
made
differenti
diagnosi
quit
difficult
make
genet
molecular
analys
imper
correct
diagnosi
evid
recurr
metastasi
document
prior
report
case
resect
seem
treatment
choic
histori
refractori
epilepsi
sever
intellectu
disabl
diagnos
use
whole
exom
sequenc
rare
potassium
channelopathi
due
heterozyg
mutat
gene
also
histori
recurr
volvulu
signific
colon
resect
pseudoobstruct
syndrom
colon
neuropathi
tpndepend
intestin
malabsorpt
result
colonoscopi
reveal
tubular
villou
adenoma
highgrad
dysplasia
consist
cin
stage
workup
includ
cea
evalu
neg
reanalysi
exom
data
known
cancerrel
gene
reveal
heterozyg
g
mutat
result
stop
codon
gene
present
mother
exom
sequenc
conclus
case
report
present
novel
mutat
uniqu
observ
patient
known
channelopathi
emerg
role
mutat
pediatr
cancer
possibl
mechan
second
hit
therapeut
dilemma
cin
patient
ls
import
consider
illustr
uniqu
case
also
highlight
ethic
dilemma
surround
report
incident
find
whole
exom
sequenc
context
detect
clinic
oncogenet
potenti
background
neuroblast
tumor
agelink
classif
depend
differenti
neuroblast
presenc
absenc
schwannian
stromal
develop
fall
along
spectrum
tumor
matur
dictat
tumor
aggress
cours
ganglioneuroma
intermix
ganglioneuroblastoma
matur
subtyp
tend
present
unifoc
diseas
benign
cours
object
present
uniqu
case
boy
multipl
tumor
identifi
initi
present
histolog
consist
multipl
soft
tissu
ganglioneuroma
abdomin
intermix
ganglioneuroblastoma
designmethod
patient
previous
healthi
boy
present
mass
posterior
aspect
right
thigh
increas
size
period
mri
thigh
reveal
wellcircumscrib
lesion
within
muscl
biopsi
lesion
keep
ganglioneuroma
abdomin
mri
perform
part
stage
workup
reveal
mass
right
adren
fossa
biopsi
mass
consist
intermix
ganglioneuroblastoma
nmyc
amplifi
either
lesion
remaind
stage
workup
includ
urin
vanillylmandel
acid
vma
homovanil
acid
hva
bone
scan
bilater
bone
marrow
aspir
biopsi
mibg
scan
unremark
although
metastat
diseas
present
upon
present
base
histolog
subtyp
tumor
likelihood
progress
diseas
low
therefor
observ
without
activ
treatment
remain
well
without
diseas
progress
almost
follow
diagnosi
conclus
report
metastat
ganglioneuroma
intermix
ganglioneuroblastoma
literatur
limit
knowledg
first
pediatr
case
concurr
adren
ganglioneuroblastoma
multipl
soft
tissu
ganglioneuroma
metastas
present
initi
diagnosi
rare
present
multifoc
soft
tissu
ganglioneuroma
abdomin
intermix
ganglioneuroblastoma
rais
possibl
lesion
less
matur
neuroblast
tumor
underw
matur
given
distribut
diseas
patient
possibl
patient
stage
iv
neuroblastoma
subsequ
matur
primari
tumor
metastas
background
neuroblastoma
common
extracrani
solid
tumor
children
common
cancer
infanc
tumor
may
present
spectrum
paraneoplast
syndrom
protein
lose
enteropathi
ple
describ
small
number
children
neuroblastoma
unrel
gastrointestin
involv
cancer
thought
either
rare
paraneoplast
syndrom
due
catecholamin
effect
gut
lymphat
obstruct
mass
effect
noonan
syndrom
associ
independ
neuroblastoma
ple
object
describ
clinic
cours
phenotyp
normal
babi
concurr
neuroblastoma
ple
whose
tumor
dna
found
mutat
gene
biopsi
perform
due
tumor
unresect
note
myofibroblast
prolifer
mark
inflamm
consist
imt
nextgener
sequenc
reveal
alter
gene
previous
report
poor
prognost
marker
rectal
cancer
normal
gene
initi
treat
celecoxib
methylprednisolon
howev
tumor
ruptur
result
abdomin
compart
syndrom
hypertens
obstip
bladder
outlet
obstruct
bilater
hydronephrosi
transit
vac
chemotherapi
consist
cycl
vincristin
mgkgdose
weekli
dactinomycin
mgkgdose
day
cyclophosphamid
mgkgdose
day
addit
daili
celecoxib
therapi
toler
cycl
therapi
minim
side
effect
occasion
growth
factor
support
recent
imag
reveal
tumor
measur
cm
complet
resolut
hypertens
obstip
bladder
outlet
obstruct
mark
improv
bilater
hydronephrosi
continu
regimen
complet
resect
feasibl
conclus
vac
use
combin
celecoxib
may
therapeut
option
inoper
imt
background
vagin
rm
associ
favor
prognosi
although
optim
local
control
approach
controversi
due
long
term
reproduct
musculoskelet
psycholog
sequela
rt
responsebas
local
control
approach
attempt
patient
group
iii
vagin
rm
elimin
need
rt
object
describ
new
surgic
approach
local
vagin
rm
use
minim
invas
surgic
resect
follow
autolog
buccal
graft
vaginoplasti
reconstruct
designmethod
case
seri
patient
local
vagin
botryoid
rm
institut
treat
chemotherapi
per
subset
b
result
patient
year
age
rang
month
botryoid
rm
patient
receiv
maximum
cyclophosphamid
follow
vincristinedactinomycin
therapi
surgeri
perform
differ
time
week
patient
underw
subtot
total
vaginectomi
autolog
buccal
graft
vaginoplasti
reconstruct
one
patient
surgic
margin
posit
two
closest
margin
mm
patient
receiv
rt
median
length
followup
month
patient
remain
diseasefre
background
pure
choriocarcinoma
testi
highli
malign
tumor
deriv
trophoblast
cell
potenti
earli
metastasi
account
primari
testicular
germ
cell
tumor
given
rariti
propens
older
patient
pure
choriocarcinoma
often
differenti
patient
present
pediatr
oncolog
servic
object
describ
case
pure
choriocarcinoma
peripubert
male
patient
review
pediatricadolesc
case
discuss
use
pubert
statu
testicular
tumor
work
designmethod
report
case
previous
healthi
normal
develop
tanner
iv
male
patient
present
asymmetr
enlarg
right
testicl
follow
blunt
trauma
subsequ
rightsid
chest
pain
fever
emesi
right
radic
orchiectomi
perform
patholog
show
pure
choriocarcinoma
imag
reveal
extens
metastat
diseas
includ
lung
brain
literatur
search
pubm
identifi
previous
report
case
testicular
pure
choriocarcinoma
adolesc
result
due
rariti
pure
choriocarcinoma
testi
mostli
appear
case
report
within
current
literatur
patient
report
case
n
rang
age
year
mean
age
patient
youngest
known
report
case
pure
choriocarcinoma
often
initi
misdiagnos
given
tendenc
present
symptom
secondari
lung
skin
andor
brain
metastasi
oppos
testicular
swell
like
testicular
tumor
misdiagnosi
may
relat
gap
knowledg
regard
peripubert
testicular
tumor
differenti
workup
puberti
play
import
role
frequenc
testicular
tumor
type
teenag
adolesc
patient
like
present
patient
often
fall
preand
postpubert
studi
literatur
research
studi
often
use
age
cutoff
studi
preversu
postpubert
testicular
tumor
yet
variabl
age
puberti
onset
varieti
puberti
stage
suggest
agedefin
cutoff
suboptim
conclus
peripubert
boy
risk
testicular
cancer
typic
identifi
cohort
report
testicular
pure
choriocarcinoma
highlight
uniqu
characterist
tumor
import
puberti
statu
pediatr
oncolog
workup
algorithm
background
rhabdomyosarcoma
rm
common
sarcoma
children
perian
site
unusu
occurr
associ
lower
cure
rate
case
treat
gross
total
surgic
resect
convent
radiotherapi
report
associ
sphincter
dysfunct
anal
ulcer
object
describ
case
localis
perian
embryon
rm
manag
use
neoadjuv
chemotherapi
stereotact
radiosurgeri
designmethod
singl
case
report
result
three
year
old
boy
present
pain
swell
right
perian
region
sinc
two
month
examin
reveal
cm
soft
tender
diffus
swell
right
perian
region
open
wedg
biopsi
lesion
suggest
embryon
rhabdomyosarcoma
immunohistochemistri
posit
desmin
focal
cd
neg
pan
ck
fdg
pet
ct
scan
show
cm
metabol
activ
enhanc
soft
tissu
mass
right
perian
region
extend
perineum
right
half
gluteal
cleft
evid
distal
metastas
receiv
four
cours
neoadjuv
chemotherapi
iva
ifosphamid
vincristin
actinomycin
child
treat
stereotact
radiosurgeri
dose
ctv
gtv
perian
area
subsequ
receiv
five
cours
iva
base
chemotherapi
present
case
novel
mutat
g
mutat
hotspot
associ
dna
bind
site
result
gain
function
associ
alter
cancer
spectrum
deregul
metabol
pathway
increas
metastas
enhanc
chemotherapi
resist
bind
et
moz
involv
histon
methyl
acetyl
found
report
mutat
found
missens
mutat
result
splice
variant
well
number
indel
occur
synonym
mutat
may
play
part
cancer
biolog
affect
cryptic
noncrypt
altern
splice
site
includ
supek
et
al
cell
found
mutat
extrem
recurr
affect
nucleotid
directli
adjac
splice
site
document
mutat
literatur
work
must
done
determin
relev
one
experi
would
creat
mini
gene
construct
evalu
splice
analyz
cell
activ
hypothes
synonym
mutat
may
affect
splice
rna
fold
codon
usag
serv
driver
two
concurr
aggress
primari
tumor
describ
sever
recurr
hypercalcemia
respons
denosumab
discontinu
denosumab
metastat
gctb
child
object
discuss
complic
associ
discontinu
denosumab
gctb
child
util
treat
recurr
posttherapeut
episod
hypercalcemia
twelv
yearold
male
present
episod
leftsid
hip
pain
difficulti
weightbear
mri
reveal
cystic
lesion
left
ischium
treatment
monthli
denosumab
initi
dramat
improv
note
clinic
radiograph
forti
month
asymptomat
stabl
denosumab
discontinu
one
month
later
present
nausea
vomit
hypercalcem
mgdl
acut
kidney
injuri
serum
creatinin
mgdl
calcitonin
hyperhydr
lasix
unsuccess
treat
denosumab
rapid
resolut
hypercalcemia
follow
five
month
hypercalcemia
recur
twice
resolut
within
hour
treatment
denosumab
respect
result
gctb
benign
histolog
diagnosi
local
aggress
natur
complic
treatment
definit
manag
often
surgic
preclud
patient
metastat
diseas
tumor
cell
express
receptor
activ
nuclear
factorkb
ligand
rankl
interact
rank
monocyt
activ
osteoclast
precursor
giant
cell
promot
bone
resorpt
denosumab
human
monoclon
antibodi
bind
inhibit
rankl
suppress
bone
turnov
upon
discontinu
denosumab
inhibitori
effect
osteoclast
hyperact
may
caus
rebound
hypercalcemia
phenomenon
may
pronounc
skelet
immatur
child
increas
rate
bone
metabol
treatment
denosumab
resolv
episod
hypercalcemia
conclus
patient
highlight
util
low
dose
denosumab
manag
sever
hypercalcem
episod
follow
longterm
treatment
denosumab
research
need
determin
ideal
dose
effect
recurr
treatment
recommend
monitor
potenti
need
gradual
discontinu
therapi
background
interdigit
reticulum
cell
sarcoma
rare
spindl
cell
sarcoma
lymph
node
stromal
cell
known
interdigit
reticulum
cell
tumor
cell
posit
protein
cd
hladr
treatment
regimen
vari
poor
overal
prognosi
abl
identifi
case
report
literatur
adult
popul
none
pediatr
popul
object
introduc
pediatr
case
interdigit
reticulum
cell
sarcoma
designmethod
clinic
case
report
result
patient
year
old
male
adopte
brought
us
industri
region
china
month
old
still
live
china
diagnos
fibrosarcoma
lower
back
underw
complet
resect
wide
margin
treat
vincristin
dactinomycin
adjuv
chemotherapi
prior
move
us
reportedli
remiss
followup
visit
year
age
us
right
axillari
mass
note
ct
scan
underw
complet
resect
mass
well
wedg
resect
left
lower
lobe
pulmonari
nodul
stabl
sinc
age
final
patholog
site
reveal
atyp
spindl
cell
sarcoma
mostli
suggest
interdigit
reticulum
cell
sarcoma
treat
ifosfamid
doxorubicin
offstudi
per
children
oncolog
group
protocol
six
week
complet
therapi
scan
remain
stabl
prior
therapi
continu
subcentimet
right
upper
lobe
pulmonari
nodul
uncertain
etiolog
stabl
sinc
year
age
sinc
diseas
slow
grow
parent
opt
observ
scan
month
prior
proceed
resect
remain
nodul
next
month
conclus
exceedingli
rare
case
interdigit
reticulum
cell
sarcoma
pediatr
patient
industri
region
china
optim
treatment
regimen
yet
determin
impact
exposur
industri
region
cancer
incid
unknown
background
type
diabet
associ
autoimmun
diseas
name
thyroid
celiac
diseas
autoimmun
gastric
diseas
two
condit
initi
present
howev
exceedingli
rare
describ
child
novel
simultan
present
thrombocytopenia
hyperglycemia
lead
concurr
diagnos
immun
thrombocytopenia
itp
object
describ
child
sever
thrombocytopenia
hyperglycemia
lead
new
diagnos
itp
explor
known
comorbid
autoimmun
diagnos
signific
behind
less
commonli
report
pair
designmethod
five
yearold
male
present
bruis
viral
uri
one
week
prior
cbc
cmp
reveal
thrombocytopenia
kcmm
hyperglycemia
mgdl
urinalysi
posit
glucos
neg
keton
bleed
histori
neg
physic
exam
reveal
wet
purpura
scatter
bruis
present
consist
itp
hyperglycemia
attribut
acut
ill
stress
respons
receiv
ivig
platelet
improv
kcmm
elev
serum
glucos
persist
overnight
hemoglobin
elev
indic
chronic
hyperglycemia
autoantibodi
test
obtain
prior
ivig
demonstr
elev
antiglutam
acid
decarboxylas
antibodi
diagnost
start
insulin
therapi
stabil
serum
glucos
result
pleomorph
natur
nonspecif
symptomatolog
autoimmun
diseas
challeng
confound
associ
condit
genet
immun
dysregul
disord
consid
present
associ
condit
thrombocytopenia
unusu
pair
knowledg
five
pediatr
case
describ
associ
none
simultan
present
result
cell
destruct
insulinproduc
pancreat
betacel
itp
mediat
circul
autoantibodi
platelet
condit
share
basi
autoimmun
dysregul
independ
mechan
associ
may
signific
implic
treatment
recent
studi
suggest
tradit
treatment
fail
rituximab
therapi
target
b
lymphocyt
may
prove
benefici
mani
autoimmun
disord
includ
itp
conclus
complex
autoimmun
disord
consid
patient
develop
multipl
autoimmun
condit
less
commonli
recogn
associ
like
itp
earli
recognit
manag
critic
patient
success
respons
convent
treatment
util
antibodi
therapi
resist
case
consid
background
synovi
sarcoma
malign
mesenchym
malign
commonli
origin
deep
soft
tissu
extrem
report
head
neck
region
object
present
male
severalmonth
histori
progress
left
upper
extrem
pain
weak
exacerb
slip
fall
left
elbow
designmethod
mri
demonstr
intraspin
extradur
tumor
involv
left
aspect
spinal
canal
neural
foramina
paraspin
soft
tissu
level
biopsi
reveal
malign
mesenchym
neoplasm
neg
immunohistochem
marker
rhabdomyosarcoma
ewe
sarcoma
molecular
studi
posit
fusion
transcript
confer
diagnosi
synovi
sarcoma
positron
emiss
tomographi
scan
neg
metastat
diseasewhil
await
diagnost
biopsi
result
patient
develop
worsen
left
arm
pain
swell
accompani
increas
facial
edema
venou
doppler
ultrasound
reveal
extens
deep
vein
thrombos
span
intern
jugular
vein
proxim
brachial
vein
transthorac
echocardiogram
reveal
echogen
mass
right
atrium
extend
tricuspid
valv
right
ventricl
comput
tomographi
cardiac
angiogram
demonstr
contigu
intracardiac
mass
superior
vena
cava
left
brachiocephal
intern
jugular
vein
underw
urgent
surgeri
due
impend
hemodynam
deterior
patholog
resect
specimen
left
brachiocephal
vein
right
atriumtricuspid
annulu
consist
synovi
sarcoma
result
subsequ
receiv
neoadjuv
treatment
chemotherapi
convent
radiat
follow
surgic
resect
postop
proton
radiat
boost
adjuv
chemotherapi
evid
diseas
upon
complet
therapi
monitor
regular
surveil
conclus
primari
synovi
sarcoma
involv
spine
rare
tumor
thrombi
describ
synovi
sarcoma
first
known
report
extens
right
side
heart
multidisciplinari
care
neurosurgeri
cardiothorac
surgeri
otolaryngolog
oncolog
radiat
oncolog
key
render
patient
free
diseas
rare
case
polycythemia
chuvash
polycythemia
nathan
hall
ashish
risal
background
chuvash
polycythemia
rare
form
congenit
polycythemia
caus
alter
oxygensens
pathway
recogn
chuvash
republ
russian
feder
clinic
distinct
entiti
polycythemia
vera
autosom
recess
inherit
pattern
specif
mutat
von
hippellindau
vhl
gene
result
amino
acid
substitut
lead
upregul
hypoxia
induc
factor
despit
normal
oxygen
level
lead
chronic
increas
red
blood
cell
product
mutat
vhl
gene
chromosom
mutat
subsequ
found
peopl
european
africanamerican
pakistanibangladeshi
ethnic
patient
year
old
femal
pakistani
descent
present
neurologist
longstand
histori
headach
lab
evalu
reveal
hemoglobin
level
hematocrit
famili
histori
posit
father
undiagnos
polycythemia
regular
phlebotomi
perform
parent
cousin
object
describ
rare
case
chuvash
polycythemia
diagnosi
treatment
outcom
pediatr
patient
designmethod
case
report
result
extens
workup
polycythemia
conduct
confirm
hgb
hct
level
primari
secondari
polycythemia
work
polycythemia
vera
exon
neg
erythopoetin
level
normal
addit
oxygen
affinifi
studi
found
normal
gene
test
perform
reveal
homozyg
mutat
vhl
gene
confirm
diagnosi
chuvash
polycythemia
date
treatment
chuvash
polycythemia
howev
symptom
manag
phlebotomi
thought
accept
phlebotomi
help
headach
ruddi
complexion
morbid
may
lead
iron
defici
anemia
also
signific
increas
stroke
thrombot
event
patient
paradox
increas
bleed
event
well
stroke
hemorrhag
complic
includ
pulmonari
hypertens
hemangioma
conclus
chuvash
polycythemia
rare
caus
polycythemia
promptli
diagnos
treat
base
upon
clinic
symptom
prevent
long
term
morbid
mortal
background
osteosarcoma
common
primari
bone
tumor
children
metastat
diseas
seen
patient
lung
common
site
metastasi
follow
boney
site
bone
marrow
metastasi
affect
hematopoiesi
extrem
rare
case
report
literatur
describ
case
metastat
osteosarcoma
diffus
infiltr
bone
marrow
contigu
distant
locat
physiolog
function
bone
marrow
compromis
patient
show
suppress
hematopoiet
cell
lineag
designmethod
discuss
includ
clinic
present
diagnost
featur
note
initi
diseas
evalu
magnet
reson
imag
computer
tomographi
scan
bone
scintigraphi
serial
blood
count
provid
histolog
find
biopsi
primari
tumor
bone
marrow
also
compar
contrast
symptom
cours
diseas
typic
metastat
osteosarcoma
yearold
caucasian
femal
present
intermitt
pain
right
leg
week
imag
show
destruct
mass
right
distal
femur
local
bone
marrow
soft
tissu
involv
biopsi
reveal
highgrad
osteoblast
osteosarcoma
metastat
evalu
demonstr
sub
centimet
nodul
addit
extens
skelet
diseas
involv
bilater
femur
bilater
humeri
skull
rib
pelvi
complet
blood
count
done
prior
biopsi
remark
white
blood
count
hemoglobin
platelet
bone
marrow
evalu
perform
sampl
bilater
iliac
crest
demonstr
pleomorph
tumor
cell
marrow
involv
osteoid
format
along
normal
hematopoiet
cell
avail
clinic
trial
patient
receiv
standard
therapi
consist
methotrex
adriamycin
cisplatin
platelet
count
recov
initi
cours
chemotherapi
suggest
marrow
diseas
respond
extent
unfortun
respons
site
poor
result
death
progress
diseas
month
treatment
conclus
bone
marrow
involv
impair
hematopoiesi
quit
uncommon
metastat
osteosarcoma
patient
osteosarcoma
present
abnorm
complet
blood
count
evalu
bone
marrow
metastas
patient
typic
dismal
prognosi
background
zr
year
old
previous
healthi
male
present
extens
indur
cellul
right
forearm
thigh
associ
right
axillari
inguin
lymphadenopathi
fever
fail
oral
antibiot
hospit
start
appropri
parenter
antibiot
clinic
improv
develop
palpabl
hepatosplenomegali
neutropenia
mild
anemia
object
report
rare
case
subcutan
panniculitislik
tcell
lymphoma
designmethod
bone
marrow
biopsi
obtain
signific
hemophagocytosi
blast
popul
observ
due
concern
hemophagocyt
lymphohystiocytosi
work
obtain
nonspecif
ultim
skin
lymph
node
biopsi
reveal
rare
diagnosi
subcutan
panniculitislik
tcell
lymphoma
sptcl
matur
tcell
lymphoma
extranod
cutan
origin
result
process
typic
present
singl
multipl
focal
nodul
plaqu
extrem
trunk
face
associ
fever
lymphadenopathi
hepatosplenomegali
cytopenia
rare
hemophagocytosi
extrem
rare
diagnosi
defin
epidemiolog
incid
organ
treatment
approach
current
treatment
approach
includ
steroid
alon
immunosuppress
agent
multiag
chemotherapi
even
autolog
stem
cell
transplant
current
median
surviv
roughli
depend
greatli
upon
phenotyp
cell
receptor
tcr
phenotyp
significantli
better
prognosi
aggress
phenotyp
often
associ
hemophagocytosi
found
tcr
concern
aggress
phenotyp
thu
begun
treatment
multiag
chemotherapi
regimen
receiv
two
cycl
doxorubicin
vincristin
prednison
cyclophosphamid
per
ahod
receiv
methotrex
cytarabin
per
mri
extrem
ct
abdomen
therapi
show
near
resolut
size
induat
plaqu
plan
treat
least
month
pend
respons
conclus
case
stress
import
broaden
differenti
diagnosi
patient
respond
appropri
treatment
provid
much
need
insight
success
treat
pediatr
patient
rare
diagnosi
sptcl
associ
hemophagocytosi
background
technolog
chang
practic
medicin
practition
access
email
electron
medic
record
use
desktop
laptop
comput
face
challeng
thousand
healthcar
mobil
applic
app
avail
smart
phone
app
selfcontain
program
piec
softwar
design
run
handheld
devic
perform
specif
purpos
object
identifi
need
pediatricspecif
app
pediatr
hematologyoncolog
pho
commun
tool
improv
workflow
enhanc
traine
patient
educ
designmethod
hematolog
oncolog
mesh
term
list
search
appl
itun
store
simpl
keyword
english
languag
master
list
uniqu
app
creat
app
divid
four
categori
medic
teach
provid
tool
resourc
consum
sever
subcategori
result
search
hematologyoncolog
mesh
term
itun
store
result
app
iphon
app
ipad
total
iphon
app
consid
potenti
use
pho
field
categori
medic
teach
provid
tool
yield
highest
number
interest
app
howev
resourc
found
pediatr
hemoncori
stage
journal
confer
use
handbook
consumerrel
app
potenti
use
four
nonenglish
app
spanish
app
found
conclus
mobil
technolog
app
conveni
may
lead
superior
faster
clinic
decisionmak
improv
accuraci
enhanc
product
pho
howev
clearli
need
design
pediatr
hematooncologyspecif
app
aspho
take
lead
coordin
respons
fastmov
field
design
organ
app
encourag
pho
use
new
phospecif
app
optim
patient
care
educ
background
neutropen
enterocol
occur
commonli
individu
hematolog
malign
neutropen
develop
breakdown
gut
mucos
integr
result
cytotox
chemotherapi
clinic
manifest
includ
fever
abdomin
symptom
pain
distent
cramp
tender
nausea
vomit
wateri
bloodi
diarrhea
diagnosi
confirm
imag
treatment
broad
spectrum
antibiot
tubercul
enter
rare
unit
state
us
nonspecif
sign
symptom
often
result
diagnost
delay
object
report
aml
complic
typhliti
tubercul
enter
designmethod
case
report
result
yearold
hispan
femal
aml
receiv
treatment
children
oncolog
groupprotocol
b
follow
inductioni
neutropen
statu
comput
tomographi
ct
reveal
abnorm
mucos
enhanc
ascend
colon
ct
scan
remaind
treatment
demonstr
necrot
abdomin
lymph
node
ln
persist
ileocec
inflamm
remain
primarili
unchang
despit
antibiot
therapi
bowel
rest
end
therapi
persist
fever
set
protract
cours
typhliti
imag
show
mildli
promin
left
supraclavicular
ln
partial
improv
colon
wall
thicken
confin
cecum
proxim
ascend
colon
ct
also
reveal
nonspecif
pulmonari
nodul
lung
parenchym
diseas
hilar
adenopathi
excision
biopsi
left
ln
show
necrot
granuloma
rare
acidfast
bacilli
afb
afb
stain
tuberculosi
tb
polymeras
chain
reaction
test
stool
cultur
also
posit
born
us
famili
el
salvador
report
visit
two
year
prior
diagnosi
known
tb
exposur
twoweek
start
antitubercul
therapi
defervesc
neutrophil
count
improv
nine
month
post
complet
therapi
remain
first
remiss
hypocellular
bone
marrow
bone
marrow
afb
stain
cultur
neg
date
conclus
tubercul
enter
rare
suspect
even
harder
identifi
pediatr
oncolog
popul
due
overlap
symptom
cancer
treatment
publish
report
gastrointestin
tb
children
commonli
report
abdomin
pain
fever
weight
loss
present
symptom
highlight
decept
clinic
present
diseas
set
cancer
diagnosi
acut
lymphoblast
leukemia
chronic
myelogen
leukemia
biphenotyp
leukemia
juvenil
myelomonocyt
leukemia
donor
type
haploident
match
unrel
donor
match
sibl
donor
patient
mc
alon
respond
dli
three
respond
develop
grade
iiiv
acut
graft
versu
host
diseas
gvhd
develop
limit
chronic
gvhd
patient
mc
also
mrd
posit
respond
dli
one
respond
develop
extens
chronic
gvhd
respond
lowlevel
mrd
time
dli
nonrespond
mc
mrd
posit
diseas
develop
gvhd
neither
patient
mc
morpholog
relaps
respons
dli
develop
gvhd
mc
predat
morpholog
relaps
day
two
patient
dli
delay
conclus
administ
promptli
evid
mc
alon
dli
donor
type
increas
donor
chimer
low
risk
gvhd
may
prevent
relaps
advoc
close
monitor
donor
chimer
hct
earli
administr
dli
use
dose
escal
regimen
background
donor
patient
african
descent
requir
hematopoiet
stem
cell
transplant
hsct
limit
nation
registri
donor
pool
limit
match
donor
disqualifi
total
nucleat
cell
tnc
count
marrow
graft
requir
donat
threshold
probabl
like
peopl
african
descent
often
lower
white
blood
cell
count
european
counterpart
addit
patient
sickl
cell
diseas
scd
tnc
threshold
higher
diseas
tnckg
recipi
bodi
weight
versu
tnckg
threshold
establish
anecdot
base
hypothesi
higher
tnc
dose
would
decreas
reject
risk
graft
dose
tradit
done
use
tnc
graft
content
may
better
predictor
transplant
outcom
object
divers
popul
hsct
donor
determin
whether
tnc
concentr
percentag
differ
ethnic
determin
whether
tnc
dose
affect
posttranspl
morbid
mortal
designmethod
retrospect
chart
review
allogen
hsct
donor
recipi
mann
whitney
u
test
use
compar
tnc
concentr
percentag
group
univari
logist
regress
analysi
use
evalu
transplant
outcom
result
includ
allogen
hsct
patient
donor
diagnos
scd
n
leukemialymphomamyeloma
n
myelodysplast
syndrom
n
n
donor
caucasian
black
asian
hispan
otherunknown
tnc
concentr
bone
marrow
graft
lower
black
vs
nonblack
donor
n
vs
median
vs
p
median
fraction
higher
black
vs
nonblack
donor
vs
p
time
engraft
incid
acut
chronic
gvhd
incid
reject
mortal
vari
significantli
base
tnc
dose
conclus
data
show
significantli
lower
tnc
concentr
higher
fraction
graft
collect
black
vs
nonblack
donor
differ
outcom
suggest
tnc
threshold
bone
marrow
harvest
lower
black
donor
background
limit
data
exist
regard
burden
late
morbid
follow
allohct
children
nonmalign
diseas
object
assess
incid
sever
late
effect
survivor
allohct
nonmalign
condit
designmethod
conduct
prospect
assess
patient
columbia
univers
medic
center
surviv
year
diseasefre
allohct
childhood
age
transplant
begin
march
patient
particip
comprehens
clinic
visit
includ
object
lab
imag
test
screen
late
effect
qualiti
life
evalu
pediatr
qualiti
life
inventori
pedsql
assess
educ
attain
late
effect
grade
common
terminolog
criteria
advers
event
version
result
januari
patient
age
year
enrol
studi
mean
year
allohct
diagnos
includ
hemoglobinopathi
n
bone
marrow
failur
n
hlhimmunodefici
n
among
particip
match
sibl
donor
unrel
donor
receiv
bone
marrow
cord
blood
pbsc
underw
myeloabl
condit
reducedtox
reducedintens
fifti
percent
particip
develop
least
one
chronic
health
condit
develop
grade
condit
grade
condit
frequent
late
effect
ovarian
failur
femal
growth
impair
low
bone
miner
densiti
thyroid
dysfunct
chronic
kidney
diseas
treatmentrel
malign
addit
histori
chronic
gvhd
histori
late
acut
viral
infect
requir
hospit
urin
microalbuminuria
hyperferritinemia
mild
pulmonari
function
test
abnorm
without
clinic
signific
mean
pedsql
score
within
standard
deviat
popul
norm
domain
overal
score
impair
rang
standard
deviat
popul
norm
thirti
eight
percent
particip
delay
educ
attain
heterogen
cohort
longterm
survivor
allohct
nonmalign
diseas
mildtomoder
late
effect
common
sever
late
effect
infrequ
ongo
studi
abl
identifi
risk
factor
advers
longterm
outcom
background
allogen
hematopoiet
cell
transplant
hct
remain
standard
therapi
variou
rare
inherit
metabol
diseas
imd
surviv
improv
assess
longterm
outcom
often
hamper
patient
attrit
distanc
treat
center
object
pilot
methodolog
remot
studi
parent
patient
perspect
behavior
emot
function
follow
hct
imd
designmethod
univers
minnesota
bmt
databas
queri
surviv
imd
patient
diseas
characterist
parentspati
invit
studi
particip
research
electron
data
captur
redcap
system
use
electron
administ
retriev
standard
behavior
assess
system
children
second
edit
survey
tool
onetim
crosssect
analysi
respons
parentpati
pair
analyz
pair
sampl
ttest
subscal
area
anxieti
depress
atyp
attent
problem
result
identifi
patient
transplant
imd
survivor
parent
andor
patient
enrol
parentpati
pair
success
complet
survey
imd
diagnos
includ
hurler
syndrom
pair
adrenoleukodystrophi
pair
mannosidosi
pair
maroteauxlami
syndrom
pair
median
time
transplant
assess
year
iqr
rang
signific
differ
percept
anxieti
p
depress
p
atyp
p
attent
problem
p
compar
parent
patient
respons
major
patient
perform
averag
level
comparison
age
gender
base
norm
parent
score
patient
score
perspect
subscal
analyz
conclus
effect
remot
assess
behavior
emot
function
via
electron
method
feasibl
larg
cohort
imd
patient
surviv
hct
importantli
score
anxieti
depress
atyp
attent
disord
significantli
differ
parent
patient
report
suggest
patient
unabl
provid
selfreport
function
parent
perspect
may
serv
adequ
represent
continu
followup
popul
critic
provid
appropri
counsel
regard
longterm
outcom
patient
famili
consid
hct
treatment
option
imd
background
infant
young
children
undergo
hematopoiet
stem
cell
transplant
hsct
increas
risk
late
effect
due
exposur
develop
organ
chemotherapi
radiat
therapi
typic
util
part
condit
regimen
busulfan
bu
base
myeloabl
condit
regimen
develop
elimin
radiat
exposur
young
children
hope
late
effect
would
minim
report
late
effect
date
focus
outcom
older
children
adult
remain
pauciti
data
regard
late
effect
young
children
undergo
hsct
follow
bubas
regimen
object
aim
singlecent
retrospect
studi
describ
late
effect
observ
cohort
young
patient
underw
cord
blood
transplant
cbt
use
bubas
condit
regimen
designmethod
medic
record
patient
underw
cbt
chemotherapybas
cytoreduct
year
age
septemb
surviv
year
review
overal
surviv
descript
statist
mean
height
standard
deviat
score
cumul
incid
key
late
effect
calcul
cox
regress
model
explor
associ
predictor
late
effect
median
age
transplant
year
rang
median
age
followup
year
rang
overal
surviv
year
postcbt
rang
nearli
patient
experienc
least
one
signific
late
effect
two
late
effect
document
patient
dental
problem
document
patient
commonli
observ
late
effect
includ
short
statur
cognit
pulmonari
pubert
delaygonad
failur
short
statur
cognit
deficit
frequent
patient
inherit
metabol
diseas
conclus
avoid
irradi
young
undergo
cbt
may
decreas
elimin
late
effect
result
inform
clinic
care
guidelin
longterm
followup
well
add
grow
inform
regard
late
effect
hsct
gener
longterm
survivor
cbt
infanc
earli
childhood
requir
regular
followup
identifi
late
effect
amelior
associ
consequ
background
pediatr
patient
undergo
hematopoiet
stem
cell
transplant
hsct
increas
risk
invas
fungal
diseas
ifd
gold
standard
fungal
prophylaxi
regimen
hsct
cincinnati
children
hospit
medic
center
cchmc
util
three
altern
dose
strategi
antifung
prophylaxi
popul
genotypedirect
voriconazol
alternateday
micafungin
onceweekli
liposomalamphotericinb
lamb
limit
data
regard
efficaci
regimen
compar
superior
object
aim
studi
assess
efficaci
regimen
prevent
ifd
pediatr
allogen
hsct
patient
secondari
aim
includ
safeti
comparison
pharmacoeconom
assess
designmethod
retrospect
chart
review
conduct
patient
year
receiv
allogen
hsct
januari
juli
proven
probabl
possibl
ifd
defin
use
updat
european
organ
research
treatment
cancer
mycos
studi
group
definit
examin
first
day
posttranspl
result
allogen
transplant
perform
patient
patient
met
inclus
criteria
seventyeight
patient
receiv
lamb
receiv
micafungin
receiv
voriconazol
start
day
zero
proven
probabl
ifd
occur
patient
three
micafungin
group
candida
parapsilosi
voriconazol
group
saccharomyc
cerevisia
candida
glabrata
lamb
group
candida
glabrata
p
eighteen
patient
antifung
prophylaxi
chang
due
possibl
ifd
occur
micafungin
group
overal
micafungin
group
advers
event
ae
total
ae
compar
lamb
voriconazol
group
p
result
show
rate
proven
probabl
ifd
similar
three
regimen
although
possibl
infect
increas
altern
day
micafungin
overal
safeti
toler
significantli
better
micafungin
group
compar
lamb
voriconazol
group
sub
analys
ongo
delin
patient
activ
gvhd
increas
immun
suppress
data
along
pharmacoeconom
result
add
insight
risk
benefit
balanc
regimen
background
cyclin
depend
kinas
ubiquit
express
prolin
direct
serinethreonin
kinas
preclin
clinic
data
suggest
activ
lie
crossroad
neurosci
inflamm
cancer
immun
surveil
lab
identifi
novel
role
tcell
acut
graftversushost
diseas
agvhd
hypothes
inhibit
donor
tcell
lead
reduc
migrat
secondari
lymphoid
organ
slo
reduc
sever
agvhd
murin
model
allogen
hematopoiet
stem
cell
transplant
allohsct
object
investig
role
tcell
traffick
syngen
allogen
hsct
model
translat
goal
use
inhibit
novel
strategi
prevent
agvhd
designmethod
small
molecul
inhibitor
roscovitin
use
vitro
vivo
experi
pharmacolog
inhibit
respect
donor
tcell
knockout
hematopoiet
chimer
mice
adopt
transfer
haploident
mice
studi
role
tcell
function
agvhd
lineag
specif
cell
knockout
mice
use
futur
experi
fluoresc
activ
cell
sort
use
studi
quantit
differ
migrat
roscovitin
treat
donor
tcell
versu
appropri
control
cellular
interact
pattern
differenti
label
tcell
subset
use
real
time
imag
laser
scan
microscopi
result
baselin
syngen
experi
compar
allogen
model
result
loss
express
donor
tcell
associ
reduc
migrat
prolifer
differenti
donor
tcell
express
import
develop
agvhd
loss
donor
tcell
reduc
mortal
morbid
due
agvhd
discuss
addit
result
confer
identifi
malign
diseas
total
bodi
irradi
chronic
gvhd
signific
risk
factor
find
larger
prospect
studi
long
term
follow
cohort
need
confirm
expand
find
divya
devadasan
chiaowang
sun
tim
town
frederick
goldman
background
hematopoiet
stem
cell
transplant
hsct
patient
sickl
cell
diseas
scd
cur
though
signific
toxic
myeloabl
condit
limit
util
previous
develop
knockin
mice
produc
normal
aa
sickl
ss
human
hemoglobin
recapitul
sever
anemia
hyposthanuria
limit
lifespan
found
scd
patient
reduc
intens
prepar
regimen
decreas
transplant
toxic
prefer
nonmalign
disord
newer
agent
develop
includ
treosulfan
alkyl
antickit
antibodi
creat
bone
marrow
bm
nich
block
ckit
function
object
optim
nonmyeloabl
condit
murin
model
scd
allow
suffici
donor
rbc
chimer
diseas
amelior
designmethod
mice
receiv
vari
condit
regimen
rescu
control
aa
marrow
includ
irradi
gy
tbi
treosulfan
ip
ip
hematolog
effect
respect
treatment
determin
assess
marrow
cellular
peripher
cbc
erythroid
donor
chimer
isoelectr
focus
urin
concentr
abil
surrog
renal
tubular
function
also
assess
result
erythroid
hyperplasia
note
bm
scd
mice
treosulfan
independ
dosedepend
manner
decreas
bm
cellular
induc
cytopenia
control
scd
mice
overal
scd
mice
abl
toler
dose
treosulfan
tbi
rel
control
treosulfantr
scd
mice
evid
donor
erythroid
engraft
week
posttranspl
sustain
donor
erythroid
chimer
normal
reticulocyt
urin
osmol
found
scd
mice
sustain
donor
erythroid
chimer
nonengraft
mice
remain
hyposthanur
anim
follow
longterm
fertil
surviv
conclus
scd
mice
close
mimic
human
diseas
phenotyp
abl
condit
intoler
treosulfan
alon
unabl
sustain
erythroid
chimer
major
scdtransplant
anim
suggest
current
dose
nonmyeloabl
nonetheless
anim
least
donor
erythroid
chimer
normal
urin
osmol
cbc
consist
clinic
experi
scd
transplant
incomplet
donor
erythroid
engraft
suffici
amelior
diseas
phenotyp
current
studi
assess
combinatori
effect
treosulfan
background
transplantassoci
thrombot
microangiopathi
tatma
occur
around
hematopoiet
cell
transplant
hct
recipi
howev
tatma
pediatr
patient
receiv
hct
hemoglobinopathi
larg
undescrib
herein
report
three
patient
hemoglobinopathi
develop
sequela
sever
progress
tatma
despit
treatment
eculizumab
patient
year
old
male
sickl
cell
diseas
scd
present
tatma
relat
massiv
pericardi
effus
tamponad
uncontrol
hypertens
day
post
myeloabl
match
relat
umbil
cord
blood
transplant
despit
discontinu
tacrolimu
effus
worsen
requir
polypharmaci
antihypertens
therapi
treatment
eculizumab
effus
resolv
hypertens
improv
tma
lab
normal
month
posttranspl
continu
chronic
kidney
diseas
estim
gfr
patient
year
old
male
scd
develop
posterior
revers
encephalopathi
syndrom
pre
seizur
day
follow
reducedintens
match
sibl
bone
marrow
transplant
despit
discontinu
tacrolimu
one
month
later
present
refractori
statu
epilepticu
requir
six
antiepilept
hypertens
imag
confirm
recurr
pre
left
tempor
hemorrhag
laboratori
test
consist
tatma
post
treatment
eculizumab
seizur
abat
tma
lab
normal
current
month
posttranspl
residu
neurocognit
defect
patient
year
old
asian
femal
betathalassemia
major
receiv
myeloabl
match
unrel
bone
marrow
transplant
six
month
posttranspl
present
tma
relat
intract
hypertens
acut
kidney
injuri
requir
dialysi
seizur
renal
biopsi
mri
brain
show
chang
consist
tma
minim
respons
discontinu
tacrolimu
therapeut
plasma
exchang
follow
eculizumab
therapi
hematolog
paramet
normal
taken
dialysi
howev
develop
sever
chronic
kidney
diseas
estim
gfr
hypertens
die
sixteen
month
posttranspl
due
respiratori
failur
caus
rsv
patient
hemoglobinopathi
ongo
endotheli
dysfunct
may
place
greater
risk
tatma
latter
longterm
devast
clinic
consequ
investig
need
order
determin
preemptiv
eculizumab
may
warrant
treatment
tatma
seemingli
highrisk
popul
object
use
reducedintens
condit
regimen
select
tcelldeplet
peripher
blood
stem
cell
pbsc
graft
allow
engraft
low
incid
graftversushost
diseas
gvhd
designmethod
ten
pediatr
scd
patient
underw
tcelldeplet
transplant
altern
donor
indic
transplant
includ
vasoocclus
pain
crisi
n
concurr
kostmann
n
stroke
n
condit
transcrani
doppler
development
delay
nocturn
hypoxia
n
patient
receiv
median
prbc
transfus
rang
within
three
year
prior
transplant
condit
regimen
consist
melphalan
thiotepa
x
fludarabin
rabbitatg
x
without
posttranspl
immunosuppress
six
patient
receiv
rituximab
condit
seven
patient
receiv
plan
donor
lymphocyt
infus
dli
day
methotrex
iv
gvhd
prophylaxi
companion
studi
two
patient
receiv
therapeut
dli
infus
posttranspl
result
median
age
transplant
year
rang
eight
patient
mismatchedrel
two
match
unrel
donor
median
pbsc
dose
rang
patient
receiv
patient
engraft
anc
median
day
rang
nine
ten
patient
aliv
median
followup
month
rang
three
patient
ebvrel
posttranspl
lymphoprolif
disord
ptld
one
die
consequ
treatment
ptld
seriou
viral
diseas
observ
acut
grade
iiiv
gvhd
develop
transplant
dli
one
case
occur
dli
patient
chronic
gvhd
conclus
reducedintens
condit
regimen
follow
tcelldeplet
altern
donor
transplant
provid
reliabl
engraft
low
incid
gvhd
approach
may
increas
avail
transplant
pediatr
patient
scd
match
sibl
donor
background
exist
literatur
show
mix
conclus
regard
impact
abo
incompat
outcom
follow
hematopoiet
cell
transplant
futur
umbil
cord
blood
ucb
expans
technolog
bright
assess
whether
typicallyoverlook
graft
characterist
impact
variou
outcom
follow
ucb
transplant
ucbt
nonmalign
disord
nmd
object
determin
impact
abo
match
statu
outcom
interest
patient
undergo
first
ucbt
nmd
designmethod
prospect
maintain
institut
bmt
program
databas
queri
patient
undergo
first
ucbt
nmd
demograph
diseas
transplantrel
characterist
ucb
recipi
abo
compat
consid
match
major
mismatch
recipi
isoagglutinin
ucb
antigen
minor
mismatch
ucb
isoagglutinin
recipi
antigen
bidirect
mismatch
doubl
ucbt
compat
statu
domin
unit
consid
impact
abo
incompat
assess
follow
overal
surviv
graft
failur
agvhd
grade
iiiv
iiiiv
cgvhd
time
neutrophil
platelet
recoveri
posttranspl
prbc
transfus
requir
donor
hematopoiet
chimer
result
decemb
patient
undergon
first
ucbt
variou
nmd
sixtyon
percent
underli
storag
disord
marrow
failur
anoth
indic
among
four
abo
compat
group
signific
differ
seen
age
gender
nmd
diagnosi
categori
condit
intens
hlamatch
cell
dose
number
ucb
unit
transplant
era
perform
score
gvhd
prophylaxi
cmv
serostatu
abo
compat
statu
appear
impact
outcom
assess
though
trend
toward
increas
grade
iii
iv
agvhd
seen
recipi
major
mismatch
unit
multivari
initi
subgroup
analys
abo
compat
significantli
impact
studi
endpoint
includ
posttranspl
prbc
transfus
burden
conclus
abo
compat
statu
appear
impact
select
posttranspl
outcom
follow
ucbt
larg
nmd
cohort
background
bl
patient
relaps
prognosi
dismal
due
chemoimmunotherapi
resist
group
success
modifi
expand
peripher
blood
natur
killer
cell
expbnk
car
target
bl
cell
vitro
nsg
mice
romidepsin
histon
deacetylas
hdac
inhibitor
increas
express
ligand
bl
investig
effect
romidepsin
alon
combin
car
modifi
expbnk
cell
bl
cell
vitro
human
bl
nsg
mice
designmethod
car
modifi
expbnk
cell
produc
describ
daudi
raji
cell
treat
romidepsin
gener
provid
celgen
rajiluc
engraft
mice
inject
romidepsin
pb
follow
car
expbnk
cell
mock
expbnk
cell
inject
later
tumor
regress
andor
progress
monitor
weekli
result
hdac
level
significantli
increas
bl
cell
compar
white
blood
cell
total
acetyl
enhanc
raji
follow
romidepsin
importantli
romidepsin
significantli
inhibit
bl
cell
prolifer
p
induc
apoptosi
rituximab
sensit
bl
cell
cell
cycl
arrest
resist
bl
cell
p
romidepsin
significantli
inhibit
vivo
daudi
raji
cell
growth
xenograft
nsg
mice
reduc
tumor
burden
p
bioluminesc
p
vitro
cytotox
car
expbnk
cell
significantli
enhanc
romidepsin
treat
bl
cell
compar
untreat
e
p
n
compar
mock
expbnk
p
n
human
raji
xenograft
nsg
mice
surviv
time
romidepsincar
expbnk
treat
mice
significantli
extend
compar
untreat
mice
median
day
p
car
expbnk
treat
mice
median
day
p
romidepsin
treat
mice
median
day
p
addit
observ
enhanc
micab
express
daudi
xenograft
mice
romidepsin
treatment
conclus
result
suggest
therapeut
potenti
combin
car
modifi
expbnk
cell
romidepsin
chemoimmunotherapi
resist
bl
continu
investig
whether
enhanc
micab
express
mice
associ
extend
surviv
donor
condit
regimen
receiv
howev
b
cell
myeloid
donor
chimer
last
follow
best
follow
low
toxic
myeloabl
condit
regimen
match
relat
mrd
match
unrel
donor
murd
compar
uncondit
match
sibl
donor
msd
recipi
haploident
donor
recipi
poor
myeloid
chimer
donor
cell
despit
receiv
mac
condit
sixteen
patient
ivig
b
myeloid
chimer
donor
b
myeloid
chimer
donor
thirteen
patient
b
myeloid
chimer
donor
continu
ivig
mean
count
last
follow
highest
receiv
msd
uncondit
transplant
recipi
low
toxic
condit
higher
count
compar
ric
mac
condit
across
type
donor
msd
uncondit
transplant
best
thymic
output
last
follow
follow
mrd
murd
low
toxic
myeloabl
condit
conclus
cell
donor
chimer
influenc
condit
donor
type
howev
condit
mrd
murd
demonstr
better
myeloid
cell
chimer
compar
uncondit
msd
haploident
donor
recipi
mac
sustain
output
seen
year
posthsct
scid
even
though
uncondit
msd
recipi
poor
myeloid
chimer
highest
thymic
output
last
follow
background
mani
studi
demonstr
evolut
immunereconstitut
scarc
data
consid
longterm
qualiti
life
qol
one
studi
suggest
poor
function
compar
healthi
control
object
object
assess
qol
scid
survivor
centr
accord
genet
diagnosi
designmethod
scid
patient
year
posttranspl
attend
posttranspl
clinic
follow
invit
answer
pediatr
qualiti
life
inventori
pedsql
gener
score
scale
questionnair
part
routin
psycholog
assess
pedsql
questionnair
consist
parent
patient
report
domain
physic
emot
social
school
psychosoci
total
result
fiftynin
patient
respond
compris
patient
age
year
famili
fourteen
children
age
year
old
exclud
child
questionnair
twentyeight
patient
contact
three
refus
median
interv
posthsct
year
rang
proport
respond
accord
scid
genotyp
scid
defici
adenosin
deaminas
ada
artemi
qol
patient
defici
artemi
scid
significantli
differ
publish
uk
norm
patient
report
domain
contrast
previou
studi
howev
ada
scid
survivor
significantli
lower
qol
across
except
emot
compon
parent
scid
report
significantli
lower
qol
domain
compar
uk
normal
whilst
parent
ada
scid
report
significantli
lower
qol
across
except
emot
domain
qol
score
significantli
differ
artemi
defici
scid
domain
parent
children
scid
report
significantli
lower
qol
school
domain
parent
scid
ongo
intraven
immunoglobulin
therapi
report
lower
qol
compar
without
therapi
conclus
contrast
previous
number
scid
genotyp
associ
normal
qol
particular
risk
factor
includ
ada
scid
need
ongo
medic
larger
qualit
studi
need
clarifi
qol
differ
scid
survivor
